Pharmaceutical composition for the treatment of cancer comprising an Anti-cancer agent and a novel compound having

By developing a pharmaceutical composition and anticancer agent containing a new compound inhibiting activity against prostaglandin E2 receptor, the problem of insufficient effectiveness of prostaglandin E2 receptor antagonists in the prior art in the treatment of cancer is solved, and the colorectal effect is achieved Effective inhibition of cancer and lung cancer tumors.

CN119013017APending Publication Date: 2024-11-22ZHINAFU PHARM TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033450.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-15
Filing Date
2023-02-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing prostaglandin E2 receptor antagonists have not been fully utilized clinically and have insufficient effectiveness in treating cancer, especially in inhibiting the growth of colorectal and lung cancer tumors.

Method used

A pharmaceutical composition containing a novel compound with an anticancer agent with an inhibitory activity against the prostaglandin E2 receptor was developed for inhibiting tumor growth and in combination with chemotherapeutic agents and immune checkpoint inhibitors to enhance anticancer effects .

Benefits of technology

This pharmaceutical composition significantly inhibits tumor growth of colorectal and lung cancers, and shows synergistic effects when used in combination with other anticancer agents, improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013017A_ABST
    Figure CN119013017A_ABST
Patent Text Reader

Abstract

The present invention provides a pharmaceutical composition for the treatment of cancer comprising a novel compound having inhibitory activity on prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compounds of the present invention inhibit the activity of the prostaglandin E2 receptor and inhibit tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that anticancer activity exhibits a synergistic effect when administered in combination with other anticancer agents, such as chemotherapeutic agents and / or immune checkpoint inhibitors. Therefore, the pharmaceutical composition for treating cancer comprising the novel compound as an active ingredient and an anti-cancer agent can be effectively used for preventing and treating cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical composition for treating cancer, comprising as active ingredients a novel compound having inhibitory activity on prostaglandin E2 receptors and an anticancer agent. Background Art

[0002] Prostaglandin (PG), like thromboxane, is a physiologically active substance called prostaglandins, and is a lipid with a prostanoid acid backbone. Under the action of phospholipase A2, arachidonic acid is released from cell membrane phospholipids to biosynthesize prostaglandins such as prostaglandins. According to the difference between the oxygen atom and the double bond type connected to its five-membered ring, prostaglandins are divided into A to J groups. In addition, according to the difference between the double bond number on the prostanoid acid backbone side chain, prostaglandins are divided into 1 to 3 groups. For example, prostaglandin E (PGE) includes PGE1, PGE2 and PGE3, which differ from each other in the double bond number on the prostanoid acid backbone side chain.

[0003] Regarding prostaglandins, PGG2 is biosynthesized from arachidonic acid under the action of cyclooxygenase I (COX-I) or cyclooxygenase II (COX-II), and PGH2 is generated from PGG2. Then, PGD2, PGE2, and PGF are generated based on the difference in the breakage of the bond between oxygen atoms. 2α etc. The production reaction of each prostaglandin occurs under the action of specific enzymes, and it is well known that these enzymes have tissue specificity. On the other hand, among prostaglandins, it is generally believed that PGE plays a role in various important biological activities, and through the mediation of specific receptors, PGE is involved in the regulation of the immune system, as well as vasodilation, blood pressure reduction and uterine contraction. Like other PG receptors, the PGE2 receptor is a seven-transmembrane G protein-coupled receptor. The abbreviation of PGE2 receptor is EP, and EP has been found to have 4 subtypes (EP1, EP2, EP3 and EP4). Each subtype is involved in various phenomena in the body. That is, EP1 is involved in the regulation of intracellular Ca 2+ With the increase of ATP concentration, EP2 and EP4 are involved in the increase of cAMP level, while EP3 is involved in the decrease of cAMP level.

[0004] On the other hand, cancer is one of the leading causes of death worldwide. Tumors are composed of abnormally proliferating malignant cancer cells and a functionally supportive microenvironment. The tumor microenvironment is composed of a complex series of cells, extracellular matrix components, and signaling molecules, which are established by changing the information exchange between stromal cells and tumor cells. As tumor volume increases, it leads to the production of various factors, such as angiogenic factors (which promote blood vessel growth), which can help tumor growth or help evade the attack of the host immune response. In this microenvironment, PGE2 plays a role as an immunomodulatory factor produced in tumors. The EP receptors of PGE2, particularly EP2 and EP4, are abnormally overexpressed in several types of cancer, particularly in gastrointestinal (GI) cancer and pancreatic cancer. In addition, overexpression of PGE2 and / or EP2 and / or EP4 is closely associated with cancers such as esophageal squamous cell carcinoma, lung squamous cell carcinoma, prostate cancer, and head and neck squamous cell carcinoma. In addition, it is well known that from an epidemiological perspective, PGE2 signaling is mainly involved in the information exchange between tumor cells and stromal cells, creating a microenvironment that is conducive to tumor growth. Notably, some tumor cells overexpress EP2 and / or EP4, thereby PGE2 signaling can directly induce tumor cell proliferation.

[0005] Furthermore, it has been reported that PGE2 antagonists, such as EP2 and / or EP4 antagonists, are effective for chronic inflammatory diseases and neurodegenerative diseases such as epilepsy, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and traumatic brain injury.

[0006] Against this technical background, research on a prostaglandin E2 receptor antagonist that can be utilized clinically in various ways is underway (Korean Patent Application Publication No. 10-2013-0092579), but has not yet been completed. Summary of the Invention

[0007] Technical issues

[0008] Therefore, the present inventors have conducted research on developing safe and effective anticancer agents and have discovered that novel compounds with inhibitory activity against prostaglandin E2 receptors exhibit excellent anticancer effects when used in combination with chemotherapeutic agents and / or immune checkpoint inhibitors. Based on the above findings, the present inventors have completed the present invention.

[0009] Solution to the problem

[0010] To achieve the above objectives, in one aspect of the present invention, a pharmaceutical composition and a kit for treating cancer are provided, comprising as active ingredients a compound of Formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof; and an anticancer agent:

[0011] [Formula I]

[0012]

[0013] Effects of the Invention

[0014] The new compound of the present invention inhibits the activity of prostaglandin E2 receptors and suppresses tumor growth in colorectal cancer and lung cancer tumor models. In addition, when used in combination with other anticancer agents such as chemotherapeutics and / or immune checkpoint inhibitors, it was found that the anticancer activity showed a synergistic effect. Therefore, a pharmaceutical composition for treating cancer comprising a new compound with inhibitory activity on prostaglandin E2 receptors and an anticancer agent as an active ingredient can be effectively used to prevent and treat cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is a graph showing the results of observing changes in mouse body weight in the mouse colorectal cancer CT26 animal model according to the administration of A01 (Example 34b), anti-PD-1 antibody, or a combination of A01 and anti-PD-1 antibody.

[0016] Figure 2 The figure is a graph showing the results of measuring tumor size in the mouse-derived colorectal cancer CT26 animal model according to the administration of A01, anti-PD-1 antibody, or a combination of A01 and anti-PD-1 antibody.

[0017] Figure 3 This is a graph showing the results of observing changes in mouse body weight in the mouse colorectal cancer MC38 animal model according to the administration of A02 (Example 1b), anti-PD-1 antibody, or a combination of A02 and anti-PD-1 antibody.

[0018] Figure 4 The figure is a graph showing the results of measuring tumor size in the mouse-derived colorectal cancer MC38 animal model according to the administration of A02, anti-PD-1 antibody, or a combination of A02 and anti-PD-1 antibody.

[0019] Figure 5 Graph showing the results of measuring tumor size in a mouse-derived lung cancer TC1 animal model according to the administration of a combination of cisplatin, pemetrexed, and an anti-PD-1 antibody; or a combination of cisplatin, pemetrexed, an anti-PD-1 antibody, and A01. DETAILED DESCRIPTION

[0020] Pharmaceutical composition comprising a prostaglandin E2 receptor inhibitory compound and an anticancer agent

[0021] In one aspect of the present invention, a pharmaceutical composition for preventing or treating cancer is provided, which comprises a prostaglandin E2 receptor inhibitory compound, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof; and an anticancer agent.

[0022] Prostaglandin E2 receptor inhibitory compounds

[0023] One aspect of the prostaglandin E2 receptor inhibitory compound can be a compound represented by the following formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof:

[0024] [Formula I]

[0025]

[0026] in,

[0027] One of X and Y is S and the other is CR 1 ,and is a single bond or a double bond, wherein there are two double bonds;

[0028] R 1 and R 2 Selected from hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl and C6-C 10 The group consisting of aryl groups, wherein the C1-C6 alkyl and C1-C6 alkoxy groups can each be independently optionally substituted by one or more halogen, hydroxyl, cyano or amino groups, and the C3-C8 cycloalkyl and C6-C 10 The aryl groups may each independently be optionally substituted with one or more halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and

[0029] R 3 for or

[0030] R 1 Selected from hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl and C6-C 10 The group consisting of aryl groups, wherein the C1-C6 alkyl and C1-C6 alkoxy groups can each be independently optionally substituted by one or more halogen, hydroxyl, cyano or amino groups, and the C3-C8 cycloalkyl and C6-C 10 The aryl groups may each independently be optionally substituted with one or more halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and

[0031] R 2 and R 3 Together with the carbon atoms to which they are attached, they form in, and The nitrogen atoms on One or two carbon atoms in the group may be optionally substituted by halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy;

[0032] W is -(CH2) o -、-(CH2) o -C≡C-, -C(O)-, -O-, -S-, -NH- or -N(C1-C6 alkyl)-, wherein the H in the CH2 may be optionally substituted with one or more halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy;

[0033] Cy is selected from C6-C 14 The group consisting of aryl, 4- to 14-membered heteroaryl, 4- to 14-membered heterocycloalkyl, C3-C8 cycloalkyl and C3-C8 cycloalkenyl, and optionally substituted with one or more R';

[0034] R a is hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, oxo or -V-Cy2, wherein the C1-C6 alkyl and C1-C6 alkoxy may be optionally substituted with one or more halogen, hydroxy, cyano or amino groups,

[0035] Wherein, V is absent or -NH-, -NHCH2-, -NHCH3-, -CONH-, -NHCO-, -NHSO2-, -S-, -SO2-, -CH2-, -OCH2- or -O-,

[0036] Cy2 is selected from C6-C 14 aryl, 4- to 14-membered heteroaryl, 4- to 14-membered heterocycloalkyl, C3-C8 cycloalkyl, and C3-C8 cycloalkenyl, and may be optionally substituted with one or more R";

[0037] R' is each independently selected from the group consisting of halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl) and -N(C1-C6 alkyl)2, wherein the C1-C6 alkyl and C1-C6 alkoxy may be optionally substituted with one or more halogen, hydroxy, cyano or amino;

[0038] R" is selected from halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -CO-(C1-C6 alkyl), -C(O)H, -COO-(C1-C6 alkyl), -COOH, -CONH2, -CONH-(C1-C6 alkyl), -CON(C1-C6 alkyl)2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-CO-(C1-C6 alkyl), -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH, 3 to 7 membered heterocycloalkyl, C3-C8 cycloalkyl and -(CH2) p -(C3-C8 cycloalkyl), wherein the C1-C6 alkyl and C1-C6 alkoxy groups are optionally substituted with one or more halogen, hydroxy, cyano or amino groups, and the 3- to 7-membered heterocycloalkyl and C3-C8 cycloalkyl groups are optionally substituted with one or more halogen, hydroxy, cyano, oxo or amino groups;

[0039] R 4 is hydrogen or C1-C6 alkyl;

[0040] R 5 、R 6 and R 7 Each is defined as follows:

[0041] (i)R 5 and R 6 is H, and R 7 For non-existence,

[0042] (ii)R 5 and R 6 Together for -(CH2) q -, and R 7 does not exist, or

[0043] (iii)R 5 is H, and R 6 and R 7 Together for -(CH2) r -;and

[0044] P is absent or -CH2-, if R 7 If does not exist, then P also does not exist;

[0045] R 8for Where Z is -(CH2) s , and R 8 ' is hydrogen, hydroxy, C1-C6 alkyl or C1-C6 alkoxy;

[0046] l, m and n are each independently an integer from 0 to 2, wherein at least one of m and n is not 0, if P and R 7 If it does not exist, then l is 0;

[0047] o and p are each independently an integer from 0 to 3;

[0048] q and r are each independently an integer of 1 or 2; and

[0049] s is an integer from 0 to 3.

[0050] In some embodiments, X is S and Y is CR 1 , or X is CR 1 and Y is S. In a certain embodiment, is a single bond or a double bond, wherein there are two double bonds, so that the 5-membered ring containing X and Y forms a thiophene ring.

[0051] In some embodiments, R 1 It can be hydrogen, halogen, hydroxyl, cyano, amino, C1-C3 alkyl, C1-C3 alkoxy, -NH-(C1-C3 alkyl) or -N(C1-C3 alkyl)2, wherein the C1-C3 alkyl and C1-C3 alkoxy can each be independently optionally substituted with one or more halogen, hydroxyl, cyano or amino. In a certain embodiment, R 1 It can be hydrogen, halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl or C1-C3 haloalkoxy. 1 It can be hydrogen, halogen, C1-C3 alkyl or C1-C3 haloalkyl.

[0052] In some embodiments, R 2 It can be hydrogen, halogen, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C3-C6 cycloalkyl or phenyl, wherein the C1-C3 alkyl and C1-C3 alkoxy can each be independently optionally substituted with one or more halogen, hydroxyl, cyano or amino groups. In a certain embodiment, R 2 It can be hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, cyclobutyl or phenyl. In a certain embodiment, R 2 It can be hydrogen, fluorine, chlorine, bromine, methyl, ethyl, trifluoromethyl, difluoromethyl, cyclopropyl, cyclobutyl or phenyl.

[0053] In some embodiments, R 3 Can

[0054] In another embodiment, R 2 and R 3 Together with the carbon atoms to which they are attached, they can form Thus forming a 4H-thieno[3,2-b]pyrrole fused ring, in this case Can be used with connected to the nitrogen atoms on the .

[0055] In one embodiment, One or two carbon atoms in may be optionally substituted by halogen, C1-C3 alkyl or C1-C3 haloalkyl. In a certain embodiment, One or two carbon atoms in can be optionally substituted by fluorine, chlorine, bromine, methyl, ethyl, trifluoromethyl, difluoromethyl, etc. In a certain embodiment, One or two carbon atoms in the group may be optionally substituted with a C1-C3 alkyl group.

[0056] In some embodiments, W may be -(CH2) o -、-(CH2) o -C≡C-, -C(O)-, -O-, -NH- or -N(C1-C3 alkyl)-, wherein the H in the CH2 may be optionally substituted with one or more halogen, hydroxyl, C1-C3 alkoxy or C1-C3 haloalkoxy.

[0057] In a certain embodiment, W can be -(CH2) o -, -C(O)-, -O-, -NH- or -N(C1-C6 alkyl)-. In another embodiment, W may be -(CH2) o -or-(CH2) o -C≡C-.

[0058] In certain embodiments, the H in CH2 may be optionally substituted with one or more halogens, hydroxyl groups, or C1-C3 alkoxy groups. In certain embodiments, the H in CH2 may be optionally substituted with hydroxyl groups, methoxy groups, ethoxy groups, trifluoromethoxy groups, difluoromethoxy groups, etc. In certain embodiments, o may be an integer of 0, 1, or 2. In certain embodiments, o may be an integer of 0 or 1.

[0059] In some embodiments, Cy may be C6-C 10aryl, a 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, or a 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, and S. In a certain embodiment, Cy can be phenyl, naphthyl; a heteroaryl selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, quinolinyl, and isoquinolinyl; or a heterocycloalkyl selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, pyrazolidinyl, imidazolidinyl, thiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl, and morpholinyl.

[0060] In certain embodiments, Cy may be phenyl, a 5- to 10-membered heteroaryl group containing 1 or 2 nitrogen atoms, or a 4- to 7-membered heterocycloalkyl group containing 1 or 2 nitrogen atoms. In certain embodiments, Cy may be phenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl. In certain embodiments, Cy may be phenyl, pyrazolyl, pyridinyl, pyrimidinyl, indolyl, or piperazinyl.

[0061] The Cy may be optionally substituted with one or more R'. In certain embodiments, R' may be halogen, hydroxy, cyano, amino, oxo, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NH-(C1-C3 alkyl), or -N(C1-C3 alkyl). In certain embodiments, R' may be halogen, amino, C1-C3 alkyl, or C1-C3 haloalkyl. In certain embodiments, R' may be one or more fluorine, chlorine, bromine, amino, methylamino, dimethylamino, ethylamino, or diethylamino.

[0062] In some embodiments, R a It can be hydrogen, halogen, amino, C1-C3 alkyl, C1-C3 haloalkyl, -NH-(C1-C3 alkyl) or -N(C1-C3 alkyl)2 or -V-Cy2. In a certain embodiment, R a Can be hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl or -V-Cy2. In a certain embodiment, R a It can be hydrogen, fluorine, chlorine, bromine, methyl, ethyl, trifluoromethyl, difluoromethyl or -V-Cy2. In a certain embodiment, R a It can be -V-Cy2.

[0063] In some embodiments, V may be absent or -NH-, -NHCH2-, -NHCH3-, -S-, -SO2-, -CH2-, -OCH2-, or -O-. In a certain embodiment, V may be absent or -CH2- or -O-. In a certain embodiment, V may be absent or -CH2-.

[0064] In some embodiments, Cy2 can be selected from C6-C 10 The group consisting of aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O and S, C3-C8 cycloalkyl and C3-C8 cycloalkenyl. In certain embodiments, Cy2 can be phenyl; a heteroaryl selected from the group consisting of pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, quinolinyl, and isoquinolinyl; a heterocycloalkyl selected from the group consisting of azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, pyrazolidinyl, imidazolidinyl, thiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl, and morpholinyl; a cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; or a cyclobutenyl, cyclopentenyl, cyclohexenyl, or cycloheptenyl.

[0065] In certain embodiments, Cy2 can be selected from the group consisting of phenyl, 5- to 10-membered heteroaryl containing 1 or 2 heteroatoms selected from N or O, 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N or O, C4-C7 cycloalkyl, and C4-C7 cycloalkenyl. In certain embodiments, Cy2 can be phenyl, pyrrolyl, furanyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, cyclopentyl, cyclohexyl, cyclopentenyl, or cyclohexenyl. In certain embodiments, Cy2 can be phenyl, furanyl, pyrazolyl, pyridinyl, pyrimidinyl, piperidinyl, morpholinyl, cyclohexyl, or cyclohexenyl.

[0066] Said Cy2 may be optionally substituted by R". In some embodiments, R" is selected from halogen, hydroxyl, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p-NH-COO-(C1-C6 alkyl), -(CH2) p -OH, 3 to 5 membered heterocycloalkyl containing 1 heteroatom selected from N, O and S, C3-C5 cycloalkyl and -(CH2) p -(C3-C5 cycloalkyl) group, wherein the C1-C6 alkyl and C1-C6 alkoxy groups may be optionally substituted with one or more halogen, hydroxyl, cyano or amino groups, and the 3- to 5-membered heterocycloalkyl and C3-C5 cycloalkyl groups may be optionally substituted with one or more halogen, hydroxyl, cyano, oxo or amino groups. In a certain embodiment, the 3- to 5-membered heterocycloalkyl group may be aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl and tetrahydrofuranyl or C3-C5 cycloalkyl. In a certain embodiment, p may be an integer of 0, 1 or 2. In a certain embodiment, p may be an integer of 0 or 1.

[0067] In certain embodiments, R" can be halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH; azetidinyl or oxetanyl optionally substituted by hydroxy or oxo; cyclopropyl or cyclopropylmethyl optionally substituted by hydroxy or oxo.

[0068] In another embodiment, R" can be halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2; azetidinyl or oxetanyl optionally substituted by hydroxy or oxo; cyclopropyl or cyclopropylmethyl optionally substituted by hydroxy or oxo.

[0069] In certain embodiments, R" can be halogen, hydroxy, methyl, ethyl, hydroxymethyl, hydroxyethyl, aminomethyl, aminoethyl, trifluoromethyl, difluoromethyl, trifluoroethyl, difluoroethyl, methoxy, ethoxy, isopropoxy, trifluoromethoxy, difluoromethoxy, cyano, amino, oxo, -S-CH3, -S-CH2CH3, -SO2-CH3, -SO2-CH2CH3, -COOCH3, -COOCH2CH3, -COOCH2CH2CH3, -COOCH(CH3)2, -COOCH2CH(CH3) )2, -COOC(CH3)4, -COOH, -CONH2, -CH2NH2, -CH2CH2NH2, -CH2NHCOOCH3, -CH2NHCOOCH2CH3, -CH2NHCOOCH2CH2CH3, -CH2NHCOOCH(CH3)2, -CH2NHCOOCH2CH(CH3)2, -CH2NHCOOC(CH3)3, -CH2OH, -CH2CH2OH, azetidinyl, oxetanyl, cyclopropyl or cyclobutylmethyl.

[0070] In a certain embodiment, R a is -V-Cy2, and Having a structure selected from the group consisting of: Cy and Cy2, wherein each of them may be optionally substituted with R' and R":

[0071]

[0072]

[0073] In some embodiments, R 4 It can be hydrogen or C1-C3 alkyl.

[0074] In some embodiments, R 5 and R 6 Can be H, R 7 It may not exist, and the structure connected to the amide bond in Formula I may be the following structure:

[0075] (Wherein, n and m can be integers of 1 or 2, respectively.)

[0076] In another embodiment, R 5 and R 6 Can be expressed together as -(CH2) q -, and R 7 It may be absent, in which case the structure connected to the amide bond in Formula I may be the following structure:

[0077] (Wherein, n, m, and q can be integers of 1 or 2, respectively.)

[0078] In another embodiment, R 5 Can be H, and R 6 and R 7 Can be expressed together as -(CH2) r In this case, the structure connected to the amide bond in Formula I can be the following structure:

[0079] (Wherein, n, m, r, and l can be integers of 1 or 2, respectively.)

[0080] In a certain embodiment, the structure connected to the amide bond in Formula I includes isomers of the structure, for example, the following structure, but not limited thereto:

[0081]

[0082] In some embodiments, R 8 Can Wherein, Z can be -(CH2) s , and R 8 ' can be a hydroxyl group or a C1-C6 alkoxy group, and s can be an integer of 0 or 1. In a certain embodiment, s can be 0, and R 8 ' can be a hydroxyl group.

[0083] In the present invention, Formula I may be the following Formula IA-1 or IA-2:

[0084] [Formula IA-1]

[0085]

[0086] [Formula IA-2]

[0087]

[0088] in,

[0089] R 1 and R 2 Selected from hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl and C6-C 10 The group consisting of aryl groups, wherein the C1-C6 alkyl and C1-C6 alkoxy groups can each be independently optionally substituted by one or more halogen, hydroxyl, cyano or amino groups, and the C3-C8 cycloalkyl and C6-C 10 The aryl groups may each independently be optionally substituted with one or more halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;

[0090] R 3 for and

[0091] W, Cy, Ra, R 4 、R 8 , n, m, r and l are as defined above in Formula I. 1 、R 2 ,W,Cy,R a 、R 4 、R 8 The specific examples and embodiments described for , n, m, r, and l are also applicable to Formulas IA-1 and IA-2 as long as they are structurally acceptable.

[0092] In some embodiments of Formulas IA-1 and IA-2, R 1 It can be hydrogen, halogen, hydroxyl, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl) or -N(C1-C6 alkyl)2, wherein the C1-C6 alkyl and C1-C6 alkoxy can each be independently optionally substituted with one or more halogen, hydroxyl, cyano or amino. In a certain embodiment, R 1 It can be hydrogen, halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl or C1-C3 haloalkoxy. 1 It can be hydrogen, halogen, C1-C3 alkyl or C1-C3 haloalkyl.

[0093] In some embodiments, R 2 It can be hydrogen, halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C3-C6 cycloalkyl or phenyl, wherein the C1-C3 alkyl and C1-C3 alkoxy can each be independently optionally substituted with one or more halogen, hydroxy, cyano or amino. In a certain embodiment, the C3-C6 cycloalkyl and phenyl can be optionally substituted with one or more halogen, C1-C3 alkyl or C1-C3 haloalkyl. In a certain embodiment, R 2 It can be hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, cyclobutyl or phenyl.

[0094] In some embodiments, W may be -(CH2) o -、-(CH2) o -C≡C-, -C(O)-, -O-, -NH- or -N(C1-C3 alkyl)-. In one embodiment, W may be -(CH2) o-, -C(O)-, -O-, -NH- or -N(C1-C6 alkyl)-. In this case, the H in CH2 described in W may be optionally substituted with one or more halogens, hydroxyls or C1-C6 alkoxyls.

[0095] In some embodiments, Cy may be C6-C 10 Cy is phenyl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, or 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, and S. In certain embodiments, Cy is phenyl, 5- to 10-membered heteroaryl containing 1 or 2 nitrogen atoms, or 4- to 7-membered heterocycloalkyl containing 1 or 2 nitrogen atoms. For example, Cy is phenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl. In certain embodiments, Cy is phenyl, pyrazolyl, pyridinyl, pyrimidinyl, indolyl, or piperazinyl. In certain embodiments, Cy is phenyl, pyrazolyl, or piperazinyl.

[0096] The Cy may be optionally substituted with one or more R'. In some embodiments, R' may be halogen, hydroxy, cyano, amino, oxo, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NH-(C1-C3 alkyl) or -N(C1-C3 alkyl). In a certain embodiment, R' may be halogen, amino, C1-C3 alkyl or C1-C3 haloalkyl.

[0097] In some embodiments, R a Can be hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl or -V-Cy2. In a certain embodiment, R a It can be -V-Cy2.

[0098] In some embodiments, V may be absent or -NH-, -NHCH2-, -NHCH3-, -S-, -SO2-, -CH2-, -OCH2-, or -O-. In a certain embodiment, V may be absent or -CH2- or -O-.

[0099] In some embodiments, Cy2 can be selected from C6-C 10Cy2 can be selected from the group consisting of phenyl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O and S, C3-C8 cycloalkyl and C3-C8 cycloalkenyl. In a certain embodiment, Cy2 can be selected from the group consisting of phenyl, 5- to 10-membered heteroaryl containing 1 or 2 heteroatoms selected from N or O, 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N or O, C4-C7 cycloalkyl and C4-C7 cycloalkenyl.

[0100] In certain embodiments, Cy2 can be phenyl, furanyl, pyrazolyl, pyridinyl, pyrimidinyl, piperidinyl, morpholinyl, cyclohexyl or cyclohexenyl. In certain embodiments, Cy2 can be phenyl, furanyl, pyrazolyl, pyridinyl, morpholinyl, piperidinyl, cyclohexyl or cyclohexenyl.

[0101] The Cy2 may be optionally substituted with one or more R". In some embodiments, R" may be selected from halogen, hydroxyl, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH, 3 to 5 membered heterocycloalkyl containing 1 heteroatom selected from N, O and S, C3-C5 cycloalkyl and -(CH2) p -(C3-C5 cycloalkyl). In this case, the C1-C6 alkyl and C1-C6 alkoxy groups may be optionally substituted with one or more halogen, hydroxy, cyano or amino groups, and the 3 to 5 membered heterocycloalkyl and C3-C5 cycloalkyl groups may be optionally substituted with one or more halogen, hydroxy, cyano, oxo or amino groups.

[0102] In a certain embodiment, R "can be selected from halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2)p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH; azetidinyl or oxetanyl optionally substituted by hydroxy or oxo; and cyclopropyl or cyclopropylmethyl optionally substituted by hydroxy or oxo.

[0103] In some embodiments, R 4 It can be hydrogen or C1-C3 alkyl.

[0104] In some embodiments, the compound having Formula IA-1 or IA-2 above can be represented by Formula IA-3 or IA-4.

[0105] [Formula IA-3]

[0106]

[0107] [Formula IA-4]

[0108]

[0109] Among them, R 1 、R 2 、R 3 、R 4 and R 8 As defined above in Formulas IA-1 and IA-2.

[0110] In the present invention, the compound represented by formula I may be a compound represented by formula IB-1.

[0111] [Formula IB-1]

[0112]

[0113] in,

[0114] R 1 Selected from hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl and C6-C 10 The group consisting of aryl groups, wherein the C1-C6 alkyl and C1-C6 alkoxy groups can each be independently optionally substituted by one or more halogen, hydroxyl, cyano or amino groups, and the C3-C8 cycloalkyl and C6-C 10 The aryl groups may each independently be optionally substituted with one or more halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;

[0115] One or two carbon atoms in may be optionally substituted with halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy; and

[0116] W, Cy, R a 、R 4 、R 5 、R 6 、R 7 、R 8 , P, n, m and l are as defined in Formula I above.

[0117] Regarding W, Cy, and R in Formula I a 、R 4 、R 8 、R 6 、R 7 、R 8 The specific examples and embodiments described for , P, n, m and l are also applicable to Formula IB-1 as long as they are structurally acceptable.

[0118] In some embodiments, the compound having formula IB-1 can be represented by formula IB-2, IB-3, or IB-4:

[0119] [Formula IB-2]

[0120]

[0121] [Formula IB-3]

[0122]

[0123] [Formula IB-4]

[0124]

[0125] In some embodiments of Formulas IB-2, IB-3, and IB-4, R 1 It can be hydrogen, halogen, hydroxyl, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl) or -N(C1-C6 alkyl)2, wherein the C1-C6 alkyl and C1-C6 alkoxy can each be independently optionally substituted with one or more halogen, hydroxyl, cyano or amino. In a certain embodiment, R 1 It can be hydrogen, halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl or C1-C3 haloalkoxy.

[0126] In some embodiments, One or two carbon atoms in may be optionally substituted by halogen, C1-C3 alkyl or C1-C3 haloalkyl. One or two carbon atoms in the group may be optionally substituted with a C1-C3 alkyl group.

[0127] In some embodiments, W may be -(CH2) o -、-(CH2) o -C≡C-, -C(O)-, -O-, -NH- or -N(C1-C3 alkyl)-. In one embodiment, W may be -(CH2) o -or-(CH2) o -C≡C-. In this case, the H in the CH2 may be optionally substituted by one or more halogens, hydroxyls or C1-C6 alkoxyls.

[0128] In some embodiments, Cy can be selected from C6-C 10 In one embodiment, Cy is phenyl, or a 5- to 10-membered heteroaryl group containing 1 or 2 nitrogen atoms. In one embodiment, Cy is phenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, or indazolyl. In one embodiment, Cy is phenyl, pyridyl, pyrimidinyl, or indolyl.

[0129] The Cy may be optionally substituted with one or more R'. In some embodiments, R' may be halogen, hydroxy, cyano, amino, oxo, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NH-(C1-C3 alkyl) or -N(C1-C3 alkyl). In a certain embodiment, R' may be halogen, amino, C1-C3 alkyl or C1-C3 haloalkyl.

[0130] In some embodiments, R a Can be hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl or -V-Cy2. In this case, V can be absent or -NH-, -NHCH2-, -NHCH3-, -S-, -SO2-, -CH2-, -OCH2- or -O-. In certain embodiments, V can be absent or -CH2- or -O-. In certain embodiments, V can be absent or -CH2-.

[0131] In some embodiments, Cy2 can be selected from C6-C 10Cy2 may be phenyl or a 5- to 10-membered heteroaryl group containing 1 or 2 nitrogen atoms. In certain embodiments, Cy2 may be phenyl, pyrrolyl, furanyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, cyclopentyl, cyclohexyl, cyclopentenyl, or cyclohexenyl. In certain embodiments, Cy2 may be phenyl, pyrazolyl, pyridyl, or pyrimidinyl.

[0132] The Cy2 may be optionally substituted with one or more R". In some embodiments, R" may be selected from halogen, hydroxyl, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH, 3 to 5 membered heterocycloalkyl containing 1 heteroatom selected from N, O and S, C3-C5 cycloalkyl and -(CH2) p -(C3-C5 cycloalkyl). The C1-C6 alkyl and C1-C6 alkoxy groups may be optionally substituted with one or more halogen, hydroxy, cyano or amino groups, and the 3- to 5-membered heterocycloalkyl and C3-C5 cycloalkyl groups may be optionally substituted with one or more halogen, hydroxy, cyano, oxo or amino groups.

[0133] In a certain embodiment, R" can be selected from halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2; azetidinyl or oxetanyl optionally substituted by hydroxy or oxo; and cyclopropyl or cyclopropylmethyl optionally substituted by hydroxy or oxo.

[0134] In some embodiments, R 4 It can be hydrogen or C1-C3 alkyl.

[0135] In some embodiments, R 8 Can Wherein, Z can be -(CH2) s , and R 8 ' can be a hydroxyl group or a C1-C6 alkoxy group. In this case, s can be an integer of 0 or 1.

[0136] In certain embodiments, l, m, and n may each independently be an integer of 1 or 2. In certain embodiments, o and p may each independently be an integer of 0 to 2. In certain embodiments, q and r may each independently be an integer of 1 or 2. In certain embodiments, s may be an integer of 0 or 1.

[0137] In some embodiments, the compound having the above formula IB-1 can be represented by formula IB-5, IB-6, IB-7 or IB-8: [Formula IB-5]

[0138]

[0139] [Formula IB-6]

[0140]

[0141] [Formula IB-7]

[0142]

[0143] [Formula IB-8]

[0144]

[0145] Among them, R 1 ,W,Cy,R a 、R 4 and R 8 As defined in Formula IB-1.

[0146] In a certain embodiment, the compound of formula I of the present invention can be selected from the group consisting of the following compounds:

[0147]

[0148]

[0149]

[0150]

[0151]

[0152]

[0153]

[0154] In a certain embodiment, the compound of formula I of the present invention can be selected from the group consisting of the following compounds:

[0155]

[0156] definition

[0157] All technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art. Unless otherwise indicated, conventional measurement methods, preparation methods, conventional ingredients or substances are used based on conventional techniques such as pharmacology, pharmaceutical chemistry, mass spectrometry, NMR, HPLC, and biochemistry.

[0158] Unless otherwise indicated, in this disclosure and the appended claims, "or" and "and" mean "and / or." The terms "comprising" and "including" are open ended and mean that the compounds, compositions or methods may include additional features or components other than those listed.

[0159] The "*" at the end of a residue linker herein indicates the position at which it is attached to the rest of the compound.

[0160] In the present invention, the term "halogen" may be F, Cl, Br or I.

[0161] In the present invention, unless otherwise specified, the term "alkyl" refers to a straight chain or branched hydrocarbon group, which may be unsubstituted or substituted. 15 Alkyl, C1-C 12 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pent-1-yl, pent-2-yl, pent-3-yl, 3-methylbut-1-yl, 3-methylbut-2-yl, 2-methylbut-2-yl, 2,2,2-trimethylethan-1-yl, n-hexyl, n-heptyl, and n-octyl, and all possible isomers thereof.

[0162] In the present invention, unless otherwise indicated, the term "alkoxy" refers to a straight or branched hydrocarbon group, which may be unsubstituted or substituted, connected through an oxygen radical. Alkoxy groups may include, but are not limited to, methoxy, ethoxy, propoxy, and butoxy, or all possible isomers thereof, such as isopropoxy, isobutoxy, and tert-butoxy.

[0163] In the present invention, the term "cycloalkyl" refers to a saturated hydrocarbon ring having a specific number of carbon atoms as ring elements (i.e., C3-C8 cycloalkyl refers to a cycloalkyl group having 3, 4, 5, 6, 7 or 8 carbon atoms as ring elements). 15 Cycloalkyl, C3-C 13 Cycloalkyl, C3-C 11 The cycloalkyl group may be a C3-C8 cycloalkyl group, a C3-C6 cycloalkyl group or a C3-C5 cycloalkyl group, and the cycloalkyl group having a polycyclic hydrocarbon ring may have two or more bridged or fused cycloalkyl groups.

[0164] In the present invention, the term "cycloalkenyl" refers to a non-aromatic, unsaturated monocyclic or polycyclic hydrocarbon ring having at least one carbon-carbon double bond and containing a specific number of carbon atoms. For example, cycloalkenyl includes, but is not limited to, cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, cyclohexa-1,3-dien-1-yl, and the like.

[0165] In the present invention, the term "hydroxyl" refers to an -OH group.

[0166] In the present invention, the term "oxo" refers to a substituent having a =0 structure, wherein a double bond exists between the atom and the oxygen atom.

[0167] In the present invention, the term "haloalkyl" refers to an alkyl group in which at least one hydrogen atom is replaced by a halogen atom. In some embodiments, 1, 2, or 3 of the hydrogen atoms in the alkyl group may be replaced by halogen atoms. In certain embodiments, the hydrogen atoms may be replaced by the same halogen atom (e.g., fluorine), or by a combination of different halogen atoms (e.g., fluorine and chlorine).

[0168] In the present invention, the term "haloalkoxy" refers to an alkoxy group in which at least one hydrogen atom is substituted by a halogen atom, and the above description of "haloalkyl" also applies to "haloalkoxy".

[0169] In the present invention, the term "aryl" refers to a monocyclic or polycyclic aromatic hydrocarbon group. The adjacent carbon atoms of the aryl group have alternating (resonant) double bonds, and it can also include forms in which two or more rings are simply connected to each other (pendant) or fused. The aryl group can be, for example, C6-C 14 Aryl, C6-C 10 Aryl or C6-C9 aryl, and may include, but is not limited to, for example, phenyl, biphenyl, naphthyl, toluoyl, naphthyl, anthracenyl or all possible isomers thereof.

[0170] In the present invention, the term "heteroaryl" refers to a heterocyclic aromatic group containing at least one heteroatom selected from B, N, O, S, P(=O), Si and P as a ring-forming atom. The heteroaryl group may also include a form in which two or more rings are simply linked to each other (pendant) or fused.

[0171] In some embodiments, the heteroaryl group may contain 1 to 4, 1 to 3, 1 or 2, or 1 heteroatom selected from N, O, and S. In a certain embodiment, the heteroaryl group may contain 1 to 3 N, 1 or 2 N, or 1 N. In some embodiments, the heteroaryl group may contain 4 to 14, 5 to 10, or 5 to 6 ring atoms.

[0172] Examples of monocyclic heteroaryl groups may include, but are not limited to, thienyl, furyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like. Examples of bicyclic heteroaryl groups may include indolyl, isoindolyl, indazolyl, indolizinyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, benzotriazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, purinyl, phthalazinyl, pteridinyl, furopyridinyl, oxochromenyl, dioxoisoindolinyl, imidazopyridinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrazolopyridinyl and the like, but are not limited thereto.

[0173] In the present invention, unless otherwise specified, the term "heterocycloalkyl" refers to a monocyclic or polycyclic, saturated or partially unsaturated ring system containing at least one heteroatom selected from B, N, O, S, P(=O), Si and P and having the specified number of ring elements (i.e., a 3- to 7-membered heterocycloalkyl refers to a heterocycloalkyl having 3, 4, 5, 6 or 7 ring elements, including heteroatoms). A polycyclic heterocycloalkyl may have two or more bridged or fused heterocycloalkyl groups.

[0174] In some embodiments, the heterocycloalkyl group may contain 1 to 4, 1 to 3, 1 or 2, or 1 heteroatom selected from N, O, and S. In a certain embodiment, the heterocycloalkyl group may contain 1 to 3 N, 1 or 2 N, or 1 N. In some embodiments, the heterocycloalkyl group may contain 3 to 7, 3 to 6, 4 to 6, 4 to 10, or 4 to 14 ring atoms.

[0175] For example, heterocycloalkyl groups include aziridinyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, sulfolane, dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolinyl, thiazolinyl, thiazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, isoxazolinyl, isoxazolidinyl, triazolinyl, triazolidinyl, tetrazolinyl, tetrazolidinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, dioxacycloalkyl, tetrahydrotriazinyl, hexahydrotriazinyl, morpholinyl, thiomorpholinyl, piperidinyl, dihydropyridinyl, tetrahydro Pyridyl, piperazinyl, tetrahydropyrimidinyl, dihydropyrimidinyl, dihydropyridazinyl, tetrahydropyridazinyl, tetrahydrooxazinyl, hexahydroazepinyl, perhydroazepinyl, perhydrooxepanyl, indolinyl, isoindolinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzoxazolyl, dihydrobenzothiazolyl, chromanyl, chromanyl, azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.2.1]heptyl, 7-azabicyclo[4.1.0]-heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, tropanyl, 2-oxa-6-azaspiro[3.3]heptyl and N-oxides, sulfones or sulfoxides thereof, but are not limited thereto.

[0176] In some embodiments, heterocycloalkyl groups include aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, pyrazolidinyl, imidazolidinyl, thiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, or morpholinyl.

[0177] In the present invention, the term "substituted" group refers to a group in which one or more hydrogen atoms are replaced by one or more non-hydrogen atom groups, provided that the valence requirements are met and the substitution produces a chemically stable compound. In the present invention, unless explicitly stated as "unsubstituted", all substituents should be interpreted as being able to be unsubstituted or substituted. Without limiting specific substituents, the "optionally substituted" parts mentioned herein include parts that are unsubstituted or substituted by any substituent, for example, including halogen, hydroxyl, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl, C6-C 14 In one embodiment, the "optionally substituted" moiety includes a moiety substituted with halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl) or -N(C1-C6 alkyl)2.

[0178] In the present invention, when the combination of substituents mentioned is one group, for example, arylalkyl, cycloalkylalkyl, etc., the last mentioned group contains the atom attached to the terminal end of the molecule.

[0179] In the present invention, the numerical range expressed using the term "to" means a range including the numerical values ​​described before and after the term "to" as the lower limit and the upper limit, respectively.

[0180] In the present invention, the term "solvate" may refer to a compound of the present invention or a salt thereof that contains a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Thus, the preferred solvent may be any volatile, non-toxic and / or suitable solvent for human administration.

[0181] In the present invention, the term "stereoisomer" may refer to a compound of the present invention or a salt thereof that has the same chemical formula or molecular formula but is optically or stereologically different, specifically, a diastereomer, an enantiomer or a geometric isomer.

[0182] In some embodiments, the compounds of the present invention may be in the form of racemates, single enantiomers, mixtures of enantiomers, single diastereomers, mixtures of diastereomers, etc., containing one or more asymmetric centers. In certain embodiments, due to the limited rotation or nature of the asymmetric center, the compounds of the present invention may be in the form of enantiomers or diastereomers.

[0183] When two or more asymmetric centers exist in the compounds of the present invention, the chemical structures disclosed herein may exist as several diastereomers and enantiomers, and pure isomers, separated isomers, partially pure isomers, racemic mixtures, etc. are all within the scope of the present invention.

[0184] The purification of isomers and separation of isomeric mixtures can be achieved by standard techniques known in the art. For example, diastereomeric mixtures can be separated into their individual diastereomers by chromatography or crystallization, and racemates can be separated into their individual enantiomers by resolution or chromatography on a chiral phase.

[0185] In addition, when the compounds of the present invention contain groups capable of tautomerism, all tautomeric forms are included within the scope of the present invention. For example, 2-hydroxypyridine can include 2-pyridone, and all these isomeric forms are included in the present invention.

[0186] As used herein, "pharmaceutically acceptable salts" may include acid or base salts of the parent compound, and may also include inorganic or organic acid salts of basic residues such as amines, and alkali or organic salts of acidic residues such as carboxylic acids, but are not limited thereto.

[0187] For example, pharmaceutically acceptable salts of the compounds of the present invention can be formed from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. In certain embodiments, pharmaceutically acceptable salts of the present invention include inorganic base addition salts, such as lithium salts, sodium salts, potassium salts, magnesium salts, calcium salts, aluminum salts, ammonium salts, copper salts, iron salts, ferrous salts, manganese salts, zinc salts, etc. In certain embodiments, pharmaceutically acceptable salts of the present invention can include organic base addition salts, such as salts derived from arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, isopropylamine, lysine, meglumine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, dicyclohexylamine, and tris(hydroxymethyl)methylamine.

[0188] In addition, the compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. For example, the salts can be salts derived from hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, and the like.

[0189] Pharmaceutically acceptable salts of the compounds can be prepared, for example, by dissolving the compound of Formula I in a water-miscible organic solvent, such as acetone, methanol, ethanol, acetonitrile, and the like, and adding an excess of an organic acid or an acidic aqueous solution of an inorganic acid, followed by precipitation or crystallization. Subsequently, after evaporating the solvent or excess acid from the mixture, the mixture can be dried to obtain an addition salt or filtered to precipitate a salt.

[0190] On the other hand, the acid addition salt forms of the present invention can be readily converted into the free base form by treatment with an appropriate base, and the base addition salt forms can be readily converted into the free acid form by treatment with an appropriate acid.

[0191] Conventional preparation methods of compounds

[0192] On the other hand, the compounds can be prepared by chemical modifications well known to those skilled in the art of organic / pharmaceutical chemistry, a representative method of which is shown below.

[0193] The following general reaction schemes are general illustrations of representative preparation methods for compounds of Formula I. One of ordinary skill in the art will be able to readily prepare compounds of Formula I based on the preparation methods specifically disclosed in the Examples herein by selecting starting materials, reaction temperatures, reaction conditions, catalysts, solvents, processing methods, etc., appropriate for the desired compound.

[0194] For example, compounds of formula I having a thiophene ring can be prepared according to the following reaction schemes 1 to 5:

[0195] [Reaction Scheme 1]

[0196]

[0197] [Reaction Scheme 2]

[0198]

[0199] [Reaction Scheme 3]

[0200]

[0201] [Reaction Scheme 4]

[0202]

[0203] [Reaction Scheme 5]

[0204]

[0205] For example, the compound of formula I having a 4H-thieno[3,2-b]pyrrole fused ring can be prepared according to the following reaction scheme 6: [Reaction Scheme 6]

[0206]

[0207] When preparing compounds according to the above reaction schemes 1 to 6, suitable amino-cycloalkyl-carboxylate compounds such as 3-aminocyclobutane-1-carboxylic acid methyl ester, 3-aminobicyclo[1.1.1]pentane-1-carboxylic acid methyl ester, 4-aminobicyclo[1.1.1]octane-1-carboxylic acid methyl ester, etc. can be used instead of 3-aminobicyclo[1.1.1]pentane-1-carboxylic acid methyl ester hydrochloride to prepare compounds in which various cyclic structures are bonded to amide bonds.

[0208] The compound of the present invention, its solvate, stereoisomer or pharmaceutically acceptable salt exhibits tumor growth inhibitory effect.

[0209] In a certain embodiment of the present invention, the compound is administered to mouse-derived colorectal cancer and lung cancer tumor models, and as a result, tumor growth is inhibited compared with the control group.

[0210] anticancer agents

[0211] The anticancer agent of the present invention may be selected from the group consisting of chemotherapeutic agents, targeted anticancer agents, oncolytic viruses, antibody therapeutic agents, cell therapeutic agents, immune checkpoint inhibitors, and combinations thereof.

[0212] The term "chemotherapeutic agent" as used herein is also referred to as an antineoplastic agent or a cytotoxic agent. It is a general term for drugs that exhibit anticancer activity primarily by directly acting on DNA, blocking DNA replication, transcription, and translation processes, or interfering with the synthesis of nucleic acid precursors in metabolic pathways, and inhibiting cell division. Antineoplastic drugs exhibit cytotoxicity by acting on normal cells as well as tumor cells. Chemotherapeutic agents can be used for maintenance therapy. In addition, the term "maintenance therapy" as used herein refers to the use of drugs to treat cancer after initial anticancer treatment, and refers to a treatment method performed to prevent or delay cancer recurrence.

[0213] Specifically, the chemotherapeutic drug can be any one selected from the group consisting of an alkylating agent, a microtubule inhibitor, an antimetabolite, and a topoisomerase inhibitor. The alkylating agent can be any one selected from the group consisting of mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine, procarbazine, busulfan, streptozotocin, carmustine, lomustine, dacarbazine, cisplatin, carboplatin, and oxaliplatin. The microtubule inhibitor can be any one of docetaxel, paclitaxel, vinblastine, oncovin and navelbine. The antimetabolite can be any one selected from the group consisting of fluorouracil, capecitabine, cytarabine, gemcitabine, fludarabine, methotrexate, pemetrexed and mercaptopurine. The topoisomerase inhibitor can be any one selected from the group consisting of topotecan, irinotecan, etoposide, bleomycin, adriamycin and cerubidine.

[0214] As used herein, the term "targeted anticancer agent" refers to a therapeutic agent that specifically kills cancer cells by targeting specific proteins or gene changes that occur only in cancer cells, blocking signals involved in cancer growth and progression. These agents are categorized as monoclonal antibodies, which act extracellularly, and small molecules, which act intracellularly. Monoclonal antibodies are anticancer agents that block cancer cell-inducing signals transmitted to the outside of cells, acting on activation signals related to proliferation and cell death. Small molecules, on the other hand, act on the complex signal transduction pathways that occur within cells.

[0215] Specifically, the proteins to be targeted can be EGFR, VEGFR, CD20, CD38, RNAK-L, BTK, Bcr-abl, PDGFR / FGFR family, MEK / RAF / KRAS, HER2 / Neu, ubiquitin, JAK, ALK, PARP, TGFβRI, proteasome, Bcl-2, C-Met, VR1, VR2, VR3, c-kit, AXL, RET, Braf, DNMT, CDK4 / 6, STING, etc.

[0216] The targeted anticancer agent may be selected from the group consisting of cetuximab, trastuzumab, pertuzumab, gefitinib, erlotinib, osimertinib, panitumumab, axitinib, lenvatinib, bevacizumab, ramucirumab, aflibercept, rituximab, obituzumab, and selenostatin. nutuzumab), daratumumab, denosumab, ibrutinib, dasatinib, nilotinib, imatinib, bosutinib, galunisertib, vactosertib, nintedanib, sunitinib, sorafenib, cabozantinib, regorafenib, masitinib ib), semaxanib, tivozanib, vandetanib, pazopanib, trametinib, dabrafenib, sotorasib, afatinib, lapatinib, neratinib, lenalidomide, ixazomib, ruxolitinib, lestaurtinib, pacritinib , cobimetinib, selumetinib, binimetinib, alectinib, crizotinib, venetoclax, bemcentinib, gilteritinib, selpercatinib, pralsetinib, vemurafenib, olaparib, talazoparib, niraparib,Any one of the group consisting of rucaparib, azacitidine, decitabine, guadecitabine, abemaciclib, ribociclib, palbociclib, CDN, SB11285 and DMXAA.

[0217] The term "epidermal growth factor receptor (EGFR)" as used herein is a cell membrane receptor that regulates cell growth, division, survival and death, and EGFR expression is increased in tumor tissues of various cancers. Tumor tissues in which EGFR is increased are known to have higher invasiveness, metastasis and resistance to anticancer agents. EGFR inhibitors are substances that inhibit EGFR, and in one embodiment can be cetuximab, trastuzumab, pertuzumab, gefitinib, erlotinib, osimertinib or panitumumab.

[0218] The term "vascular endothelial growth factor receptor (VEGFR)" as used herein is a cell membrane receptor for vascular endothelial growth factor that induces angiogenesis. VEGFR inhibitors inhibit tumor growth and metastasis by inhibiting angiogenesis. In one embodiment, the VEGF inhibitor or VEGFR inhibitor can be axitinib, lenvatinib, bevacizumab, ramucirumab, or aflibercept.

[0219] The term "CD20 (B lymphocyte antigen CD20)" as used herein refers to a protein expressed on the surface of B cells and is a target protein for the treatment of B cell lymphoma. Inhibitors targeting CD20 may be rituximab or obinutuzumab.

[0220] The term "CD38 (cluster of differentiation 38)" used herein is a protein that regulates cell proliferation and death and serves as a receptor for a signal transduction system in immune cells. An inhibitor targeting this protein may be daratumumab.

[0221] The term "RANK-L (receptor activator of nuclear factor kappa-β ligand)" as used herein refers to the RANK receptor expressed on the cell surface of osteoclasts. Upon binding to the ligand, it becomes activated, causing bone destruction. RANK-L inhibitors, specifically denosumab, are primarily used in cancer patients with bone metastases or osteoporosis.

[0222] The term "BTK (Bruton's tyrosine kinase)" as used herein is an enzyme involved in B cell proliferation, which, when overexpressed, can develop into blood cancers. In one embodiment, the inhibitor targeting BTK can be ibrutinib.

[0223] The term "Bcr-abl" used herein is a fusion protein that is highly expressed in patients with chronic myeloid leukemia. It is known that this protein can induce abnormal proliferation of blood cells. Specifically, the inhibitor of this protein can be dasatinib, nilotinib, imatinib or bosutinib.

[0224] The term "tumor growth factor β receptor (TGFβR)" as used herein is a cell membrane receptor for tumor growth factor, which regulates the growth, migration, differentiation, and death of epithelial and hematopoietic cells. Inhibitors targeting TGFβR may be galunisertib or vactosertib, but are not limited thereto.

[0225] The term "PDGFR (platelet-derived growth factor receptor)" as used herein is a cell membrane receptor for PDGF, which is often expressed in cancer cells and is known to participate in angiogenesis to regulate cancer growth, metastasis, and drug resistance. FGFR (fibroblast growth factor receptor) is a receptor for fibroblast growth factor (FGF), and regulates various biological processes including cell growth, differentiation, migration, etc. FGFR genes often mutate, and these mutants are common in breast cancer, uterine cancer, ovarian cancer, cervical cancer, etc. The inhibitor of targeting PDGFR or FGFR can be nintedanib, sunitinib, sorafenib, cabozantinib, lenvatinib, regorafenib, masitinib, semaxanib, tivozanib, vandetanib, axitinib, or pazopanib.

[0226] The term "MEK / RAF / KRAS" as used herein refers to intracellular signal transduction mediators involved in cell proliferation, cell cycle regulation, cell survival, angiogenesis, cell migration, etc., and is overactivated in cancer cells. Inhibitors targeting MEK / RAF / KRAS can be trametinib, dabrafenib, or sotorasib.

[0227] As used herein, the term "HER-2 / neu (human epidermal growth factor receptor 2)" regulates cell proliferation by activating PI3K / AkT. It is overexpressed in metastatic breast cancer and ovarian cancer, among other conditions, and is known to induce resistance to anticancer agents. Anticancer agents targeting HER2 / neu may include trastuzumab, afatinib, lapatinib, or neratinib.

[0228] The term "ubiquitin" as used herein maintains cellular homeostasis (ubiquitin-proteasome system, UPS) by binding to other proteins and inducing proteolysis by the proteasome (a proteolytic enzyme). Abnormal expression or activity of the UPS has been observed in a variety of tumors, and UPS inhibitors have shown anti-cancer activity. Specifically, inhibitors targeting ubiquitin or the proteasome can be lenalidomide or ixazomib.

[0229] The term "JAK (Janus kinase)" as used herein refers to an upstream protein of STAT, a transcription factor that regulates cell proliferation, cell survival, cell migration, and immune response. JAK inhibitors are known to reduce cell proliferation and induce cell death by inhibiting STAT activity. Inhibitors targeting JAK may include ruxolitinib, lestaurtinib, or pacritinib.

[0230] As used herein, the term "MAP2K (mitogen-activated protein kinase)" is an intracellular signaling mediator that participates in cell proliferation, cell cycle regulation, cell survival, angiogenesis, cell migration, etc. through phosphorylation of MAPK and is overactivated in cancer cells. MAP2K-targeting inhibitors may include cobimetinib, selumetinib, trametinib, or binimetinib.

[0231] The term "ALK (anaplastic lymphoma kinase)" as used herein is a signal transduction mediator that promotes cell proliferation, cell migration, and angiogenesis and inhibits cell death, and is overactivated in various cancer tissues. The inhibitor targeting ALK may be alectinib or crizotinib.

[0232] The term "Bcl-2" as used herein is a protein that inhibits cell death and is overexpressed or overactivated in various cancer tissues. An inhibitor targeting Bcl-2 may be venetoclax.

[0233] The term "C-Met" used herein is a receptor for hepatocyte growth factor (HGF) and activates signal transduction related to cell growth, formation, motility, survival, angiogenesis, etc. The anticancer agent targeting C-Met may be crizotinib or cabozantinib.

[0234] As used herein, the term "VR (vanilloid receptor), also known as TRPV (transient receptor potential vanilloid), exists in any form of VR1, VR2, VR3, VR4, VR5, and VR6. VR is known to regulate cancer cell proliferation, death, migration, invasion, and angiogenesis at every stage of the cancer progression process.

[0235] The term "c-kit," as used herein, is also referred to as CD117 and induces signal transduction that activates cell survival, proliferation, and differentiation. c-kit is a proto-oncogene, and overexpression or mutation of this gene is associated with the development of cancer.

[0236] As used herein, the term "AXL (tyrosine protein kinase receptor UFO)" refers to a tyrosine kinase receptor present on the cell surface that mediates signal transduction involved in cell proliferation and survival. It is known to be associated with resistance to anticancer agents in anticancer therapy. In one embodiment, the anticancer agent targeting AXL can be bemcentinib or gilteritinib.

[0237] The term "RET (rearranged during transfection)" as used herein is a receptor that mediates signals involved in cell proliferation, cell death, and survival, and mutations in RET are known to be involved in the development of cancer. The inhibitor targeting RET may be selpercatinib or pralsetinib, but is not limited thereto.

[0238] The term "Braf" as used herein is a MAPK signal transduction mediator involved in cell proliferation, cell cycle regulation, cell survival, angiogenesis, cell migration, etc., and its genetic mutation is observed in cancer cells. The inhibitor targeting Braf may be vemurafenib.

[0239] The term "PARP (poly (ADP ribose) polymerase)" as used herein is a protein that is activated by recognizing damaged DNA in the cell nucleus and then activating proteins involved in DNA repair. Inhibitors targeting PARP inhibit the proliferation of cancer cells by inhibiting DNA repair in cancer cells. In certain embodiments, the inhibitor targeting PARP can be olaparib, talazoparib, niraparib, or rucaparib.

[0240] The term "DNA methyltransferase (DNMT)" as used herein is an enzyme that attaches methyl groups to histone proteins that encase DNA, inhibiting gene expression through this process. Inhibitors targeting DNMT exhibit anti-cancer activity by inhibiting hypermethylation of cancer suppressor genes and inducing normal expression of cancer suppressor genes. In certain embodiments, the inhibitor targeting DNMT can be azacitidine, decitabine, or guadecitabine.

[0241] The term "CDK (cyclin-dependent kinase) 4 / 6" as used herein is a protein that promotes cell growth by regulating the cell cycle and is overactivated during the development and progression of various malignant tumors. Inhibitors targeting CDK4 / 6 exhibit anti-cancer activity by inhibiting the cell cycle of cancer cells, inhibiting cell proliferation, and inducing cell death. Inhibitors targeting CDK4 / 6 can be abemaciclib, ribociclib, or palbociclib.

[0242] As used herein, the term "STING (stimulator of interferon genes)" refers to an in vivo sensor that recognizes DNA fragments from cancer cells and activates immune cells, such as dendritic cells, by stimulating interferon genes. STING agonists exhibit immune-enhancing effects and inhibit cancer angiogenesis. For example, STING agonists can include CDNs, SB11285, DMXAA, and the like.

[0243] The term "oncolytic virus therapeutic agent" as used herein is a therapeutic agent that kills cancer by inserting a specific gene that targets cancer cells into a virus that can proliferate and be infectious. The oncolytic virus therapeutic agent may be Talimogene Laherparepvec.

[0244] The term "antibody therapeutic agent" used herein refers to a therapeutic agent that exhibits an anti-cancer effect using an antibody that recognizes a specific protein of cancer cells as an antigen. The antibody therapeutic agent can be cetuximab, trastuzumab, emtansine, emtansine, rituximab, ibritumomab, tositumomab, brentuximab, ofatumumab, obinutuzumab, necitumumab, bevacizumab, ramucirumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, ipilimumab, etc.

[0245] The term "immune cell therapeutic agent" as used herein is a therapeutic agent that shows an anti-cancer effect by activating the immune response in the body using immune cells such as dendritic cells, natural killer cells, T cells, etc. Immune cell therapeutic agents are used by extracting and enhancing immune cells in the body or genetically modifying them and then injecting them back into the body. Representative immune cell therapeutic agents can include T cell receptor-modified T cells (TCR-T), chimeric antigen receptor-modified T cells (CAR-T), etc. Specifically, it can be tisagenlecleucel or axicabtageneciloleucel, but is not limited thereto.

[0246] The term "immune checkpoint inhibitor" as used herein is a substance that inhibits the activity of immune checkpoint proteins, which inhibits the differentiation, proliferation and activity of immune cells, and is known to eliminate cancer cells by preventing cancer cells from playing a role in escaping the immune system. Immune checkpoint inhibitors can be any one of the groups selected from anti-CTLA-4 antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-PDP-L2 antibodies, anti-B7-H4 antibodies, anti-HVEM antibodies, anti-TIM3 antibodies, anti-GAL9 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, anti-KIR antibodies, anti-BTLA antibodies and anti-TIGIT antibodies. In a certain embodiment, immune checkpoint inhibitors can be ipilimumab, pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab and durvalumab, etc., but are not limited thereto.

[0247] The term "ADC (antibody-drug conjugate)" as used herein refers to a therapeutic agent that exhibits a high degree of anti-cancer activity by chemically combining an antibody and a cytotoxic drug for targeted delivery. Examples include gemtuzumab-ozogamicin, brentuximab-vedotin, trastuzumab-emtansine, inotuzumab-ozogamicin, and eribulin-mesylate.

[0248] Anticancer agents may include one or more anticancer agents. Specifically, the compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof can be used together with two anticancer agents. For example, two anticancer agents can be chemotherapeutics and targeted anticancer agents; chemotherapeutics and oncolytic viruses; targeted anticancer agents and antibody therapeutics; chemotherapeutics and cell therapeutics; or chemotherapeutics and immune checkpoint inhibitors. In addition, two anticancer agents can be targeted anticancer agents and oncolytic viruses; targeted anticancer agents and antibody therapeutics; targeted anticancer agents and cell therapeutics; or targeted anticancer agents and immune checkpoint inhibitors. In addition, two anticancer agents can be oncolytic viruses and antibody therapeutics; oncolytic viruses and cell therapeutics; and oncolytic viruses and immune checkpoint inhibitors. In addition, two anticancer agents can be antibody therapeutics and cell therapeutics; or antibody therapeutics and immune checkpoint inhibitors.

[0249] The compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof can be used together with three anticancer agents. In addition to the two anticancer agents, a different anticancer agent can be further included and used.

[0250] According to one embodiment, the compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof can be used together with two or more chemotherapeutic agents and immune checkpoint inhibitors. For example, the two or more chemotherapeutic drugs can include an alkylating agent and an antimetabolite.

[0251] The compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof can be used together with four anticancer agents. In addition to the three anticancer agents, different anticancer agents can be further included and used.

[0252] The compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof can be used together with five anticancer agents. In addition to the four anticancer agents, different anticancer agents can be further included and used.

[0253] The compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof can be used together with six anticancer agents.

[0254] The compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof can be used in combination with an anti-cancer vaccine.

[0255] The term "anti-cancer vaccine" as used herein refers to an active immunotherapy that activates the immune system by administering tumor-specific antigens (TSAs) harbored by cancer cells to cancer patients, thereby enhancing the body's immune function and removing cancer cells. Depending on the type of antigen and the method of antigen delivery, anti-cancer vaccines can include DNA vaccines, peptide vaccines, cell vaccines, and the like. Cell vaccines and DNA vaccines developed by introducing antigens are currently being developed.

[0256] The compound, solvate, stereoisomer or pharmaceutically acceptable salt thereof can be used in combination with an anticancer agent and an anticancer vaccine. Here, the compound and the anticancer agent are the same as described above.

[0257] Medical applications, pharmaceutical compositions, and methods of administration

[0258] The cancer can be, but is not limited to, squamous cell carcinoma, basal cell carcinoma, glioblastoma, bone cancer, gastric cancer, kidney cancer, lung cancer, bladder cancer, prostate cancer, breast cancer, prostate cancer, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, head and neck cancer, renal cell carcinoma, esophageal cancer, pancreatic cancer, brain cancer, gastrointestinal cancer, liver cancer, leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, colorectal cancer, bile duct cancer, choriocarcinoma, oral cancer, neuroblastoma, skin cancer, testicular cancer, stromal tumor, germ cell tumor, or thyroid cancer.

[0259] Here, the disease associated with overexpression of prostaglandin E2 and / or overexpression of prostaglandin E2 receptors, such as cancer, may be caused by overexpression or overactivation of prostaglandin E2 and / or prostaglandin E2 receptors.

[0260] As used herein, the term "prevent" refers to preventing a disease, such as preventing a disease, condition or disorder from occurring in a subject who may be susceptible to the disease, condition or disorder but who has not yet experienced or displayed the pathology or signs of the disease.

[0261] In the present invention, the term "treating" refers to inhibiting the disease, e.g., inhibiting the disease, condition or disorder in a subject experiencing or exhibiting the pathology or signs of the disease, condition or disorder, i.e., preventing the pathology and / or signs from further developing, or ameliorating the disease, e.g., improving the disease, condition or disorder in a subject experiencing or exhibiting the pathology or signs of the disease, condition or disorder, i.e., reversing the pathology and / or signs, e.g., reducing the severity of the disease.

[0262] In certain embodiments, the compounds as shown in Formula I, IA-1, IA-2, IA-3, IA-4, IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7 or IB-8 exhibit effective inhibitory activity on prostaglandin E2 receptors such as EP2 and / or EP4, and can exert a therapeutic effect by regulating the activity of prostaglandin E2 through the antagonistic effect on prostaglandin E2 receptors as described above.

[0263] According to a certain embodiment of the present invention, when the compound and anti-PD-1 antibody are administered in combination to a tumor animal model transplanted with mouse-derived colorectal cancer, an enhanced anti-cancer effect is exhibited compared to the administration of the compound or anti-PD-1 antibody alone.

[0264] Furthermore, according to a certain embodiment of the present invention, when the compound, a chemotherapeutic agent, and an anti-PD-1 antibody are administered in combination to a tumor animal model transplanted with mouse-derived lung cancer, an enhanced anti-cancer effect is exhibited compared to the standard treatment method of administering a chemotherapeutic agent and an anti-PD-1 antibody in combination.

[0265] Therefore, a pharmaceutical composition comprising as an active ingredient a compound represented by Formula I, IA-1, IA-2, IA-3, IA-4, IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7 or IB-8, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof; and an anticancer agent can be used to treat cancer.

[0266] In one embodiment, the pharmaceutical composition may comprise conventional pharmaceutically acceptable carriers, excipients, or additives. The pharmaceutical composition may be formulated according to conventional methods and may be prepared into various oral dosage forms, such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions, or parenteral dosage forms, such as intramuscular, intravenous, or subcutaneous injections.

[0267] When the pharmaceutical composition is prepared as an oral preparation, examples of the additives or carriers used may include cellulose, calcium silicate, corn starch, lactose, sucrose, glucose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers, diluents, etc. When the pharmaceutical composition of the present invention is prepared as an injection, the additives or carriers may include water, physiological saline, glucose aqueous solution, similar sugar aqueous solution, alcohol, glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester, glyceride, surfactant, suspending agent, emulsifier, etc.

[0268] The dosage of the pharmaceutical composition is the amount of effective treatment or prevention for the subject or patient, and can be administered orally or parenterally as needed. When administered orally, the amount of 0.01 to 1000 mg per kg body weight per day, more specifically, 0.1 to 300 mg per kg body weight, is administered one to several times based on the active ingredient, or when administered parenterally, the amount of 0.01 to 100 mg per kg body weight per day, more specifically, 0.1 to 50 mg per kg body weight, is administered based on the active ingredient. The dosage of a specific subject or patient should be determined based on several relevant factors such as body weight, age, sex, the patient's health status, diet, administration time, administration method, severity of the disease, and it should be understood that the dosage can be appropriately increased or decreased by an expert. The above dosage is not intended to limit the scope of the present invention in any way. A physician or veterinarian of ordinary skill in the art can easily determine and prescribe the pharmaceutical composition of the effective amount required for the prescription. For example, the dosage of the compound of the present invention used in the pharmaceutical composition prescribed by a physician or veterinarian can start at a level lower than that required to achieve the desired therapeutic effect, and can be gradually increased until the desired effect is achieved.

[0269] In certain embodiments, the pharmaceutical composition includes within its scope a pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to a certain embodiment as an active ingredient, alone or in combination with a pharmaceutical carrier. The term "therapeutically effective amount" or "effective amount" refers to an amount sufficient to produce a beneficial or desired clinical result, such as an amount sufficient to alleviate, improve, stabilize, reverse, slow or delay the progression of a disease.

[0270] Optionally, the compound according to a certain embodiment can be administered alone or in combination with other anticancer agents simultaneously, separately or sequentially.

[0271] In another aspect, a method for preventing or treating cancer is provided, comprising administering to a subject a pharmaceutical composition comprising, as an active ingredient, a compound of Formula I, IA-1, IA-2, IA-3, IA-4, IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7, or IB-8, a solvate, stereoisomer, or pharmaceutically acceptable salt thereof; and an anticancer agent. Terms and elements referred to in the description of the method are the same as those described above.

[0272] The administration may be oral or parenteral. When administered orally, the dosage is 0.01 to 1000 mg per kg body weight per day, more specifically 0.1 to 300 mg per kg body weight, based on the active ingredient, administered in one or several doses, or when administered parenterally, the dosage is 0.01 to 100 mg per kg body weight per day, more specifically 0.1 to 50 mg per kg body weight, based on the active ingredient. The dosage for a specific subject or patient should be determined based on several relevant factors such as body weight, age, sex, patient's health status, diet, administration time, administration method, severity of the disease, and may be appropriately increased or decreased by a specialist.

[0273] In the present invention, the term "subject" refers to a subject in need of treatment or prevention of a disease, and more specifically refers to mammals such as humans or non-human primates, mice, dogs, cats, horses and cows.

[0274] In another aspect, a pharmaceutical composition for preventing or treating cancer is provided, comprising as an active ingredient a compound of Formula I, IA-1, IA-2, IA-3, IA-4, IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7, or IB-8, a solvate, stereoisomer, or pharmaceutically acceptable salt thereof; and an anticancer agent. Terms and elements used in the description of the method are the same as those described above.

[0275] In another aspect, a pharmaceutical composition is provided for use in preparing a medicament for preventing or treating cancer, the pharmaceutical composition comprising as an active ingredient a compound of Formula I, IA-1, IA-2, IA-3, IA-4, IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7, or IB-8, a solvate, stereoisomer, or pharmaceutically acceptable salt thereof; and an anticancer agent. Terms and elements referred to in the description of the method are the same as those mentioned above.

[0276] Reagent test kit

[0277] In another aspect of the present invention, a kit for preventing or treating cancer is provided, comprising as an active ingredient the compound, a solvate, stereoisomer, or pharmaceutically acceptable salt thereof; and an anticancer agent. The terms or elements mentioned in the description of the kit are the same as those mentioned above.

[0278] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are only used to illustrate the present invention, and the content of the present invention is not limited by the following examples.

[0279] [Preparation Example]

[0280] Preparation Example 1: 6-aminospiro[3.3]heptane-2-carboxylic acid methyl ester hydrochloride

[0281]

[0282] Methyl 6-((tert-Butyloxycarbonyl)amino)spiro[3.3]heptane-2-carboxylate (10 g, 37.1 mmol) was added to a 4N HCl solution in dioxane, stirred for 15 hours, and then concentrated under reduced pressure. The crude product was washed with diethyl ether (100 mL) and dried to afford Intermediate A (7.32 g, 96% yield) as a white solid. 1 H NMR (300Hz, DMSO-d6) δ8.09 (bs, 2H), 3.58 (s, 3H), 3.03 (p, J = 8.4Hz, 1H), 2.43-2.31 (m, 1H), 2.28-1.95 (m, 6H).

[0283] Preparation Example 2: Methyl 2-azidoacetate

[0284]

[0285] To a 0.5 M solution of methyl 2-bromoacetate (7.65 g, 50.0 mmol) in DMSO was added NaN3 (4.88 g, 75.0 mmol) and stirred for 24 hours. The reaction solution was diluted with EtOAc (100 mL) and washed with distilled water. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure to afford Intermediate B (4.09 g, 75% yield) as a colorless liquid. 1 H NMR (300MHz, chloroform-d) δ3.91 (s, 2H), 3.83 (s, 3H).

[0286] Preparation Example 3: 3-Bromo-2,5-dimethylthiophene

[0287]

[0288] To a solution of 2,5-dimethylthiophene (11.2 g, 100 mmol) in acetic acid (0.2 M) was added NBS (17.8 g, 100 mmol) and stirred for 15 hours. The reaction solution was concentrated, diluted with ether, and then washed with distilled water, sodium bicarbonate solution, and brine. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to obtain Intermediate C (8.80 g, 46% yield) as a colorless liquid. 1 H NMR(300MHz,chloroform-d)δ6.60-6.56(m,1H),2.42(s,3H),2.35(s,3H).

[0289] Preparation Example 4: Methyl 4-bromo-2,5-dimethylthiophene-3-carboxylate

[0290] Step 1: Synthesis of 3,4-dibromo-2,5-dimethylthiophene

[0291]

[0292] To a solution of tetrabromothiophene (8.0 g, 20.0 mmol, 1.0 equiv) in THF (60 mL, 0.3 M) at -78°C was added n-BuLi (2.0 M in cyclohexane, 25.0 mL, 50.0 mmol, 2.5 equiv), and the mixture was stirred at -78°C for 1 hour. Iodomethane (3.8 mL, 60.0 mmol, 3.0 equiv) was added, and the mixture was stirred at room temperature for 20 hours. The reaction solution was added to saturated ammonium chloride and extracted with EtOAc. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by column chromatography to afford 3,4-dibromo-2,5-dimethylthiophene (4.9 g, 90% yield).

[0293] Step 2: Synthesis of 4-bromo-2,5-dimethylthiophene-3-carboxylic acid

[0294]

[0295] To a solution of 3,4-dibromo-2,5-dimethylthiophene (4.9 g, 18.1 mmol, 1.0 equiv) in THF (60 mL) was added n-BuLi (2.0 M in cyclohexane, 8.2 mL, 0.9 equiv) at -78°C and stirred at -78°C for 30 minutes. An excess of dry ice was added, followed by stirring at room temperature for 30 minutes. The reaction mixture was added to 1N NaOH and extracted with Et2O. The aqueous layer was acidified with 1N HCl solution. The resulting precipitate was removed by filtration, washed with distilled water, and then dried to yield 4-bromo-2,5-dimethylthiophene-3-carboxylic acid (3.3 g, 77% yield).

[0296] Step 3: Synthesis of methyl 4-bromo-2,5-dimethylthiophene-3-carboxylate

[0297]

[0298] To a solution of 4-bromo-2,5-dimethylthiophene-3-carboxylic acid (2.64 g, 11.2 mmol, 1.0 equiv) and K2CO3 (3.1 g, 22.4 mmol, 2.0 equiv) in DMF (15 mL) was added iodomethane (1.4 mL, 22.4 mmol, 2.0 equiv) and stirred for 12 hours. The reaction solution was added to distilled water and extracted with DCM. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by column chromatography to obtain Intermediate D (2.55 g, 91% yield).

[0299] Preparation Example 5: 3-Fluoro-[1,1'-biphenyl]-4-carboxylic acid

[0300]

[0301] To 1.0 g of phenylboronic acid (8.20 mmol, 1.0 equiv) and 1.80 g of 4-bromo-2-fluorobenzoic acid (8.20 mmol, 1.0 equiv) was added 6.47 g of a 26% Me₄N·OH aqueous solution (18.45 mmol, 2.25 equiv), and the mixture was stirred at 50°C. Under Ar substitution conditions, 25 mL of distilled water and 25 mg of 5% Pd / C (0.025 w / w) were added, and the mixture was stirred at 80°C for 1.5 hours. The reaction solution was cooled to room temperature and filtered through Celite to remove the Pd / C. 2.2 mL of a 6 M HCl aqueous solution (13.12 mmol, 1.6 equiv) was added to the reaction solution, and after neutralization and crystallization, 10 mL of distilled water was added and the mixture was stirred for 30 minutes. The precipitated crystals were washed with distilled water and then dried under reduced pressure to obtain Intermediate E (1.5 g, 85% yield). 1H NMR (500MHz, Chloroform-d) δ8.14 (t, J = 7.9 Hz, 1H), 7.65 (d, J = 7.2 Hz, 2H), 7.54-7.49 (m, 3H), 7.48-7.41 (m, 2H). LC / MS(ESI)m / z:217.2[M+H] + .

[0302] Preparation Example 6: 2-Amino-[1,1'-biphenyl]-4-carbonyl chloride

[0303] Step 1: Synthesis of 2-amino-[1,1'-biphenyl]-4-carboxylic acid

[0304]

[0305] 3-Amino-4-bromobenzoic acid (5.0 g, 23.2 mmol), 5% Pd / C (255 mg, 0.45 mmol), K2CO3 (12.8 g, 92.6 mmol) and phenylboronic acid (3.2 g, 25.5 mmol) were added to a sealed tube. Distilled water (46 mL, 0.5 M) was added and stirred at 100°C for 12 hours. The reaction solution was cooled to room temperature, filtered through a plug of celite, and then washed with distilled water (2 x 20 mL). The solution was slowly acidified with 1N citric acid solution, the precipitate was filtered, and then dried to give Intermediate F (3.5 g, 71% yield). 1 H NMR (300MHz, DMSO-d6) δ12.69(s,1H),7.47(d,J=6.5Hz,4H),7.41-7.34(m,2H),7.21(dd,J=7.9,1.6Hz,1H),7.08(d,J=7.8Hz,1H),5.04(s,2H).

[0306] Step 2: Synthesis of 2-amino-[1,1'-biphenyl]-4-carbonyl chloride

[0307]

[0308] Thionyl chloride (3.5 mL, 48.1 mmol) was added to a stirred solution of 2-amino-[1,1'-biphenyl]-4-carboxylic acid (2.5 g, 11.73 mmol) in ethyl acetate (39 mL, 0.3 M). The reaction mixture was stirred at reflux for 4 hours, then cooled to room temperature and concentrated under reduced pressure to yield Intermediate F (2.95 g).

[0309] Preparation Example 7: (2'-Methoxy-[1,1'-biphenyl]-4-yl)methanol

[0310] Step 1: Synthesis of methyl 2'-methoxy-[1,1'-biphenyl]-4-carboxylate

[0311]

[0312] A solution of 4-(methoxycarbonylphenyl)boronic acid (1.08 g, 6 mmol), Na2CO3 (1.91 g, 18 mmol), Pd(OAc)2 (0.269 g, 1.2 mmol) and PPh3 (0.63 g, 2.4 mmol) in a stirred solution of 2-bromoanisole (0.75 mL, 6 mmol) in toluene (0.6 M) was stirred at 100 ° C for 6 hours. The reaction solution was extracted with ethyl acetate (20 mL × 3), the organic layer was washed with brine solution, then dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane: ethyl acetate = 97:3 to 95:5) to give methyl 2'-methoxy-[1,1'-biphenyl]-4-carboxylate (507 mg, yield 35%). 1 H NMR(500MHz, CDCl3)δ8.08(d,J=8.4Hz,2H),7.61(d,J=8.4Hz,2H),7.39-7.30( m, 2H), 7.04 (s, 1H), 6.99 (d, J = 8.2Hz, 1H), 3.93 (d, J = 1.9Hz, 3H), 3.81 (s, 3H).

[0313] Step 2: Synthesis of (2'-methoxy-[1,1'-biphenyl]-4-yl)methanol

[0314]

[0315] Methyl 2'-methoxy-[1,1'-biphenyl]-4-carboxylate (507 mg, 2.09 mmol) was dissolved in THF (0.2 M), and LiAlH4 (397 mg, 10.5 mmol) was added and stirred for 3 hours. The reaction mixture was cooled to 0°C, and then distilled water (1.6 mL) and aqueous NaOH were added. The mixture was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane:ethyl acetate = 7:3) to obtain Intermediate G (340 mg). 1 H NMR (500MHz, CDCl3) δ7.55(d,J=8.1Hz,2H),7.41(d,J=7.9Hz,2H),7.34(d,J=7.5H z, 2H), 7.05 (s, 1H), 7.01 (d, J = 8.0Hz, 1H), 4.70 (s, 2H), 3.81 (s, 3H), 2.23 (s, 1H).

[0316] Preparation Example 8: 3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

[0317]

[0318] Under an N atmosphere, to a solution of 3-fluoro-5-bromoaniline (380 mg, 2.0 mmol) in dioxane (20.0 mL) were added bis(pinacolato)diboron (1.1 g, 4.4 mmol), KOAc (1.18 g, 12 mmol), and Pd(dppf)Cl (146.0 mg, 0.2 mmol), and the mixture was stirred at 90°C for 32 hours. The reaction solution was cooled to room temperature, filtered through celite, and washed with EtOAc. The organic layer was concentrated under reduced pressure to provide Intermediate H (1.4 g).

[0319] Preparation Example 9: 2-(3-Fluoro-5-(methylthio)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0320] Step 1: Synthesis of (3-bromo-5-fluorophenyl)(methyl)sulfane

[0321]

[0322] A solution of 3,5-difluorobromobenzene (3 g, 15.54 mmol) in N,N-dimethylformamide (30 mL) was cooled to 0°C, and sodium thiomethoxide solution (7.1 mL, 15.54 mmol) was added and stirred for 30 minutes. The reaction mixture was diluted with distilled water, extracted with hexane, washed with brine, and dried over sodium sulfate. The organic layer was concentrated under reduced pressure to yield (3-bromo-5-fluorophenyl)(methyl)sulfane (2.6 g, 75% yield) as a clear liquid.

[0323] Step 2: Synthesis of 2-(3-fluoro-5-(methylthio)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane become

[0324]

[0325] Under N2, a sealed tube was purged with (3-bromo-5-fluorophenyl)(methyl)sulfane (1 g, 4.523 mmol), potassium acetate (2.2 g, 22.615 mmol), (pinacol)diboron (1.7 g, 6.784 mmol), and Pd(dppf)Cl2 (complexed with DCM; 369 mg, 0.452 mmol). Dioxane was added, and the mixture was stirred at 80°C for 12 hours. The reaction mixture was cooled to room temperature, and ethyl acetate was added. The precipitate was removed by filtration through celite. The organic layer was concentrated under reduced pressure, and the crude product was purified by flash column chromatography (hexane / ethyl acetate, concentration from 0% to 100%) to obtain Intermediate I (932 mg, 70% yield) as a yellow liquid.

[0326] Preparation Example 10: 3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

[0327] Step 1: Synthesis of 3-bromo-5-fluorobenzamide

[0328]

[0329] A solution of 3-bromo-5-fluorobenzoic acid (1 g, 4.566 mmol) in thionyl chloride (4 mL) was stirred at reflux for 2 hours. The reaction solution was concentrated under reduced pressure, 28% aqueous ammonia (1.5 mL) was added, and then stirred for 12 hours. The reaction solution was washed three times with distilled water to obtain 3-bromo-5-fluorobenzamide (533 mg, 54% yield) as a white solid. 1 H NMR (300MHz, Chloroform-d) δ7.74-7.72(m,1H),7.49-7.45(m,1H),7.44-7.40(m,1H),5.83(s,2H).

[0330] Step 2: Synthesis of 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

[0331]

[0332] 3-Bromo-5-fluorobenzamide was reacted in the same manner as in Preparation Example 8 to obtain Intermediate J.

[0333] Preparation Example 11: 3-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

[0334]

[0335] Intermediate K was obtained by the same method as Preparation Example 10, except that 3-bromo-5-fluorobenzoic acid in Step 1 was replaced by 3-bromo-5-methoxybenzoic acid. 1 H NMR (300MHz, DMSO-d6) δ8.03(s,1H),7.77(dd,J=1.6,0.9Hz,1H),7.53(dd,J=2.7,1.6 Hz, 1H), 7.33 (s, 1H), 7.27 (dd, J = 2.7, 0.9Hz, 1H), 3.81 (s, 3H), 1.16 (d, J = 2.6Hz, 12H).

[0336] Preparation Example 12: tert-Butyl (3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate

[0337] Step 1: Synthesis of (3-bromo-5-methoxyphenyl)methanamine

[0338]

[0339] 3-Bromo-5-methoxybenzonitrile (1 g, 4.716 mmol) was dissolved in THF (9 mL), and then BH3-THF (1 M in THF, 6 mL, 5.895 mmol) was slowly added at 0°C. The reaction solution was stirred at 80°C for 16 hours, then the solvent was concentrated under reduced pressure and acidified by adding 1N HCl. The reaction solution was stirred at room temperature for 2 hours, then EA and distilled water were added, and the aqueous layer was extracted. The aqueous layer was neutralized with 2N NaOH (pH = 10), then extracted with EA and brine. The organic layer was concentrated under reduced pressure to obtain (3-bromo-5-methoxyphenyl)methanamine (741 mg, 72% yield). 1 H NMR (300MHz, Chloroform-d) δ7.08-7.03 (m, 1H), 6.92 (t, J = 2.0Hz, 1H), 6.83-6.79 (m, 1H), 3.81 (s, 2H), 3.78 (s, 3H).

[0340] Step 2: Synthesis of tert-butyl (3-bromo-5-methoxybenzyl)carbamate

[0341]

[0342] (3-bromo-5-methoxyphenyl)methylamine (741 mg, 3.429 mmol) and Boc2O (749 mg, 3.429 mmol) were dissolved in DCM. TEA (0.53 mL, 3.772 mmol) was added at 0°C and stirred for 16 hours. The DCM was partially concentrated and extracted with ethyl acetate and brine. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The product was purified by silica gel column (EA: hexane = 1: 3) to give tert-butyl (3-bromo-5-methoxybenzyl)carbamate (766 mg, 70% yield). 1 H NMR (300MHz, Chloroform-d) δ7.00 (s, 1H), 6.94 (t, J = 2.1Hz, 1H), 6.75 (s, 1H), 4.84 (s, 1H), 4.25 (s, 2H), 3.78 (s, 3H), 1.46 (s, 9H).

[0343] Step 3: (3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)amino Synthesis of tert-butyl formate

[0344]

[0345] Intermediate L was obtained by reacting tert-butyl (3-bromo-5-methoxybenzyl)carbamate in the same manner as in Preparation Example 8. 1H NMR (300MHz, Chloroform-d) δ7.30(s,1H),7.22(s,1H),6.95(s,1H),4.79(s,1H),4.29(s,2H),3.82(s,3H),1.46(s,9H),1.34(s,12H).

[0346] Preparation Example 13: 3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol

[0347] Step 1: Synthesis of (3-bromo-5-fluorophenyl)methanol

[0348]

[0349] 3-Bromo-5-fluorobenzoic acid (657.0 mg, 3.0 mmol) was added to THF (15.0 mL), cooled to 0°C, and BH3·DMS (5 M, 1.2 mL, 6.0 mmol) was added over 15 minutes, followed by stirring for 12 hours. The reaction solution was cooled to 0°C, and an excess of methanol was added. The solution diluted with ethyl acetate was washed with 1N aqueous sodium hydroxide solution and brine, dried over sodium sulfate, and then concentrated under reduced pressure. The crude product was purified by column chromatography (0 to 30% ethyl acetate / hexane) to give (3-bromo-5-fluorophenyl)methanol (400 mg, 65% yield). 1 H NMR (300MHz, CDCl3) δ7.33-7.28 (m, 1H), 7.17 (dt, J = 8.1, 2.1Hz, 1H), 7.04 (ddd, J = 9.1, 2.4, 1.3Hz, 1H), 4.69 (s, 2H).

[0350] Step 2: Synthesis of (3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol become

[0351]

[0352] (3-Bromo-5-fluorophenyl)methanol was reacted in the same manner as in Preparation Example 8 to obtain Intermediate M.

[0353] Preparation Example 14: 3-(3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxetan-3-ol

[0354] Step 1: Synthesis of 3-(3-bromo-5-methoxyphenyl)oxetan-3-ol

[0355]

[0356] To a solution of 1,3-dibromo-5-methoxybenzene (1.06 g, 4.0 mmol) in THF (0.2 M) at -78°C was added TMEDA (923 μL, 6.0 mmol) and n-BuLi (2.5 M in THF, 2.4 mL, 6.0 mmol) and stirred for 1 hour. Oxetanone (1.02 mL, 4.8 mmol) was added to the reaction mixture and the temperature was slowly raised to room temperature. After 4 hours, the resulting reaction mixture was diluted with aqueous ammonium chloride (40 mL) and ethyl acetate (40 mL), and the aqueous layer was extracted with ethyl acetate (40 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane:ethyl acetate = 1:2) to yield 3-(3-bromo-5-methoxyphenyl)oxetan-3-ol (443.0 mg as a mixture, approximately 320.0 mg, 31% yield) as a colorless oil. 1 H NMR (500MHz, CDCl3) δ7.34 (s, 1H), 7.07 (d, J = 2.0Hz, 1H), 7.00 (d, J = 2.0Hz, 1H), 4.86 (d, J = 6.8Hz, 2H), 4.83 (d, J = 7.0Hz, 2H), 3.80 (s, 4H).

[0357] Step 2: 3-(3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxy Synthesis of Heterocyclobutan-3-ol

[0358]

[0359] 3-(3-bromo-5-methoxyphenyl)oxetan-3-ol was reacted in the same manner as in Preparation Example 8 to obtain Intermediate N. 1 H NMR (500MHz, CDCl3) δ7.57(s,1H),7.27(d,J=2.6Hz,1H),7.19(dd,J=2.6,1.8H z, 1H), 4.94 (d, J = 6.9Hz, 2H), 4.87 (d, J = 6.8Hz, 2H), 3.84 (s, 3H), 1.33 (s, 12H).

[0360] Preparation Example 15: 1-(3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidin-2-one

[0361] Step 1: Synthesis of 1-(3-methoxyphenyl)azetidin-2-one

[0362]

[0363] To a toluene (0.8 M) solution of 1-iodo-3-methoxybenzene (936.1 mg, 4.0 mmol) was added azetidinone (340.0 mg, 4.8 mmol), CuI (38.1 mg, 0.2 mmol), K2CO3 (1.1 g, 8.0 mmol) and N,N'-dimethylethylenediamine (43 μL, 0.4 mmol) and stirred at 140 ° C for 24 hours. The reaction solution was cooled to room temperature, diluted with brine (20 mL) and ethyl acetate (20 mL), and the aqueous layer was extracted with ethyl acetate (20 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane: ethyl acetate = 2: 1) to give 1- (3-methoxyphenyl) azetidin-2-one (436.0 mg, yield 61%) as a colorless oil (436.0 mg, 61%). 1 H NMR(500MHz, CDCl3)δ7.14(t,J=8.1Hz,1H),6.92(s,1H),6.78(dd,J=8.1,1.9Hz,1H), 6.56 (dd, J=8.4, 2.5Hz, 1H), 3.72 (s, 3H), 3.48 (t, J=4.5Hz, 2H), 2.98 (d, J=4.5Hz, 2H).

[0364] Step 2: 1-(3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)nitrogen Heterocyclic butan-2-one

[0365]

[0366] To a cyclohexane (0.1 M) solution of 1-(3-methoxyphenyl)azetidin-2-one (436.0 mg, 2.46 mmol) was added [Ir(cod)OMe]2 (195.7 mg, 0.295 mmol), 4,4'-di-tert-butyl-2'2-bipyridine (dtbpy) (158.5 mg, 0.590 mmol), bis(pinacolato)diboron (1.25 g, 4.90 mmol), and BpinH (42.8 μL, 0.295 mmol), and the mixture was stirred at 80°C for 24 hours. The reaction mixture was cooled to room temperature, diluted with brine (40 mL) and ethyl acetate (40 mL), and the aqueous layer was extracted with ethyl acetate (40 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane:ethyl acetate=1:1) to give intermediate O (405.2 mg, yield 54%) as a yellow solid. 1H NMR (500MHz, CDCl3) δ7.32 (t, J = 2.3 Hz, 1H), 7.05 (d, J = 2.5 Hz, 1H), 7.04 (d, J = 1.9 Hz, 1H), 3.81 (s, 3H), 3.62 (t, J = 4.5 Hz, 2H), 3.07 (t, J = 4.5 Hz, 2H).

[0367] Preparation 16: tert-Butyl (3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate

[0368]

[0369] Intermediate P was obtained by the same method as in Preparation Example 12, except that 3-bromo-5-methoxybenzonitrile in Step 1 of Preparation Example 12 was replaced by 3-bromo-5-fluorobenzonitrile.

[0370] Preparation Example 17: tert-Butyl 3-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidine-1-carboxylate

[0371] Step 1: Synthesis of tert-butyl 3-(3-bromo-5-fluorophenyl)azetidine-1-carboxylate

[0372]

[0373] 3- (2- ((4- methoxyphenyl) sulfonyl) hydrazono) azetidine -1- tert-butyl formate (1.0 g, 2.8 mmol), 3- bromo -5- fluorophenylboronic acid (1.23 g, 5.6 mmol) and cesium carbonate (1.83 g, 5.6 mmol) are added to dioxane (10.0 mL, 0.3 M). The tube is sealed and stirred at 110 ° C for 15 hours. The reaction solution is cooled to room temperature, quenched with saturated sodium bicarbonate aqueous solution (30 mL), then dried over magnesium sulfate and concentrated under reduced pressure. The crude product is purified by flash column chromatography (10 to 30% ethyl acetate / hexane) to give tert-butyl 3- (3- bromo -5- fluorophenyl) azetidine -1- formate (261 mg, 28%). 1 HNMR(300MHz,Chloroform-d)δ7.28(d,J=3.8Hz,1H),7.16(dt,J=8.1,2.0Hz,1H),7.00(dt,J=9.3, 1.8Hz, 1H), 4.34 (t, J = 8.7Hz, 2H), 3.93 (dd, J = 8.7, 5.8Hz, 2H), 3.69 (d, J = 14.4Hz, 1H), 1.49 (s, 9H).

[0374] Step 2: 3-(3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azacyclic Synthesis of tert-butyl butane-1-carboxylate

[0375]

[0376] Intermediate Q was obtained by reacting tert-butyl 3-(3-bromo-5-fluorophenyl)azetidine-1-carboxylate in the same manner as in Preparation Example 8. 1 H NMR(300MHz,Chloroform-d)δ7.50(s,1H),7.39(dd,J=8.7,2.2Hz,1H),7.14(dt,J=9.8,2.1Hz,1H),4.34(t ,J=8.7Hz,2H),4.00(dd,J=8.6,6.0Hz,2H),3.77(ddd,J=12.8,7.8,5.1Hz,1H),1.49(s,9H),1.37(s,12H).

[0377] Preparation Example 18: Methyl 6-(methylamino)spiro[3.3]heptane-2-carboxylate hydrochloride

[0378] Step 1: Synthesis of methyl 6-((tert-butoxycarbonyl)(methyl)amino)spiro[3.3]heptane-2-carboxylate

[0379]

[0380] To a stirred solution of methyl 6-((tert-butoxycarbonyl)amino)spiro[3.3]heptane-2-carboxylate (269 mg, 1.0 mmol) in THF (0.1 M) was added 60% NaH (60 mg, 1.50 mmol) and stirred at 0° C. for 15 minutes. Methyl iodide (0.2 mL, 3.0 mmol) was added to the reaction solution and stirred for 20 hours. The reaction solution was quenched with cold distilled water and extracted with ethyl acetate (20 mL). The organic layer was washed with distilled water and brine, dried over sodium sulfate, and then concentrated under reduced pressure to give methyl 6-((tert-butoxycarbonyl)(methyl)amino)spiro[3.3]heptane-2-carboxylate (288 mg, crude product) as a yellow liquid. 1 H NMR (400MHz, chloroform-d) δ4.6-4.14(m,1H),3.69(s,3H),3.05(p,J=8.5Hz,1H),2.39-2.25(m,1H),2.2-2.00(m,1H),1.47(s,9H).

[0381] Step 2: Synthesis of methyl 6-(methylamino)spiro[3.3]heptane-2-carboxylate hydrochloride

[0382]

[0383] To methyl 6-((tert-butoxycarbonyl)(methyl)amino)spiro[3.3]heptane-2-carboxylate (288 mg, 1.02 mmol) was added 4N HCl in dioxane at 0°C and stirred at room temperature for 15 hours. The reaction mixture was concentrated under reduced pressure to afford the hydrochloride salt of Intermediate R (244 mg) as a yellow solid. 1 H NMR (400MHz, DMSO) δ9.07(s,2H),3.59(s,2H),3.53-3.39(m,1H),3.22-2.78(m,1H),2.37(s,3H),2.34-2.23(m,2H),2.24-2.01(m,6H).

[0384] Preparation Example 19: 4-(((tert-Butyldimethylsilyl)oxy)methyl)-2,5-dimethylthiophene-3-carboxylic acid

[0385] Step 1: Synthesis of 4-bromo-2,5-dimethylthiophene-3-carbaldehyde

[0386]

[0387] To a THF (0.4 M) solution of 3,4-dibromo-2,5-dimethylthiophene (6.37 g, 23.6 mmol) and TMEDA (3.9 mL, 26 mmol) was added n-BuLi (2.5 M in THF, 9.4 mL, 23.6 mmol) at -78°C and stirred for 1 hour. DMF was added to the reaction solution, which was then slowly warmed to room temperature and stirred for 15 hours. The reaction solution was quenched with distilled water (20 mL), acidified with 1N HCl solution, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to yield 4-bromo-2,5-dimethylthiophene-3-carbaldehyde (3.64 g) as an off-white solid. 1 H NMR (300MHz, CDCl3) δ10.03(s,0H),2.74(s,1H),2.38(s,1H).

[0388] Step 2: Synthesis of (4-bromo-2,5-dimethylthiophen-3-yl)methanol

[0389]

[0390] To a THF (0.2 M) solution of 4-bromo-2,5-dimethylthiophene-3-carboxaldehyde (1.10 g, 5.02 mmol) was added LiAlH4 (191 mg, 5.02 mmol) at 0 ° C and stirred for 2 hours. The reaction solution was quenched with EtOAc (1 mL) and ice water (0.3 mL), stirred for 30 minutes, then filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (20% EtOAc in hexane) to give (4-bromo-2,5-dimethylthiophene-3-yl)methanol (754 mg, 68% yield) as a colorless liquid. 1 H NMR (400MHz, DMSO); δ4.33(s,1H),2.40(s,3H),2.36(s,1H),2.30(s,3H).

[0391] Step 3: Synthesis of ((4-bromo-2,5-dimethylthiophen-3-yl)methoxy)(tert-butyl)dimethylsilane

[0392]

[0393] To a solution of (4-bromo-2,5-dimethylthiophen-3-yl)methanol (950 mg, 4.30 mmol) in THF (0.2 M, 0°C) was added tert-butyldimethylsilyl chloride (777 mg, 5.16 mmol) and imidazole (439 mg, 6.44 mmol) and stirred for 24 hours. The reaction solution was diluted with EtOAc (20 mL) and washed with distilled water (2 x 20 mL). The organic layer was dried over sodium sulfate, filtered, and then concentrated under reduced pressure. The crude product was purified by column chromatography (5% EtOAc in hexane) to obtain ((4-bromo-2,5-dimethylthiophen-3-yl)methoxy)(tert-butyl)dimethylsilane (937 mg, 65% yield) as a colorless liquid. 1 H NMR (300MHz, chloroform-d) δ4.60(s,1H),2.45(s,2H),2.35(s,2H),1.57(s,1H),0.94(s,4H),0.12(s,3H).

[0394] Step 4: Synthesis of 4-(((tert-Butyldimethylsilyl)oxy)methyl)-2,5-dimethylthiophene-3-carboxylic acid

[0395]

[0396] To a solution of ((4-bromo-2,5-dimethylthiophen-3-yl)methoxy)(tert-butyl)dimethylsilane (335 g, 1.0 mmol) and TMEDA (165 μL, 1.10 mmol) in THF (0.2 M) was added n-BuLi (2.5 M in THF, 0.44 mL, 1.10 mmol) at -78°C and stirred for 1 hour. The reaction was quenched with CO2 gas at -78°C, then slowly warmed to room temperature and stirred for 15 hours. The reaction was quenched with distilled water (20 mL), acidified with 1N HCl solution, and then extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered, and then concentrated under reduced pressure. The crude product was purified by column chromatography (20% ethyl acetate in hexane) to give intermediate S (300 mg) as a white solid. 1 H NMR(300MHz,chloroform-d)δ4.74(s,2H),2.67(s,3H),2.38(s,3H),0.94(s,9H),0.18(s,6H).

[0397] Preparation Example 20: Methyl 3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate

[0398] Step 1: Synthesis of methyl (Z)-2-azido-3-(4-bromothiophen-2-yl)acrylate

[0399]

[0400] To a solution of 4-bromothiophene-2-carboxaldehyde (3.82 g, 20.0 mmol, 1.0 equivalent) and intermediate B (6.91 g, 60.0 mmol, 3.0 equivalent) in MeOH (30 mL) was added 4 M NaOMe (15 mL, 60.0 mmol) at -25°C, and the mixture was stirred at 0°C for 2 hours. Ice was added to the reaction solution, washed with distilled water, filtered, and the reaction product was dried to obtain methyl (Z)-2-azido-3-(4-bromothiophen-2-yl)acrylate. 1 H NMR (300MHz, chloroform-d) δ7.37 (dd, J = 1.4, 0.7 Hz, 1H), 7.22 ( dd, J = 1.4, 0.6 Hz, 1H), 7.03 ( d, J = 0.7 Hz, 1H), 3.90 ( s, 3H).

[0401] Step 2: Synthesis of methyl 3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate

[0402]

[0403] A solution of methyl (Z)-2-azido-3-(4-bromothiophen-2-yl)acrylate (4.79 g, 16.6 mmol, 1.0 equivalent) in o-xylene (60 mL) was stirred at 160° C. for 1 hour. The reaction solution was partially concentrated, filtered, washed with hexane, and dried to obtain Intermediate T. 1 H NMR (300MHz, chloroform-d) δ9.10 (s, 1H), 7.23 (s, 1H), 7.15 (d, J = 1.9Hz, 1H), 3.93 (s, 3H).

[0404] Preparation Example 21: Methyl 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylate

[0405] Step 1: Preparation of 4-bromo-5-methylthiophene-2-carbaldehyde

[0406]

[0407] To a solution of 5-methylthiophene-2-carboxaldehyde (2.78 g, 22.0 mmol) in THF (0.5 M) at 0°C was added bromine (1.7 mL, 33 mmol) and stirred for 25 hours. 10% aqueous Na2S2O3 solution (30 mL) and 10% aqueous NaHCO3 solution (30 mL) were added to the reaction solution, which was then extracted with EtOAc (150 mL). The organic phase was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to afford 4-bromo-5-methylthiophene-2-carboxaldehyde (862 mg, 16% yield) as a colorless solid. 1 H NMR(300MHz,chloroform-d)δ9.80(s,1H),7.62(s,1H),2.51(s,3H).

[0408] Step 2: Preparation of (Z)-2-azido-3-(4-bromo-5-methylthiophen-2-yl) methyl acrylate

[0409]

[0410] To a solution of 4-bromo-5-methylthiophene-2-carboxaldehyde (850 mg, 4.14 mmol) in MeOH (1.5 M) at -25°C was added 4 M NaOMe (3 mL, 11.6 mmol) and Intermediate B (1.43 g, 12.4 mmol). The reaction mixture was stirred at 0°C for 2 hours, then diluted with EtOAc and washed with brine. The organic phase was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to give (Z)-2-azido-3-(4-bromo-5-methylthiophen-2-yl)acrylate (813 mg, 65% yield) as a yellow solid. 1H NMR(300MHz,chloroform-d)δ7.15(s,1H),6.99(s,1H),3.91(s,3H),2.45(s,3H).

[0411] Step 3: Preparation of methyl 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylate

[0412]

[0413] A solution of (Z)-2-azido-3-(4-bromo-5-methylthiophen-2-yl)acrylate (795 mg, 2.63 mmol) in 4 mL of xylene was added to o-xylene (5 mL) over 10 minutes. After stirring at reflux for 1 hour, the reaction was cooled to room temperature and partially concentrated. The solid was filtered to afford Intermediate U (554 mg, 77% yield) as an off-white solid. 1 H NMR (300MHz, chloroform-d) δ8.99 (s, 1H), 7.10 (d, J = 1.9Hz, 1H), 3.93 (s, 3H), 2.50 (s, 3H).

[0414] Preparation Example 22: Ethyl 3-bromo-6-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylate

[0415] Step 1: 1 Synthesis of -(3,4-dibromothiophen-2-yl)ethan-1-one

[0416]

[0417] To a solution of AlCl3 (1.33 g, 10.0 mmol, 2.0 equiv) in DCM (20 mL) at 0°C was added 3,4-dibromothiophene (1.2 g, 5.0 mmol) and stirred for 10 minutes. Acetyl chloride (360 μL, 5.0 mmol, 1.0 equiv) was added and stirred at 0°C for 3 hours. The reaction solution was acidified with 6M HCl and extracted with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to yield 1-(3,4-dibromothiophen-2-yl)ethan-1-one. 1 H NMR (300MHz, Chloroform-d) δ7.63 (s, 1H), 2.72 (s, 3H).

[0418] Step 2: Synthesis of ethyl 3-bromo-6-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylate

[0419]

[0420] A solution of 1-(3,4-dibromothiophen-2-yl)ethan-1-one (1.42 g, 5.0 mmol), ethyl isocyanoacetate (600 μL, 5.5 mmol, 1.1 equiv), CuI (95 mg, 0.5 mmol, 0.1 equiv) and Cs2CO3 (3.26 g, 10.0 mmol, 2.0 equiv) in DMSO (5 mL) was stirred at 50 ° C for 4 hours. Distilled water was added to the reaction solution and extracted with DCM. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by flash column chromatography to give intermediate V (806 mg, yield 56%). 1 H NMR (300MHz, Chloroform-d) δ9.01 (s, 1H), 7.18 (s, 1H), 4.40 (q, J = 7.1Hz, 2H), 1.41 (t, J = 7.1Hz, 3H).

[0421] Preparation Example 23: Methyl 3-bromo-2-chloro-4H-thieno[3,2-b]pyrrole-5-carboxylate

[0422] Step 1: Synthesis of 4-bromo-5-chlorothiophene-2-carbaldehyde

[0423]

[0424] To a solution of 4-bromothiophene-2-carboxaldehyde (500 mg, 2.62 mmol, 1.0 equivalent) in DMF (5 mL) was added N-chlorosuccinimide (699 mg, 5.24 mmol), and the mixture was stirred at 70°C for 12 hours. Distilled water was added to the reaction solution, and the solid was filtered, washed with distilled water, and dried to obtain 4-bromo-5-chlorothiophene-2-carboxaldehyde (421 mg, 70% yield). 1 H NMR (300MHz, Chloroform-d) δ9.76 (s, 1H), 7.60 (s, 1H).

[0425] Steps 2 and 3: Synthesis of methyl 3-bromo-2-chloro-4H-thieno[3,2-b]pyrrole-5-carboxylate

[0426]

[0427] 4-Bromo-5-chlorothiophene-2-carbaldehyde was reacted in the same manner as in Preparation Example 20 to obtain Intermediate W. 1 H NMR (300MHz, Chloroform-d) δ9.04 (s, 1H), 7.07 (d, J = 1.9Hz, 1H), 3.92 (s, 3H).

[0428] Preparation Example 24: 4'-(Bromomethyl)-3-methoxy-1,1'-biphenyl

[0429] Step 1: Synthesis of (3'-methoxy-[1,1'-biphenyl]-4-yl)methanol

[0430]

[0431] 3-Bromoanisole (935 mg, 5 mmol), 4-(hydroxymethyl)phenylboronic acid (912 mg, 6 mmol), Na2CO3 (1.3 g, 12.5 mmol), and Pd(PPh3)4 (289 mg, 0.25 mmol) were dissolved in a mixture of H2O and DME and stirred at 85°C for 24 hours. The reaction solution was cooled to room temperature, filtered through celite, extracted with EA and brine, and the organic layer was dried over magnesium sulfate. The crude product was purified by silica gel column (EtOAc: hexane = 1:2) to give (3'-methoxy-[1,1'-biphenyl]-4-yl)methanol (1.00 g, yield 93%) as a yellow oil. 1 H NMR(300MHz,Chloroform-d)δ7.59(d,J=8.2Hz,2H),7.44(d,J=8.2Hz,2H),7.36(t,J=7.9Hz,1H),7. 21-7.16(m,1H),7.12(t,J=2.1Hz,1H),6.90(ddd,J=8.1,2.6,0.9Hz,1H),4.75(s,2H),3.87(s,3H).

[0432] Step 2: Synthesis of 4'-(bromomethyl)-3-methoxy-1,1'-biphenyl

[0433]

[0434] (3'-Methoxy-[1,1'-biphenyl]-4-yl)methanol (1.00 g, 4.667 mmol) and CBr4 (1.7 g, 5.134 mmol) were dissolved in DCM (16 mL) and stirred at 0°C for 10 minutes. PPh3 (1.35 g, 5.134 mmol) was slowly added and stirred for 40 minutes. The organic layer was concentrated under reduced pressure and purified on a silica gel column (EtOAc:hexane = 1:25) to obtain Intermediate X (1.14 g, 88% yield). 1 H NMR(300MHz,Chloroform-d)δ7.57(d,J=8.3Hz,2H),7.47(d,J=8.3Hz,2H),7.37(t,J=7.9H z,1H),7.20-7.15(m,1H),7.13-7.11(m,1H),6.94-6.89(m,1H),4.56(s,2H),3.87(s,3H).

[0435] Preparation Example 25: 4'-(Bromomethyl)-3-fluoro-5-methoxy-1,1'-biphenyl

[0436]

[0437] Using (4-bromophenyl)methanol and (3-fluoro-5-methoxyphenyl)boronic acid as starting materials, the same method as Preparation Example 24 was used to obtain Intermediate Y. 1 H NMR (300MHz, Chloroform-d) δ7.59-7.54(m,2H),7.51-7.46(m,2H),6.90(dd,J=9.2,2.2Hz,2H),6.64(dt,J=10.5,2.3Hz,1H),4.57(s,2H),3.88(s,3H).

[0438] Preparation Example 26: (2R,4R,6R)-6-aminospiro[3.3]heptane-2-carboxylic acid methyl ester hydrochloride

[0439] Step 1: Synthesis of methyl 6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptane-2-carboxylate

[0440]

[0441] Intermediate A (3 g, 14.58 mmol) and benzyl chloroformate (3.1 mL, 21.87 mmol) were dissolved in DCM (0.5 M), and DIPEA (7.62 mL, 43.75 mmol) was slowly added at 0 ° C. and stirred at room temperature for 14 hours. The reaction solution was extracted with aqueous ammonium chloride and DCM, and the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column (EtOAc: hexane = 1: 1) to give methyl 6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptane-2-carboxylate (4.4 g, yield 99%). 1 H NMR (300MHz, CDCl3) δ7.40-7.28(m,5H),5.06(s,2H),4.84(d,J=8.3Hz,1H),4.11-3.97(m,1H),3.65(s,3H),3.01(p,J=8.5Hz, 1H), 2.50 (dt, J=12.0, 6.6Hz, 1H), 2.43-2.21 (m, 4H), 2.12 (ddd, J=11.7, 8.7, 2.8Hz, 1H), 1.84 (ddd, J=15.9, 11.3, 8.7Hz, 2H).

[0442] Step 2: Purification of methyl 6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptane-2-carboxylate

[0443]

[0444] Methyl 6-(((Benzyloxy)carbonyl)amino)spiro[3.3]heptane-2-carboxylate (4.34 g) was purified by supercritical fluid chromatography (SFC) under the following conditions to isolate the compounds (2S,4S,6S)-methyl 6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptane-2-carboxylate (2.99 g) and methyl (2R,4R,6R)-methyl 6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptane-2-carboxylate (0.88 g), respectively, as yellow oils.

[0445] Chromatographic column: Daicel ChiralPak IG mobile phase (250 mm × 4.6 mm, 1 μm)

[0446] Mobile phase: [Hexane / Ethanol]; 80 / 20 (V / V), 9.4 min (2S, 4S, 6S), 10.7 min (2R, 4R, 6R)

[0447] Step 3: Synthesis of (2R,4R,6R)-6-aminospiro[3.3]heptane-2-carboxylic acid methyl ester hydrochloride

[0448]

[0449] Methyl (2R,4R,6R)-6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptane-2-carboxylate (312 mg, 1.03 mmol) was dissolved in MeOH (10.3 mL, 0.1 M) and 10% Pd / C (110 mg, 0.1 equiv) was added. The reaction solution was purged under an H2 atmosphere and stirred for 16 hours. The reaction solution was filtered through celite and concentrated under reduced pressure. Dioxane (10.3 mL, 0.1 M) and 4N HCl solution (0.8 mL, 3.09 mmol) were added to the concentrated reaction solution and stirred for another 30 minutes. The reaction solution was concentrated under reduced pressure to give intermediate Z (180 mg).

[0450] Preparation Example 27: 4'-(Bromomethyl)-3,5-dimethoxy-1,1'-biphenyl

[0451]

[0452] Using 1-bromo-3,5-dimethoxybenzene and ((4-hydroxy)tolyl)boronic acid as starting materials, the same method as Preparation Example 24 was used to obtain Intermediate AA. 1 H NMR (300MHz, Chloroform-d) δ7.55 (d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.3 Hz, 2H), 6.71 (d, J = 2.2 Hz, 2H), 6.48 (t, J = 2.2 Hz, 1H), 4.55 (s, 2H), 3.85 (s, 6H).

[0453] Preparation Example 28: 4-(2-bromoethyl)-1,1'-biphenyl

[0454] Step 1: Synthesis of 2-([1,1'-biphenyl]-4-yl)ethan-1-ol

[0455]

[0456] To a solution of 2-([1,1'-biphenyl]-4-yl)acetic acid (559 mg, 3 mmol) in THF (7 mL) was added LiAlH4 (1 M in THF, 9.0 mL, 3.0 equiv) at 0°C, stirred at 75°C for 4 hours, and then carefully quenched by the addition of 1N NaOH. The reaction solution was filtered through celite, and the filtrate was poured into distilled water and extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give 2-([1,1'-biphenyl]-4-yl)ethan-1-ol (522 mg, 87% yield). 1 H NMR (300MHz, Chloroform-d) δ7.62-7.52(m,2H),7.49-7.40(m,1H),7.39-7.29(m,2H),3.91(t,J=6.5Hz,1H),2.92(t,J=6.5Hz,1H).

[0457] Step 2: Synthesis of 4-(2-bromoethyl)-1,1'-biphenyl

[0458]

[0459] To a solution of 2-([1,1'-biphenyl]-4-yl)ethan-1-ol (522 mg, 2.8 mmol, 1.0 equiv) in DCM (12 mL) was added CBr4 (1.02 g, 3.1 mmol, 1.1 equiv) at 0°C and stirred for 15 minutes, followed by the addition of PPh3 (813 mg, 3.1 mmol, 1.1 equiv) and stirring for 40 minutes. The precipitated solid was filtered to afford Intermediate BB (639 mg, 87% yield). 1 HNMR (300MHz, Chloroform-d) δ7.61-7.53(m,4H),7.48-7.40(m,2H),7.38-7.29(m,3H),3.91(t,J=6.5Hz,2H),2.92(t,J=6.5Hz,2H).

[0460] Preparation Example 29: 4'-(Bromomethyl)-3-fluoro-1,1'-biphenyl

[0461] Step 1: Synthesis of (3'-fluoro-[1,1'-biphenyl]-4-yl)methanol

[0462]

[0463] (4-(Hydroxymethyl)phenyl)boronic acid (1.04 g, 6.857 mmol), 1-bromo-3-fluorobenzene (1 g, 5.714 mmol), Na2CO3 (1.51 g, 14.285 mmol), and Pd(PPh3)4 (330 mg, 0.286 mmol) were dissolved in DME and H2O (2:1), then heated to 85°C and stirred for 24 hours. The reaction mixture was extracted with EA and distilled water, and the crude product was purified by flash column chromatography to give (3'-fluoro-[1,1'-biphenyl]-4-yl)methanol (1.26 g) as a white solid. 1 H NMR (300MHz, Chloroform-d) δ7.63-7.56(m,2H),7.50-7.34(m,4H),7.32-7.27(m,1H),7.09-6.99(m,1H),4.76(s,2H).

[0464] Step 2: Synthesis of 4'-(bromomethyl)-3-fluoro-1,1'-biphenyl

[0465]

[0466] (3'-Fluoro-[1,1'-biphenyl]-4-yl)methanol (304 mg, 1.641 mmol) was dissolved in DCM and PBr3 (0.59 mL, 6.231 mmol) was added at 0°C and stirred for 2 hours, followed by the addition of additional PBr3 (100 μL) and stirring. After 4 hours, 1 mL of MeOH was added at 0°C and the organic layer was concentrated under reduced pressure to afford Intermediate CC (1.7 g) as a white solid. 1 H NMR (300MHz, Chloroform-d) δ7.59-7.53(m,2H),7.51-7.45(m,2H),7.43-7.26(m,3H),7.08-7.02(m,1H),4.55(s,2H).

[0467] Preparation Example 30: 2-(4-(bromomethyl)phenyl)pyrimidine

[0468]

[0469] Intermediate DD was obtained by the same method as in Preparation Example 24, except that 3-bromoanisole in Step 1 of Preparation Example 24 was replaced by 2-bromopyridine. 1 H NMR (300MHz, chloroform-d) δ8.81 (d, J = 4.9 Hz, 2H), 8.43 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 7.20 (t, J = 4.8 Hz, 1H), 4.56 (s, 2H).

[0470] Preparation Example 31: 5-(Bromomethyl)-2-phenylpyrimidine

[0471] Step 1: Synthesis of (2-phenylpyrimidin-5-yl)methanol

[0472]

[0473] (2-Chloropyrimidin-5-yl)methanol (1.156 g, 8 mmol), phenylboronic acid (1.463 g, 12 mmol), Pd(OAc)2 (179 mg, 0.8 mmol), Xphos (381 mg, 0.8 mmol) and Na2CO3 (2.199 g, 20 mmol) were dissolved in dioxane / H2O (4:1, 26 mL), purged under an Ar atmosphere, and then stirred at 100°C for 12 hours. The reaction solution was filtered through celite and then extracted with EA and brine. The organic layer was concentrated under reduced pressure and purified on a silica gel column (EtOAc: hexane = 1:1) to give (2-phenylpyrimidin-5-yl)methanol (661 mg, 44% yield). 1 H NMR (300MHz, Chloroform-d) δ8.82(s,2H),8.22-8.52(m,2H),7.58-7.47(m,3H),4.78(s,2H).

[0474] Step 2: Synthesis of 5-(bromomethyl)-2-phenylpyrimidine

[0475]

[0476] (2-Phenylpyrimidin-5-yl)methanol (661 mg, 3.549 mmol) was dissolved in DCM (11 mL), and then CBr (1.412 g, 4.258 mmol) and PPh (1.116 g, 4.258 mmol) were added at 0°C over 10 minutes and stirred for 40 minutes. The reaction solution was concentrated under reduced pressure and purified on a silica gel column (EA:hexane=1:9) to obtain intermediate EE (762 mg, 86% yield). 1 H NMR (300MHz, Chloroform-d) δ8.82(s,2H),8.43-8.46(m,2H),7.49-7.51(m,3H),4.48(s,2H).

[0477] Preparation 32: (3-Bromoprop-1-yn-1-yl)benzene

[0478]

[0479] To a solution of (3-hydroxyprop-1-yn-1-yl)benzene (10.0 g, 75.6 mmol, 9.43 mL, 1.00 equiv) and DMF (276 mg, 3.78 mmol, 0.05 equiv) in DCM (100 mL) at 0°C was added PBr3 (24.5 g, 90.8 mmol, 1.20 equiv) and stirred for 1 hour. The reaction solution was cooled to 0°C, quenched by addition of distilled water (50 mL), and extracted with DCM (2 × 50 mL). The organic layer was washed with aqueous sodium bicarbonate (1 × 100 mL) and brine (1 × 100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ether / ethyl acetate = 50 / 1 to 20 / 1) to give intermediate FF (13.8 g, 70.7 mmol, 93.5% yield) as a colorless oil.

[0480] Preparation 33: (4-(Pyridin-3-yl)phenyl)methanol

[0481]

[0482] (4-(Hydroxymethyl)phenyl)boronic acid (1.154 g, 7.595 mmol), 3-bromopyridine (1 g, 6.329 mmol), Na2CO3 (1.68 g, 15.823 mmol), and Pd(PPh3)4 (366 mg, 0.316 mmol) were dissolved in DME / H2O (2:1) and stirred at 85°C for 12 hours. The reaction solution was cooled to room temperature and then extracted with EA and distilled water. The crude product was purified by flash column chromatography to give intermediate GG (1.34 g) as a yellow solid. 1 H NMR (300MHz, Chloroform-d) δ 8.82-8.81 (m, 1H), 8.61-8.59 (m, 1H), 8.00 (d, J = 8.0Hz, 1H), 7.61-7.55 (m, 2H), 7.53-7.45 (m, 3H), 4.78 (s, 2H).

[0483] Preparation 34: (4-(5-fluoropyridin-3-yl)phenyl)methanol

[0484]

[0485] Using the corresponding starting materials and the same method as Preparation Example 33, Intermediate HH was obtained. 1 H NMR (300MHz, Chloroform-d) δ8.63-8.61(m,1H),8.45-8.44(m,1H),7.65-7.45(m,5H),4.78(s,2H).

[0486] Preparation 35: (4-(5-methoxypyridin-3-yl)phenyl)methanol

[0487]

[0488] Using the corresponding starting materials and the same method as Preparation Example 33, Intermediate II was obtained. 1 H NMR (300MHz, Chloroform-d) δ 8.49-8.48 (m, 1H), 8.30-8.29 (m, 1H), 7.67-7, 65 (m, 1H), 7.60-7.50 (m, 4H), 4.79 (s, 2H), 3.99 (s, 3H).

[0489] Preparation 36: (4-(1-Benzyl-1H-pyrazol-4-yl)phenyl)methanol

[0490]

[0491] (4-Bromophenyl)methanol (1.49 g, 8 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2.5 g, 12 mmol), Pd(PPh3)2Cl2 (561 mg, 0.8 mmol) and Na2CO3 (2.199 g, 20 mmol) were dissolved in THF / H2O (2:1, 16 mL), purged under an Ar atmosphere, and stirred at 80°C for 6 hours. The reaction solution was filtered through celite, then extracted with EA and brine, and dried over magnesium sulfate. Purification by silica gel column (EA: hexane = 1:3) gave intermediate JJ (948 mg, yield 63%). 1 H NMR (300MHz, Chloroform-d) δ7.76 (d, J = 0.8 Hz, 1H), 7.62 (d, J = 0.8 Hz, 1H), 7.43-7.50 (m, 2H), 7.31-7.41 (m, 2H), 4.69 (s, 2H), 3.95 (s, 3H).

[0492] Preparation 37: (1-Benzyl-1H-indol-5-yl)methanol

[0493] Step 1: Synthesis of methyl 1-benzyl-1H-indole-5-carboxylate

[0494]

[0495] At 0 ° C, NaH (460 mg, 19.2 mmol) was added portionwise to a solution of 1H-indole-5-carboxylic acid methyl ester (2.80 g, 16 mmol) and benzyl bromide (2.1 mL, 17.6 mmol) in DMF (30 mL) and stirred at room temperature for 12 hours. The reaction solution was extracted with EA and brine, the organic layer was dried over magnesium sulfate, and then concentrated under reduced pressure. The crude product was purified by silica gel column (EA: hexane = 1: 9) to give 1-benzyl-1H-indole-5-carboxylic acid methyl ester (5.083 g, yield 78%). 1 H NMR(300MHz,Chloroform-d)δ8.42(dd,J=0.7,1.7Hz,1H),7.88(dd,J=1.7,8.7Hz,1H),7.25-7.35(m, 4H),7.19(d,J=3.2Hz,1H),7.06-7.14(m,2H),6.65(dd,J=0.9,3.3Hz,1H),5.35(s,2H),3.93(s,3H).

[0496] Step 2: Synthesis of (1-benzyl-1H-indol-5-yl)methanol

[0497]

[0498] Methyl 1-benzyl-1H-indole-5-carboxylate (2.0 g, 7.538 mmol) was dissolved in THF (25 mL), and LiAlH4 (1 M in THF, 22.6 mL, 22.615 mmol) was added at 0°C, and the mixture was stirred at 75°C for 4 hours. The organic layer was filtered through celite, concentrated under reduced pressure, and purified on a silica gel column (EA:hexane=1:2) to give intermediate KK (1.734 g, 97% yield). 1 H NMR(300MHz,Chloroform-d)δ7.62(m,1H),7.22-7.31(m,4H),7.18(dd,J=1.7,8.5 Hz, 1H), 7.04-7.11 (m, 2H), 6.53 (dd, J = 0.8, 3.1Hz, 1H), 5.31 (s, 2H), 4.74 (s, 2H).

[0499] Preparation 38: (4-(pyridin-2-yl)phenyl)methanol

[0500]

[0501] Using the corresponding starting materials and the same method as Preparation Example 33, Intermediate LL was obtained. 1H NMR (300MHz, chloroform-d) δ8.73(d,J=4.9Hz,1H),8.01(d,J=8.2Hz,2H),7.88-7.73(m,2H),7.49(d,J=8.2Hz,2H),7.32-7.30(m,1H),4.77(s,2H).

[0502] Preparation Example 39: (6-phenylpyridin-3-yl)methanol

[0503]

[0504] To a solution of (6-bromopyridin-3-yl)methanol (940.1 mg, 5.0 mmol) in dioxane / H2O (0.25 M) were added phenylboronic acid (914.5 mg, 7.5 mmol), Pd(OAc)2 (56.1 mg, 0.25 mmol), Xphos (238.4 mg, 0.5 mmol), and Na2CO3 (1.59 g, 15.0 mmol), and the mixture was stirred at 100°C. After 18 hours, the reaction solution was cooled to room temperature, diluted with brine (50 mL) and ethyl acetate (50 mL), and the aqueous layer was extracted with ethyl acetate (30 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane:ethyl acetate = 3:7) to obtain intermediate MM (618.6 mg, 67% yield) as a white solid. 1 H NMR (500MHz, CDCl3) δ8.66-8.62(m,1H),7.99-7.93(m,2H),7.77(dd,J=8.1,2.2Hz ,1H),7.71(d,J=8.1Hz,1H),7.46(t,J=7.5Hz,2H),7.43-7.36(m,1H),4.75(s,2H).

[0505] Preparation Example 40: (4-pyridin-4-yl)phenyl)methanol

[0506]

[0507] Using the corresponding starting materials and the same method as Preparation Example 33, Intermediate NN was obtained. 1 H NMR (300MHz, Chloroform-d) δ 8.71-8.62 (m, 2H), 7.66 (d, J = 8.2Hz, 2H), 7.60-7.55 (m, 2H), 7.51 (d, J = 8.2Hz, 2H), 4.79 (s, 2H).

[0508] Preparation 41: (4-(6-methoxypyridin-2-yl)phenyl)methanol

[0509]

[0510] Using the corresponding starting materials and the same method as Preparation Example 39, Intermediate OO was obtained. 1 H NMR(300MHz,Chloroform-d)δ8.07(d,J=8.3Hz,2H),7.69-7.62(m,1H),7.48(d,J= 8.4Hz, 2H), 7.37 (d, J = 7.4Hz, 1H), 6.72 (d, J = 8.2Hz, 1H), 4.78 (s, 2H), 4.06 (s, 3H).

[0511] Preparation 42: (4-(4-methoxypyridin-2-yl)phenyl)methanol

[0512]

[0513] Using the corresponding starting materials and the same method as Preparation Example 33, the intermediate PP was obtained. 1 H NMR(300MHz,Chloroform-d)δ8.63(d,J=6.3Hz,1H),8.02(d,J=8.2Hz,2H),7.52(d,J=8 .2Hz, 3H), 7.30 (d, J = 2.5Hz, 1H), 6.97 (dd, J = 6.3, 2.5Hz, 1H), 4.78 (s, 2H), 4.03 (s, 3H).

[0514] Preparation 43: (6-(3-Fluoro-5-methoxyphenyl)pyridin-3-yl)methanol

[0515]

[0516] Using the corresponding starting materials and the same method as Preparation Example 39, Intermediate QQ was obtained. 1 H NMR (300MHz, DMSO-d6) δ8.63-8.60(m,1H),8.00(d,J=8.2Hz,1H),7.82(dd,J=8.1,2.0Hz,1 H),7.53-7.45(m,2H),6.94-6.86(m,1H),5.39(s,1H),4.58(d,J=5.6Hz,2H),3.86(s,3H).

[0517] Preparation 44: (4-(4-methyl-1H-pyrazol-1-yl)phenyl)methanol

[0518]

[0519] (4-Iodophenyl)methanol (234 mg, 1 mmol), 4-methyl-1H-pyrazole (121 μL, 1.5 mmol), Cs2CO3 (651 mg, 2 mmol) and Cu(OAc)2 (18 mg, 0.1 mmol) were dissolved in DMF (5 mL), and the reaction solution was purged under an Ar atmosphere and then stirred at 100 ° C for 12 hours. The reaction solution was extracted with EA and brine, and the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The mixture was purified by silica gel chromatography (EA: hexane = 1: 3) to give intermediate RR (191 mg, mixture). LC / MS (ESI) m / z: 189.1 [M+H].

[0520] Preparation 45: (4-(3-Methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)methanol

[0521]

[0522] 3-Methyl-5-(trifluoromethyl)-1H-pyrazole (353 mg, 2.35 mmol), (4-iodophenyl)methanol (500 mg, 2.136 mmol), KCO (590 mg, 4.272 mmol), CuI (41 mg, 0.214 mmol), and N,N-dimethylglycine (44 mg, 0.427 mmol) were dissolved in DMSO, heated to 130°C, and stirred for 24 hours. The reaction solution was cooled to room temperature and extracted with EA and distilled water. The crude product was then purified by flash column chromatography to obtain intermediate SS (562 mg, 99% yield) as a clear liquid. 1 H NMR (300MHz, Chloroform-d) δ7.54-7.40 (m, 4H), 6.46 (s, 1H), 4.78 (d, J = 5.9Hz, 2H), 2.35 (d, J = 0.7Hz, 3H), 1.87 (t, J = 5.9Hz, 1H).

[0523] Preparation 46: (5-(3-Fluoro-5-methoxyphenyl)pyridin-2-yl)methanol

[0524]

[0525] Using the corresponding starting materials and the same method as Preparation Example 39, intermediate TT was obtained. 1H NMR (300MHz, DMSO-d6) δ8.83 (d, J=2.1Hz, 1H), 8.13 (dd, J=8.2, 2.4Hz, 1H), 7.55 (d, J=8.2Hz, 1H), 7.22 -7.12 (m, 2H), 6.88 (dt, J = 11.0, 2.2 Hz, 1H), 5.49 (t, J = 5.9 Hz, 1H), 4.62 (d, J = 5.9 Hz, 2H), 3.85 (s, 3H).

[0526] [Example]

[0527] Example 1: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0528] Step 1: Synthesis of [1,1'-biphenyl]-4-yl(2,5-dimethylthiophen-3-yl)methanone

[0529]

[0530] To a solution of [1,1'-biphenyl]-4-carboxylic acid (7.8 g, 39.3 mmol) and DMF (approximately 0.1 mL) in PhCl (45 mL, 0.8 M) at 0°C was added SOCl₂ (4.9 g, 41.0 mmol). The reaction was then heated to 50°C and stirred for 1 hour. After 1 hour, the reaction was cooled to room temperature and dimethylthiophene (4.1 mL, 35.7 mmol) was added. The reaction was then cooled to 0°C and 1M TiCl₄ solution (35.7 mL, 35.7 mmol) was added. After 1 hour, the reaction was acidified by adding 1N HCl solution and extracted with heptane. The combined extracts were dried over sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to yield [1,1'-biphenyl]-4-yl(2,5-dimethylthiophen-3-yl)methanone (3.31 g, 32% yield). 1 H NMR(500MHz,chloroform-d)δ7.90(d,J=8.4Hz,2H),7.71(d,J=8.4Hz,2H),7.67(d,J=7.1H z, 2H), 7.51 (t, J = 7.5Hz, 2H), 7.43 (t, J = 7.4Hz, 1H), 6.85 (s, 1H), 2.63 (s, 3H), 2.46 (s, 3H). LC / MS(ESI)m / z:293.7[M+H] + .

[0531] Step 2: Synthesis of [1,1'-biphenyl]-4-yl(4-bromo-2,5-dimethylthiophen-3-yl)methanone

[0532]

[0533] Zinc chloride (46.0 mg, 0.34 mmol) was added to a solution of [1,1'-biphenyl]-4-yl(2,5-dimethylthiophen-3-yl)methanone (3.29 g, 11.25 mol) and PhCl (14.1 mL, 0.8 M), and the reaction was cooled to 16°C. Br2 (1.8 g, 22.5 mmol) was added at 16°C over 30 minutes. The reaction was stirred at room temperature for 30 minutes and acidified by adding 1N HCl solution. The product was extracted with heptane, and the combined extracts were dried over sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to afford [1,1'-biphenyl]-4-yl(4-bromo-2,5-dimethylthiophen-3-yl)methanone (2.61 g, 63% yield). 1 H NMR(500MHz,chloroform-d)δ7.94(d,J=7.5Hz,2H),7.72(d,J=7.7Hz,2H),7.67(d,J =7.6Hz, 2H), 7.50 (t, J = 7.3Hz, 2H), 7.44 (t, J = 7.3Hz, 1H), 2.42 (s, 3H), 2.38 (s, 3H). LC / MS(ESI)m / z:373.3[M+H] + .

[0534] Step 3: Synthesis of 3-([1,1'-biphenyl]-4-ylmethyl)-4-bromo-2,5-dimethylthiophene

[0535]

[0536] To a solution of [1,1'-biphenyl]-4-yl(4-bromo-2,5-dimethylthiophen-3-yl)methanone (2.61 g, 7.03 mmol) and DCE (14.1 mL, 0.5 M) was added Et3SiH4 (2.1 g, 17.6 mmol). The reaction solution was cooled to -8 °C and 1M TiCl4 solution (7.1 mL, 7.1 mmol) was slowly added. The reaction solution was stirred at room temperature for 1 hour and then acidified by adding 1N HCl solution. The product was extracted with heptane, then dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography to give 3-([1,1'-biphenyl]-4-ylmethyl)-4-bromo-2,5-dimethylthiophene (1.45 g, 58% yield). 1 H NMR(500MHz,chloroform-d)δ7.59(d,J=7.6Hz,2H),7.52(d,J=8.0Hz,2H),7.45(d,J=7.6 Hz, 2H), 7.35 (d, J = 7.3Hz, 1H), 7.24 (d, J = 7.9Hz, 2H), 4.00 (s, 2H), 2.40 (d, J = 4.4Hz, 6H).

[0537] Step 4: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxylic acid

[0538]

[0539] To a solution of 3-([1,1'-biphenyl]-4-ylmethyl)-4-bromo-2,5-dimethylthiophene (1.0 g, 2.80 mmol), TMEDA (0.46 mL, 3.08 mmol), and methyl tert-butyl ether (14 mL, 0.2 M) was gradually added n-BuLi (1.5 mL, 2.64 mmol) at -65°C, followed by stirring. The reaction solution was stirred for 30 minutes, then an excess of dry ice was added at -65°C and stirred for 1 hour. The reaction solution was acidified by adding 1N HCl solution, then extracted with EtOAc and distilled water. The organic layer was dried over sodium sulfate, then filtered, concentrated, and purified to give 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxylic acid (0.46 g, 51% yield). 1 H NMR(500MHz,DMSO-d6)δ12.64(s,1H),7.61(d,J=7.6Hz,2H),7.55-7.52(m,2H),7.44(t,J =7.2Hz,2H),7.36-7.32(m,1H),7.16-7.12(m,2H),4.17(s,2H),2.55(s,3H),2.31(s,3H).

[0540] Step 5: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane Synthesis of methyl 2-alkanecarboxylate

[0541]

[0542] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxylic acid (0.1 g, 0.31 mmol) in DMF (1.1 mL, 0.3 M) was added Intermediate A (70 mg, 0.34 mmol), HATU (0.13 g, 0.34 mmol), and DIPEA (0.16 mL, 0.93 mmol) and stirred at room temperature for 3 hours. The reaction solution was basified by adding 1N NaOH solution and then extracted with ethyl acetate and distilled water. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified by column chromatography to yield methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (110 mg, 75% yield). 1H NMR(500MHz,chloroform-d)δ7.57(d,J=7.6Hz,2H),7.52(d,J=7.3Hz,2H),7.46(t,J=7.3H z,2H),7.36(t,J=7.2Hz,1H),7.19(d,J=7.6Hz,2H),5.39(d,J=7.1Hz,1H),4.28(m,1H),4. 00(s,2H),3.66(s,3H),2.97(p,J=8.9,8.4Hz,1H),2.46(s,3H),2.38(s,3H),2.30(dd,J=1 4.1,7.1Hz,4H),2.21-2.14(m,1H),1.99(d,J=19.5Hz,1H),1.53(dt,J=19.1,10.0Hz,2H). LC / MS(ESI)m / z:475.2[M+H] + .

[0543] Step 6: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane Synthesis of alkane-2-carboxylic acids

[0544]

[0545] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (110 mg, 0.23 mmol) in H₂O:THF:MeOH (1:1:1) was added LiOH·H₂O (29 mg, 0.69 mmol) and stirred for 4 hours. The reaction mixture was acidified by adding 1N HCl solution and then extracted with ethyl acetate and distilled water. The organic layer was dried over sodium sulfate, filtered, and concentrated to afford Example 1 (86 mg, 81% yield) without purification. 1 H NMR (500MHz, DMSO-d6) δ12.03(s,1H),8.29(d,J=7.4Hz,1H),7.61(d,J=7.7Hz,2H),7. 51(d,J=7.6Hz,2H),7.45(t,J=7.4Hz,2H),7.34(t,J=7.2Hz,1H),7.19(d,J=7.7Hz,2H) ,4.16(h,J=8.3Hz,1H),3.90(s,2H),2.91(p,J=8.3Hz,1H),2.34(s,3H),2.32(s,3H), 2.29-2.13(m,4H),2.11-2.06(m,1H),2.02(s,1H),1.87(s,1H),1.85(d,J=9.6Hz,1H). LC / MS(ESI)m / z:460.01[M+H]+ .

[0546] The compounds of Examples 2 to 5 were prepared using the same method as Example 1 except for the differences described below.

[0547] [Table 1]

[0548]

[0549] [Table 2]

[0550]

[0551]

[0552] Example 6: 6-(4-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0553] Step 1: Synthesis of 2-([1,1'-biphenyl]-4-yl)-1-(2,5-dimethylthiophen-3-yl)ethan-1-one

[0554]

[0555] To a solution of 2-([1,1'-biphenyl]-4-yl)acetic acid (10.4 g, 49.1 mmol) and DMF (approximately 1 mL) in toluene (56 mL, 0.8 M) was added dropwise SOCl2 (6.1 g, 51.3 mmol) at 0°C, and the reaction mixture was heated to 50°C for 1 hour. The reaction mixture was cooled to room temperature, dimethylthiophene (5.1 mL, 44.6 mmol) was added, and then cooled to 0°C, and 1M TiCl4 solution (45 mL, 44.6 mmol) was added. The reaction mixture was acidified by adding 1N HCl solution, extracted with heptane, and the extracts were combined, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to give 2-([1,1'-biphenyl]-4-yl)-1-(2,5-dimethylthiophen-3-yl)ethan-1-one (8.8 g, 64% yield). 1 H NMR(500MHz,chloroform-d)δ7.60(t,J=8.6Hz,4H),7.46(t,J=7.5Hz,2H),7.36(dd,J=15.0,7.5Hz,3H),7.14(s,1H),4.17(s,2H),2.71(s,3H),2.46(s,3H).

[0556] Step 2: Synthesis of 3-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene

[0557]

[0558] To a solution of 2-([1,1'-biphenyl]-4-yl)-1-(2,5-dimethylthiophen-3-yl)ethan-1-one (4.0 g, 13.1 mmol) in diethylene glycol (17.7 mL, 0.7 M) were added 80% hydrazine hydrate (2.0 mL) and KOH (2.5 g, 44.5 mmol). The reaction solution was refluxed and stirred at 195°C for 6 hours, then cooled to room temperature, 18 mL of distilled water was added, and the solution was slowly poured into 11 mL of 6N aqueous HCl to induce precipitation, thereby obtaining 3-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene (1.97 g, 52% yield). 1 H NMR(500MHz,chloroform-d)δ7.63(d,J=7.1Hz,2H),7.55(d,J=6.5Hz,2H),7.47(t,J=7.7Hz,2H),7.37(t,J=7 .4Hz,1H),7.27(d,J=8.1Hz,2H),6.55(s,1H),2.91-2.87(m,2H),2.82-2.77(m,2H),2.44(s,3H),2.22(s,3H).

[0559] Step 3: Synthesis of 3-(2-([1,1'-biphenyl]-4-yl)ethyl)-4-bromo-2,5-dimethylthiophene

[0560]

[0561] To a solution of 3-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene (0.21 g, 0.72 mmol) in AcOH (4 mL) was added N-bromosuccinimide (0.13 g, 0.72 mmol). After stirring for 12 hours, the reaction solution was added to an excess of ice water and extracted with DCM. The DCM solution was washed with aqueous sodium carbonate solution and distilled water. The organic layer was dried over magnesium sulfate, then filtered and concentrated under reduced pressure. The remaining solution was purified by column chromatography to give 3-(2-([1,1'-biphenyl]-4-yl)ethyl)-4-bromo-2,5-dimethylthiophene (159 mg, yield 60%). 1 H NMR(500MHz,chloroform-d)δ7.62(d,J=8.0Hz,2H),7.55(d,J=8.2Hz,2H),7.47(t,J=7.7Hz,2H ), 7.36 (t, J = 7.4Hz, 1H), 7.27 (d, J = 8.1Hz, 2H), 2.85 (p, J = 3.4Hz, 4H), 2.40 (s, 3H), 2.15 (s, 3H).

[0562] Step 4: Synthesis of 4-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene-3-carboxylic acid

[0563]

[0564] To a solution of 3-(2-([1,1'-biphenyl]-4-yl)ethyl)-4-bromo-2,5-dimethylthiophene (159 mg, 0.43 mmol), THF (2.2 mL, 0.2 M) and TMEDA (70 μL, 0.47 mmol) was gradually added n-BuLi (2.5 M in THF, 0.22 mL, 0.56 mmol) at -65 ° C and stirred. After 30 minutes, an excess of dry ice was added at -65 ° C and stirred at room temperature for 1 hour. The reaction solution was acidified by adding 1 M HCl solution and then extracted with EtOAc and distilled water. The organic layer was dried over sodium sulfate, then filtered and concentrated to give 4-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene-3-carboxylic acid (72 mg, yield 51%). 1 H NMR (500MHz, DMSO-d6); δ12.69(s,1H),7.65(d,J=8.0Hz,2H),7.59(d,J=8.2Hz,2H),7.46(t,J=7.7Hz,2H),7.35( t,J=7.4Hz,1H),7.27(d,J=8.2Hz,2H),2.96(dd,J=9.4,6.5Hz,2H),2.75-2.70(m,2H),2.56(s,3H),2.15(s,3H).

[0565] Step 5: 6-(4-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene-3-carboxamido)spiro [3.3] Synthesis of methyl heptane-2-carboxylate

[0566]

[0567] To a solution of 4-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene-3-carboxylic acid (72 mg, 0.21 mmol), Intermediate A (47 mg, 0.23 mmol), and HATU (87 mg, 0.23 mmol) in DCM (1.1 mL, 0.2 M) was added DIPEA (0.11 mL, 0.63 mmol) and stirred at room temperature for 3 hours. The reaction solution was partially concentrated, and the organic layer was extracted with 1N NaOH and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated, and then purified by column chromatography to afford methyl 6-(4-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (70 mg, 70% yield). 1H NMR(500MHz,chloroform-d)δ7.61(d,J=7.1Hz,2H),7.53(d,J=8.2Hz,2H),7.46(t,J=7.7Hz,2H),7.36(t,J=7.9Hz,1H ),7.20(d,J=8.2Hz,2H),5.55(d,J=7.7Hz,1H),4.45(h,J=7.8Hz,1H),3.69(s,3H),3.05(p,J=8.5Hz,1H),2.86(dd,J=6 .4,4.0Hz,2H),2.82(dd,J=9.8,6.5Hz,2H),2.61(dt,J=11.8,5.5Hz,1H),2.48(dd,J=11.8,7.1Hz,1H),2.45(s,3H),2. 37(d,J=8.4Hz,2H),2.32-2.27(m,1H),2.19(s,3H),2.16-2.10(m,1H),1.92-1.82(m,2H); LC / MS(ESI)m / z:488.3[M+H] + .

[0568] Step 6: 6-(4-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene-3-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[0569]

[0570] To a solution of methyl 6-(4-(2-([1,1'-biphenyl]-4-yl)ethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate in H2O:THF:MeOH (1:1:1) was added LiOH·H2O (18 mg, 0.42 mmol). The reaction was stirred at room temperature for 4 hours, then acidified by the addition of 1N HCl solution and extracted with DCM. The organic layer was dried over sodium sulfate, filtered, and concentrated to afford Example 6 (46 mg, 69% yield) without purification. 1H NMR (500MHz, Methanol-d4) δ8.48(d,J=7.2Hz,1H),7.61(d,J=7.2Hz,2H),7.52(d,J=8.2Hz,2H),7. 43(t,J=7.7Hz,2H),7.32(t,J=7.4Hz,1H),7.21(d,J=8.2Hz,2H),4.36(dt,J=13.2,6.8Hz,1H),3.0 4(p,J=8.5Hz,1H),2.88-2.82(m,2H),2.80-2.75(m,2H),2.61-2.55(m,1H),2.45-2.42(m,1H),2.4 1(s,3H),2.41-2.34(m,2H),2.29-2.24(m,1H),2.22-2.16(m,1H),2.11(s,3H),2.10-2.01(m,2H). LC / MS(ESI)m / z:474.3[M+H] + .

[0571] Example 7: 6-(4-((3-fluoro-[1,1′-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0572] Step 1: Synthesis of (4-bromo-2,5-dimethylthiophen-3-yl)(3-fluoro-[1,1'-biphenyl]-4-yl)methanone

[0573]

[0574] To a solution of intermediate E (0.50 g, 2.31 mmol) and DMF (approximately 1 mL) in toluene (2.6 mL, 0.8 M) at 0°C was added SOCl2 (0.18 mL, 2.4 mmol). The reaction mixture was heated to 50°C and stirred for 1 hour, followed by the addition of intermediate C (0.40 g, 2.1 mmol). The reaction mixture was cooled to 0°C and TiCl4 (0.23 mL, 2.1 mmol) was added. 1N aqueous HCl (10 mL) was added and stirred for 5 minutes, after which the organic layer was extracted and the aqueous layer was washed twice with heptane. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and concentrated to afford (4-bromo-2,5-dimethylthiophen-3-yl)(3-fluoro-[1,1'-biphenyl]-4-yl)methanone (200 mg, 25% yield). 1 H NMR(500MHz,Chloroform-d)δ7.78(t,J=7.8Hz,1H),7.65(d,J=7.2Hz,2H),7.53-7. 49(m,3H),7.46(d,J=7.3Hz,1H),7.36(d,J=11.9Hz,1H),2.48(s,3H),2.39(s,3H).

[0575] Step 2: Synthesis of 3-bromo-4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene

[0576]

[0577] To a solution of (4-bromo-2,5-dimethylthiophen-3-yl)(3-fluoro-[1,1'-biphenyl]-4-yl)methanone (150 mg, 0.39 mmol) in DCE (0.9 mL, 0.5 M) was added Et3SiH4 (0.18 mL, 1.17 mmol). The reaction solution was cooled to -8°C, TiCl4 (43 μL, 0.39 mmol) was slowly added, and the reaction solution was stirred for 1 hour. 1N HCl aqueous solution (10 mL) was added and stirred for 5 minutes, then the organic layer was extracted and the aqueous layer was washed twice with heptane. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to give 3-bromo-4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene (74 mg, 53% yield). 1 H NMR(500MHz,Chloroform-d)δ7.57(d,J=7.1Hz,2H),7.45(t,J=7.6Hz,2H),7.37(t,J=7.4Hz,1H),7.30 (d,J=9.6Hz,1H),7.26(d,J=6.1Hz,1H),7.00(t,J=8.0Hz,1H),4.00(s,2H),2.40(s,3H),2.38(s,3H).

[0578] Step 3: Synthesis of 4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxylic acid

[0579]

[0580] To a solution of 3-bromo-4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene (74 mg, 0.20 mmol) and butanediamine (33 μL, 0.22 mmol) in THF (1.0 mL, 0.2 M) was slowly added n-BuLi (2.5 M in THF, 0.09 mL, 0.22 mmol) at -65 ° C, followed by stirring for 45 minutes and adding excess dry ice at -65 ° C. 1N HCl aqueous solution (2.0 mL) was added and stirred for 15 minutes, then the organic layer was extracted and the aqueous layer was washed twice with EA. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to give 4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxylic acid (30 mg, yield 45%). 1H NMR(500MHz,Chloroform-d)δ7.55(d,J=7.1Hz,2H),7.44(t,J=7.6Hz,2H),7.36(d,J=7.3Hz,1H),7.27 (d,J=9.5Hz,1H),7.22(d,J=7.9Hz,1H),6.91(t,J=8.0Hz,1H),4.24(s,2H),2.70(s,3H),2.33(s,3H).

[0581] Step 4: 6-(4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro [3.3] Geng alkyl Synthesis of methyl 2-carboxylate

[0582]

[0583] To a solution of 4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxylic acid (30 mg, 0.09 mmol), Intermediate A (21 mg, 0.1 mmol), and HATU (38 mg, 0.1 mmol) in DMF (0.3 mL, 0.3 M) was added DIPEA (0.05 mL, 0.27 mmol) at room temperature and stirred for 3 hours. The reaction solution was concentrated, diluted with 1N aqueous NaOH and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated, and purified by silica gel column chromatography (n-hexane and ethyl acetate) to give methyl 6-(4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (12 mg, 30% yield). 1 H NMR(500MHz,Chloroform-d)δ7.57-7.53(m,2H),7.46(t,J=7.6Hz,2H),7.38(t,J=7.9Hz,1H),7.29(s,1 H),7.26(s,1H),7.08(t,J=7.8Hz,1H),5.49(d,J=7.8Hz,1H),4.34(h,J=8.0Hz,1H),3.98(s,2H),3.67(s ,3H),2.99(p,J=8.5Hz,1H),2.53-2.47(m,1H),2.46(s,3H),2.39-2.36(m,1H),2.35(s,3H),2.33-2.29( m,2H),2.21(dd,J=11.6,8.4Hz,1H),2.06-2.00(m,1H),1.69-1.65(m,1H),1.61(dd,J=11.6,8.7Hz,1H). LC / MS(ESI)m / z:492.4[M+H]+ .

[0584] Step 5: 6-(4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[0585]

[0586] To a solution of methyl 6-(4-((3-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (12 mg, 0.02 mmol) in HO / THF / MeOH (0.3 M, 0.1 mL) was added LiOH·HO (3.0 mg, 0.06 mmol) and stirred for 4 hours. The reaction mixture was acidified by the addition of 1N aqueous HCl and extracted with EA (3 x 5 mL). The organic layer was dried over magnesium sulfate, filtered, concentrated, and then purified by silica gel column chromatography (hexane and ethyl acetate) to provide the compound of Example 7 (6.0 mg, 55% yield). 1 H NMR(500MHz,Chloroform-d)δ7.55(d,J=7.2Hz,2H),7.46(t,J=7.6Hz,2H),7.38(t,J=7.3Hz,1H),7.27( d,J=9.7Hz,2H),7.08(t,J=7.8Hz,1H),5.48(d,J=7.8Hz,1H),4.34(h,J=8.0Hz,1H),3.98(s,2H),3.03( p,J=8.4Hz,1H),2.50(dt,J=11.9,6.3Hz,1H),2.46(s,3H),2.41-2.36(m,2H),2.35(s,3H),2.34(s,1H) ,2.23(dd,J=11.7,8.2Hz,1H), 2.08(ddd,J=11.6,8.6,2.2Hz,1H), 1.64(ddd,J=20.8,11.4,8.5Hz,2H). LC / MS(ESI)m / z:478.2[M+H] + .

[0587] Example 8: 6-(4-((2-amino-[1,1′-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0588] Step 1: Synthesis of (2-amino-[1,1'-biphenyl]-4-yl)(4-bromo-2,5-dimethylthiophen-3-yl)methanone

[0589]

[0590] To a mixture of AlCl3 (1.74 g, 13.1 mmol) and DCM (42.2 mL, 0.3 M) was added intermediate C (2.5 g, 13.1 mmol) and stirred for 30 minutes. Intermediate F (2.95 g, 12.7 mmol) was then added to the reaction solution and stirred for 12 hours. The reaction solution was poured into ice, acidified with 1N aqueous citric acid solution, and then extracted twice with DCM. The organic layer was washed with distilled water and brine, dried over magnesium sulfate, concentrated under reduced pressure, and then purified by column chromatography to give (2-amino-[1,1'-biphenyl]-4-yl)(4-bromo-2,5-dimethylthiophen-3-yl)methanone (960 mg, yield 20%). 1 H NMR (300MHz, chloroform-d) δ7.50 (d, J = 4.4Hz, 4H), 7.44-7.40 (m, 1H), 7.31 (d, J = 1.2Hz, 1H), 7.26-7.22 (m, 2H), 4.02 (s, 2H), 2.41 (s, 3H), 2.37 (s, 3H).

[0591] Steps 2 to 5: 6-(4-((2-amino-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamide Synthesis of 2-(4-(2-amino-3-methyl)spiro[3.3]heptane-2-carboxylic acid

[0592]

[0593] The compound of Example 8 was prepared by reacting (2-amino-[1,1'-biphenyl]-4-yl)(4-bromo-2,5-dimethylthiophen-3-yl)methanone obtained in Step 1 in the same manner as in Steps 2 to 5 of Example 7. 1 H NMR(300MHz,chloroform-d)δ7.50-7.33(m,5H),7.08(d,J=7.7Hz,1H),6.63(d,J=8.7Hz,1H),6.57(s,1H),5.67(d,J=8.8Hz,1H),4.27(q,J=8.0H z,1H),3.91(s,2H),3.08-2.94(m,1H),2.46(s,4H),2.37(s,3H),2.31(d ,J=8.1Hz,3H),2.26-2.17(m,1H),2.11-2.01(m,1H),1.65-1.50(m,2H). LC / MS(ESI)m / z:475.5[M+H] + .

[0594] Example 9: 6-(2,5-dimethyl-4-(4-morpholinobenzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0595] Step 1: Synthesis of (4-bromo-2,5-dimethylthiophen-3-yl)(4-fluorophenyl)methanone

[0596]

[0597] At 0 ° C, SOCl2 (1.8 mL, 24.6 mmol) was added to a solution of 4-fluorobenzoic acid (3.0 g, 21.3 mmol) and DMF (about 1 mL) in toluene (24 mL, 0.8 M), and then stirred at 50 ° C for 5 hours. 3-Bromo-2,5-dimethylthiophene (3.7 g, 19.4 mmol) was added at 50 ° C, followed by a solution of TiCl4 (2.1 mL, 19.4 mmol). 1N HCl aqueous solution (30 mL) was added and stirred for 5 minutes, then the organic layer was extracted and the aqueous layer was washed twice with heptane. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to give (4-bromo-2,5-dimethylthiophen-3-yl) (4-fluorophenyl) ketone (1.45 g, yield 24%).

[0598] Step 2: Synthesis of (4-bromo-2,5-dimethylthiophen-3-yl)(4-morpholinophenyl)methanone

[0599]

[0600] To a solution of (4-bromo-2,5-dimethylthiophen-3-yl)(4-fluorophenyl)methanone (1.45 g, 4.62 mmol) and morpholine (1.2 mL, 13.9 mmol) in DMSO:H2O (8 mL, 0.6 M) was added K2CO3 (0.95 g, 6.5 mmol), then heated to 90 ° C and stirred for 8 hours. The reaction solution was diluted with distilled water and extracted twice with DCM. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to give (4-bromo-2,5-dimethylthiophen-3-yl)(4-morpholinophenyl)methanone (1.21 g, yield 69%).

[0601] Step 3: Synthesis of 4-(4-((4-bromo-2,5-dimethylthiophen-3-yl)methyl)phenyl)morpholine

[0602]

[0603] To a solution of (4-bromo-2,5-dimethylthiophen-3-yl)(4-morpholinophenyl)methanone (1.21 g, 3.2 mmol) in TFA (8 mL, 0.4 M) at -10°C was added Et3SiH (1.80 mL, 11.2 mmol) and stirred at room temperature for 12 hours. The reaction solution was poured into 10 mL of ice water and extracted with ethyl acetate (3 × 20 mL). The mixture was then washed with saturated aqueous sodium bicarbonate (20 mL), distilled water (10 mL), and brine (20 mL), and dried over sodium sulfate. The mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to yield 4-(4-((4-bromo-2,5-dimethylthiophen-3-yl)methyl)phenyl)morpholine (0.62 g, 53% yield). 1 H NMR (300MHz, Chloroform-d) δ7.08 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.3 Hz, 2H), 3.91-3.84 (m, 6H), 3.17-3.11 (m, 4H), 2.38-2.34 (m, 6H).

[0604] Step 4: Synthesis of 2,5-dimethyl-4-(4-morpholinobenzyl)thiophene-3-carboxylic acid

[0605]

[0606] To a solution of 4-(4-((4-bromo-2,5-dimethylthiophen-3-yl)methyl)phenyl)morpholine (0.62 g, 1.69 mmol), TMEDA (48 μL, 1.86 mmol), and THF (8.5 mL, 0.2 M) was slowly added n-BuLi (2.5 M in THF, 0.73 mL, 1.86 mmol) at -65°C, followed by stirring for 45 minutes. An excess of dry ice was added to the reaction solution at -65°C, and the mixture was stirred at room temperature for 1 hour. A 1N aqueous citric acid solution (2.0 mL) was added and stirred for 15 minutes. The organic layer was extracted, and the aqueous layer was washed twice with EA. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and concentrated to yield 2,5-dimethyl-4-(4-morpholinobenzyl)thiophene-3-carboxylic acid. 1 H NMR(500MHz,Chloroform-d)δ7.03(d,J=8.6Hz,2H),6.82(d,J=8.6Hz,2H),4.14( d,J=2.7Hz,2H),3.88-3.83(m,4H),3.13-3.09(m,4H),2.66(s,3H),2.32(s,3H).

[0607] Step 5: 6-(2,5-Dimethyl-4-(4-morpholinobenzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid Synthesis of methyl ester

[0608]

[0609] To a solution of 2,5-dimethyl-4-(4-morpholinobenzyl)thiophene-3-carboxylic acid (220 mg, 0.66 mmol), Intermediate A (148 mg, 0.72 mmol), and HATU (273 mg, 0.72 mmol) in DMF (2.2 mL, 0.3 M) was added DIPEA (0.4 mL, 1.98 mmol) and stirred for 3 hours. The reaction solution was concentrated, diluted with 1N NaOH aqueous solution and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography using n-hexane and ethyl acetate to obtain methyl 6-(2,5-dimethyl-4-(4-morpholinobenzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (157 mg, 49% yield). 1 H NMR(500MHz,Chloroform-d)δ7.01(d,J=8.6Hz,2H),6.85(d,J=8.7Hz,2H),5.41(d,J=7.7Hz,1H ),4.27(h,J=7.9Hz,1H),3.88(t,J=4.8Hz,6H),3.68(s,3H),3.14-3.10(m,4H),3.00(p,J=8.5Hz ,1H),2.45(s,4H),2.34(s,3H),2.31(ddd,J=12.4,8.6,4.9Hz,3H),2.21(dd,J=11.6,8.4Hz,1H) ,2.03(ddd,J=11.6,8.6,2.7Hz,1H), 1.57(dd,J=11.1,8.5Hz,1H), 1.50(dd,J=11.6,8.6Hz,1H).

[0610] Step 6: 6-(2,5-Dimethyl-4-(4-morpholinobenzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid Synthesis

[0611]

[0612] To a solution of methyl 6-(2,5-dimethyl-4-(4-morpholinobenzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (157 mg, 0.32 mmol) in H₂O / THF / MeOH (0.3 M, 1.1 mL) was added LiOH·H₂O (40 mg, 0.96 mmol) and stirred for 4 hours. The reaction mixture was acidified by the addition of 1N aqueous citric acid and extracted with ethyl acetate (3 x 5 mL). The organic layer was dried over magnesium sulfate, filtered, concentrated, and then purified by silica gel column chromatography (n-hexane and ethyl acetate) to provide the compound of Example 9 (12 mg, 8% yield). 1H NMR(500MHz,Chloroform-d)δ7.01(d,J=8.6Hz,2H),6.86(d,J=8.7Hz,2H),5.42(d,J=7 .7Hz,1H),4.26(h,J=7.9Hz,1H),3.88(t,J=4.8Hz,6H),3.15-3.10(m,4H),3.02(p,J=8 .3Hz,1H),2.45(s,4H),2.34(s,3H),2.31(dd,J=11.3,8.8Hz,3H),2.21(dd,J=11.7,8. 0Hz, 1H), 2.11-2.05 (m, 1H), 1.57 (dd, J=11.2, 8.3Hz, 1H), 1.48 (dd, J=11.6, 8.4Hz, 1H). LC / MS(ESI)m / z:469.4[M+H] + .

[0613] Example 10: 6-(4-([1,1′-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0614] Step 1: Synthesis of 4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carbonitrile

[0615]

[0616] To a solution of [1,1'-biphenyl]-4-yl(4-bromo-2,5-dimethylthiophen-3-yl)methanone (1.30 g, 3.5 mmol) obtained in Step 2 of Example 1 in DMF (58 mL, 0.06 M) was added CuCN (0.63 g, 7.0 mmol), and the mixture was stirred at 110°C for 24 hours. The reaction solution was concentrated, diluted with 1N aqueous HCl and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography (n-hexane and ethyl acetate) to obtain 4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carbonitrile (610 mg). 1 H NMR(500MHz,Chloroform-d)δ7.91(d,J=8.2Hz,2H),7.75(d,J=8.2Hz,2H),7.67(d,J =7.6Hz, 2H), 7.51 (t, J = 7.6Hz, 2H), 7.44 (t, J = 7.3Hz, 1H), 2.67 (s, 3H), 2.43 (s, 3H).

[0617] Step 2: Synthesis of 4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carboxylic acid

[0618]

[0619] 4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carbonitrile (340 mg, 1.07 mmol) was added to a 70% H2SO4 aqueous solution (5.3 mL, 0.2 M), followed by reflux and stirring at 110°C for 1 hour. The reaction solution was poured into ice water and extracted three times with DCM. The organic layer was dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography (DCM and MeOH) to obtain 4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carboxylic acid (42 mg, 12% yield). 1 H NMR (500MHz, Chloroform-d) δ7.85 (d, J = 8.4Hz, 2H), 7.66-7.61 (m, 4H), 7.48 (t, J = 7.5Hz, 2H), 7.42 (t, J = 7.3Hz, 1H), 2.68 (s, 3H), 2.27 (s, 3H).

[0620] Step 3: 6-(4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane Synthesis of methyl 2-alkanecarboxylate

[0621]

[0622] To a solution of 4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carboxylic acid (12 mg, 0.036 mmol), Intermediate A (17 mg, 0.08 mmol), and HATU (31 mg, 0.08 mmol) in DMF (0.3 mL, 0.3 M) was added DIPEA (0.04 mL, 0.22 mmol) and stirred for 3 hours. The reaction solution was concentrated, diluted with 1N aqueous NaOH and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography (n-hexane and ethyl acetate) to obtain methyl 6-(4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (33 mg, 55% yield). 1H NMR(500MHz,Chloroform-d)δ7.89(d,J=8.4Hz,2H),7.69(d,J=8.4Hz,2H),7.65(d, J=7.2Hz,2H),7.50(t,J=7.5Hz,2H),7.43(t,J=7.3Hz,1H),5.97(d,J=7.3Hz,1H),4. 09(dd,J=16.0,7.6Hz,1H),3.65(s,3H),2.96(p,J=8.5Hz,1H),2.60(s,3H),2.34(s, 4H), 2.26-2.17 (m, 4H), 2.09-2.03 (m, 1H), 1.66-1.63 (m, 1H), 1.60 (d, J = 9.0Hz, 1H). LC / MS(ESI)m / z:488.4[M+H] + .

[0623] Step 4: 6-(4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane Synthesis of alkane-2-carboxylic acids

[0624]

[0625] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-carbonyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (33 mg, 0.07 mmol) in HO / THF / MeOH (0.3 M, 0.2 mL) was added LiOH·HO (9 mg, 0.21 mmol) and stirred for 4 hours. The reaction mixture was acidified by the addition of 1N aqueous HCl and extracted with EA (3 x 20 mL). The organic layer was dried over magnesium sulfate, filtered, concentrated, and then purified by silica gel column chromatography (hexane and ethyl acetate) to provide the compound of Example 10 (20 mg, 63% yield). 1 H NMR(500MHz,Chloroform-d)δ7.89(d,J=8.3Hz,2H),7.69(d,J=8.3Hz,2H),7.64(d,J=7.3Hz,2H),7.50(t,J=7.5Hz,2H),7.43(t,J=7.3Hz,1H),6.03(d,J=7 .3Hz,1H),4.10(h,J=8.1Hz,1H),2.99(p,J=8.5Hz,1H),2.59(s,3H),2.34(s, 4H), 2.23 (dt, J=23.0, 9.6Hz, 4H), 2.10 (t, J=10.3Hz, 1H), 1.66-1.59 (m, 2H). LC / MS(ESI)m / z:474.4[M+H] + .

[0626] Example 11: 6-(4-([1,1′-biphenyl]-4-yl(hydroxy)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0627]

[0628] To a mixture of the compound of Example 10 (10 mg, 0.02 mmol) and ethanol (0.4 mL, 0.05 M) were added NaBH4 (1.5 mg, 0.04 mmol) and CaCl2 (2.0 mg, 0.02 mmol), and the mixture was stirred for 12 hours. Distilled water and ethyl acetate were added, and the aqueous layer was extracted with ethyl acetate (10 mL). The organic layer was dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography (DCM and MeOH) to obtain the compound of Example 11 (4.0 mg, 40% yield). 1 H NMR(500MHz,Methanol-d4)δ8.42(t,J=7.8Hz,1H),7.61(t,J=7.0Hz,2H),7.55(dd,J=8 .3,6.4Hz,2H),7.44(t,J=7.5Hz,2H),7.36-7.31(m,3H),5.94(d,J=3.9Hz,1H),4.00-3 .89(m,1H),2.90(dq,J=32.3,8.5Hz,1H),2.49(d,J=1.9Hz,3H),2.42(d,J=2.1Hz,3H), 2.37-2.15(m,4H),2.14-1.94(m,3H),1.74(dt,J=20.8,10.7Hz,1H),1.57-1.51(m,1H). LC / MS(ESI)m / z:474.3[M+H] - .

[0629] Example 12: 6-(4-([1,1′-biphenyl]-4-yl(methoxy)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0630] Step 1: Synthesis of [1,1'-biphenyl]-4-yl(4-bromo-2,5-dimethylthiophen-3-yl)methanol

[0631]

[0632] To a mixture of [1,1'-biphenyl]-4-yl(4-bromo-2,5-dimethylthiophen-3-yl)methanone (2.0 g, 5.39 mmol) and ethanol (108 mL, 0.05 M) obtained in step 2 of Example 1, NaBH4 (0.41 g, 10.8 mmol) and CaCl2 (0.60 g, 5.39 mmol) were added and stirred for 12 hours. Distilled water and ethyl acetate were added, and the aqueous layer was extracted with ethyl acetate (50 mL). The organic layer was dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography (DCM and MeOH) to obtain [1,1'-biphenyl]-4-yl(4-bromo-2,5-dimethylthiophen-3-yl)methanol (1.3 g, 62% yield). 1 H NMR (300MHz, Chloroform-d) δ7.65-7.57(m,4H),7.46(dd,J=7.9,3.8Hz,4H),7.37(t,J=7.3Hz,1H),6.13(dd,J=10.9,3.2Hz,1H),2.42-2.35(m,6H).

[0633] Step 2: Synthesis of 3-([1,1'-biphenyl]-4-yl(methoxy)methyl)-4-bromo-2,5-dimethylthiophene

[0634]

[0635] To a solution of [1,1'-biphenyl]-4-yl(4-bromo-2,5-dimethylthiophen-3-yl)methanol (900 mg, 2.41 mmol) in methanol (80 mL, 0.03 M) was added hydrochloric acid (35% aqueous solution, 19 mL, 214 mmol) and stirred for 12 hours. The reaction solution was concentrated, basified with aqueous sodium bicarbonate solution, and extracted with EA. The organic layer was dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography (0 to 5% MeOH in DCM) to give 3-([1,1'-biphenyl]-4-yl(methyloxy)methyl)-4-bromo-2,5-dimethylthiophene (680 mg, 50% yield). 1 H NMR (300MHz, Chloroform-d) δ7.63-7.54(m,4H),7.49-7.41(m,4H),7.35(t,J=7.3Hz,1H),5.68(s,1H),3.45(s,3H),2.41-2.35(m,6H).

[0636] Step 3: Synthesis of 4-([1,1'-biphenyl]-4-yl(methoxy)methyl)-2,5-dimethylthiophene-3-carboxylic acid

[0637]

[0638] To a solution of 3-([1,1'-biphenyl]-4-yl(methyloxy)methyl)-4-bromo-2,5-dimethylthiophene (517 mg, 1.33 mmol), TMEDA (0.22 mL, 1.46 mmol), and Et2O (6.7 mL, 0.2 M) at -65°C was slowly added n-BuLi (2.5 M in THF, 0.70 mL, 1.73 mmol). The mixture was stirred for 45 minutes, followed by the addition of excess dry ice. 1N aqueous HCl (10 mL) was added and stirred for 15 minutes, after which the organic layer was extracted and the aqueous layer was washed twice with EA. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and concentrated to afford 4-([1,1'-biphenyl]-4-yl(methyloxy)methyl)-2,5-dimethylthiophene-3-carboxylic acid (151 mg, 32% yield). 1 H NMR(300MHz,DMSO-d6)δ12.88(s,1H),7.67-7.58(m,4H),7.45(t,J=7.5Hz,2H ),7.36(d,J=8.1Hz,3H),6.11(s,1H),3.31(s,3H),2.54(s,3H),2.23(s,3H).

[0639] Step 4: 6-(4-([1,1'-biphenyl]-4-yl(methyloxy)methyl)-2,5-dimethylthiophene-3-carboxamido) Synthesis of methyl spiro[3.3]heptane-2-carboxylate

[0640]

[0641] To a solution of 4-([1,1'-biphenyl]-4-yl(methoxy)methyl)-2,5-dimethylthiophene-3-carboxylic acid (151 mg, 0.43 mmol), Intermediate A (96 mg, 0.47 mmol), and HATU (179 mg, 0.47 mmol) in DMF (1.4 mL, 0.3 M) was added DIPEA (0.22 mL, 1.3 mmol) and stirred for 3 hours. The reaction solution was concentrated, diluted with 1N aqueous NaOH and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography (n-hexane and ethyl acetate) to obtain methyl 6-(4-([1,1'-biphenyl]-4-yl(methoxy)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (138 mg, 64% yield). 1H NMR(300MHz,Chloroform-d)δ7.55(dt,J=9.7,7.2Hz,4H),7.45(t,J=7.6Hz,2H),7.35( td,J=7.6,3.6Hz,3H),5.63(s,1H),3.97(h,J=8.3Hz,1H),3.65(d,J=4.9Hz,3H),3.52(d ,J=0.9Hz,3H),2.95(dt,J=15.0,8.6Hz,1H),2.58(d,J=2.6Hz,3H),2.47(s,3H),2.44-2 .35(m,1H),2.29-2.11(m,4H),2.08-1.91(m,1H),1.78-1.65(m,1H),1.23-1.10(m,1H).

[0642] Step 5: 6-(4-([1,1'-biphenyl]-4-yl(methoxy)methyl)-2,5-dimethylthiophene-3-carboxamido) Synthesis of spiro[3.3]heptane-2-carboxylic acid

[0643]

[0644] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-yl(methoxy)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (138 mg, 0.27 mmol) in H2O / THF / MeOH (0.3 M, 0.9 mL) was added LiOH·H2O (34 mg, 0.81 mmol) and stirred for 12 hours. The reaction mixture was acidified by the addition of 1N aqueous HCl and extracted with EA (20 mL x 3). The organic layer was dried over magnesium sulfate, filtered, concentrated, and purified by silica gel column chromatography (hexane and ethyl acetate) to afford 6-(4-([1,1'-biphenyl]-4-yl(methoxy)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (121 mg, 90% yield). 1 H NMR (300MHz, DMSO-d6) δ12.02(s,1H),8.41(d,J=7.3Hz,1H),7.62(dd,J=13.7,7.8Hz,4H),7.41(tt,J=15.5,7.2Hz,5H),5.51(s,1H),4.17( h,J=8.0Hz,1H),3.30(s,3H),2.92(p,J=8.5Hz,1H),2.45-2.30(m,4H),2.28-2.14(m,6H),2.12-2.03(m,2H),1.91(tt,J=19.4,8.9Hz,2H). LC / MS(ESI)m / z:488.3[M+H] - .

[0645] Example 13: 6-(4-([1,1′-biphenyl]-4-ylmethyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0646] Step 1: Preparation of 2-([1,1'-biphenyl]-4-ylmethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane synthesis

[0647]

[0648] A solution of 4-bromomethylbiphenyl (600 mg, 2.44 mmol), K2CO3 (1.0 g, 7.28 mmol), (pinacol)diboron (740 mg, 2.92 mmol), and Pd(PPh3)4 (140 mg, 0.12 mmol) in dioxane (12 mL) was stirred at 100°C for 12 hours. Ethyl acetate (20 mL) was added, and the precipitate was removed by filtration through celite. The organic layer was concentrated under reduced pressure, and the crude product was purified by flash column chromatography (0 to 100% hexanes / EtOAc) to afford 2-([1,1'-biphenyl]-4-ylmethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (61 mg, 86% yield) as a white solid. 1 H NMR(300MHz,Chloroform-d)δ7.60-7.54(m,2H),7.49-7.45(m,2H),7.44-7. 37(m,2H),7.33-7.29(m,1H),7.27-7.24(m,2H),2.34(s,2H),1.25(s,12H).

[0649] Step 2: Synthesis of methyl 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylate

[0650]

[0651] Under N2 conditions, a solution of 3-bromobenzo[b]thiophene-2-carboxylic acid methyl ester (300 mg, 1.32 mmol), 2-(biphenyl-4-ylmethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (192 mg, 0.528 mmol) and Pd(PPh3)4 (60 mg) in THF (18 mL) and 2N K2CO3 aqueous solution was placed in a flask and stirred at 85°C for 12 hours. The reaction solution was cooled to room temperature and then extracted with distilled water and EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and then concentrated under reduced pressure. Purification by silica gel column chromatography gave 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid methyl ester (306 mg, 75% yield) as a light yellow oil. 1H NMR(400MHz,chloroform-d)δ10.07(s,1H),8.12(d,J=3.6Hz,1H),7.99-7.94(m,1H),7.78-7.73(m,1H),7.67-7.62(m,1 H),7.61-7.53(m,1H),7.52-7.46(m,2H),7.45-7.41(m,1H),7.41-7.36(m,1H),7.32(d,J=3.7Hz,1H),3.91-3.87(m,5H).

[0652] Step 3: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid

[0653]

[0654] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylate (121 mg, 0.39 mmol) in THF (0.18 mL) was added 2N aqueous NaOH (0.2 mL) and stirred at 65°C for 12 hours. The reaction solution was cooled to room temperature, then adjusted to pH 2 with 2N aqueous HCl, stirred for 2 hours, and then extracted with EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Purification by column chromatography gave 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid (51 mg, 42% yield) as a white solid. 1 H NMR(500MHz,chloroform-d)δ8.28(d,J=3.6Hz,1H),7.59-7.57(m,2H),7.54(d,J=7.9Hz,2H) ,7.47-7.44(m,2H),7.33(s,1H),7.32-7.28(m,2H),6.83(dd,J=2.8,1.7Hz,1H),4.31(s,2H).

[0655] Step 4: 6-(4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid Synthesis of esters

[0656]

[0657] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylate (30 mg, 0.1 mmol) in DCM (1 mL) was added Intermediate A (20 mg, 0.12 mmol), HATU (36 mg, 0.12 mmol), and DIPEA (0.03 mL, 0.4 mmol) and stirred for 12 hours. EtOAc and brine were added to the reaction solution, and the organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (26 mg, 59% yield) as a white solid. 1 H NMR(300MHz,chloroform-d)δ7.63(d,J=3.2Hz,1H),7.61-7.51(m,4H),7.45(d dd,J=7.6,6.8,1.3Hz,2H),7.38-7.32(m,1H),7.30(s,1H),7.27(s,1H),6.97(d t,J=3.2,0.9Hz,1H),5.82(d,J=7.7Hz,1H),4.39-4.27(m,1H),4.23(s,2H),3.6 8(s,3H),3.02(p,J=8.4Hz,1H),2.54(tt,J=7.5,5.2Hz,1H),2.46-2.38(m,1H).

[0658] Step 5: Preparation of 6-(4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid synthesis

[0659]

[0660] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (20 mg, 0.04 mmol) in THF was added 2N aqueous NaOH solution and stirred at 65°C for 12 hours. The reaction solution was cooled to room temperature, and then 2N aqueous HCl was added to adjust the pH to 2. The mixture was stirred for 2 hours and then extracted with EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered, and then concentrated under reduced pressure. Purification by column chromatography gave Example 13 (3.2 mg, 19% yield) as a white solid. 1H NMR(500MHz,chloroform-d)δ7.61(d,J=3.2Hz,1H),7.58-7.55(m,2H),7.54-7.50(m,2H),7.45- 7.40(m,2H),7.36-7.31(m,1H),7.27(s,2H),6.95(dt,J=3.3,0.9Hz,1H),5.80(d,J=7.6Hz,1H), 4.33(h,J=8.0Hz,1H),4.21(s,2H),3.04(p,J=8.5Hz,1H),2.55-2.49(m,1H),2.44-2.38(m,1H), 2.35(dd,J=8.5,2.6Hz,2H),2.26(dd,J=11.8,8.2Hz,1H),2.12-2.08(m,1H),1.78-1.71(m,2H). LC / MS(ESI)m / z:432.3[M+H] + .

[0661] Example 14: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-2-methylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0662] Step 1: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid

[0663]

[0664] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylate (120 mg, 0.4 mmol) obtained in Step 2 of Example 13 in THF / MeOH / H2O (2 / 1 / 2 mL) was added LiOH·H2O (51 mg, 1.20 mmol, 3.0 equiv) and stirred for 3 hours. The reaction mixture was partially concentrated and acidified with 1N HCl, and the aqueous layer was extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (15% EtOAc / hexane) to afford 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid (101 mg, 86% yield) as a white solid. 1 H NMR (400MHz, Chloroform-d) δ10.02 (s, 1H), 8.23 ​​(dd, J = 3.1, 1.2Hz, 1H), 7.60-7.5 2(m,6H),7.44-7.40(m,1H),7.35-7.28(m,2H),6.82(d,J=3.3Hz,1H),4.31(s,2H).

[0665] Step 2: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-2-methylthiophene-3-carboxylic acid

[0666]

[0667] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylate (70 m, 0.12 mmol) in THF (1 mL) cooled to -78°C was added n-BuLi (2.5 M in THF, 125 μL, 0.27 mmol) and stirred for 30 minutes. Iodomethane (18 μL, 0.31 mmol) was slowly added at -78°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was quenched with distilled water (15 mL) and EtOAc, and then purified by silica gel column chromatography to obtain 4-([1,1'-biphenyl]-4-ylmethyl)-2-methylthiophene-3-carboxylic acid (32 mg, 45% yield) as a white solid. 1 H NMR(300MHz,Chloroform-d)δ7.60-7.51(m,3H),7.48-7.38(m,3H),7.35-7.26 (m, 2H), 7.00 (d, J = 5.4Hz, 1H), 6.50 (d, J = 1.2Hz, 1H), 4.24 (s, 2H), 2.77 (s, 3H).

[0668] Step 3: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2-methylthiophene-3-carboxamido)spiro[3.3]heptane- Synthesis of methyl 2-carboxylate

[0669]

[0670] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)-2-methylthiophene-3-carboxylic acid (30 mg, 0.096 mmol) in MeCN (0.6 mL) was added 4-(4,6-dimethoxy-[1,3,5]triazin-2-yl)-4-methylmorpholine-4-hydrochloride (DMT-MM) (27 mg, 0.105 mmol) and stirred for 1 hour. Intermediate A (15 mg, 0.105 mmol) and N-methylpyrrolidone (25.8 μL) were added to the reaction mixture, stirred for 12 hours, and then quenched with distilled water and EtOAc. The crude product was purified by column chromatography (hexane:EA (35%)) to give methyl 6-(4-([1,1′-biphenyl]-4-ylmethyl)-2-methylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (18 mg, yield 40%). 1H NMR(500MHz,Chloroform-d)δ7.57-7.54(m,2H),7.52-7.49(m,2H),7.43(dd,J=8.5,6.9Hz,2H),7.3 6-7.32(m,1H),7.25-7.21(m,2H),6.74(s,1H),5.46(d,J=7.7Hz,1H),4.35-4.27(m,1H),4.02(s,2H) ,3.65(s,3H),2.96(q,J=8.5Hz,1H),2.50(s,3H),2.48-2.44(m,1H),2.37-2.33(m,1H),2.29(dd,J= 8.5, 4.0Hz, 2H), 2.20 (dd, J=11.7, 8.4Hz, 1H), 2.02 (ddd, J=11.6, 8.6, 2.7Hz, 1H), 1.66-1.61 (m, 2H).

[0671] Step 4: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2-methylthiophene-3-carboxamido)spiro[3.3]heptane- Synthesis of 2-carboxylic acid

[0672]

[0673] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2-methylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (10 mg) in THF / MeOH / H₂O (2 / 1 / 2 mL) was added LiOH·H₂O (2 mg, 3.0 equiv) and stirred for 3 hours. The reaction mixture was partially concentrated and then acidified with 1N aqueous HCl. The aqueous layer was extracted with EtOAc, and the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane:EA (60%)) to provide Example 14 (2.3 mg, 24% yield). 1 H NMR(500MHz,Methanol-d4)δ7.61-7.58(m,2H),7.53-7.50(m,2H),7.43(td,J=7.9, 2.1Hz,2H),7.32(td,J=7.2,1.4Hz,1H),7.24(t,J=8.4Hz,2H),6.89(s,1H),4.21-4 .16(m,1H),4.01(s,2H),2.96(q,J=8.5Hz,1H),2.44(s,3H),2.43-2.37(m,1H),2.3 5-2.26(m,3H),2.16(dd,J=11.8,8.4Hz,1H),2.10-2.05(m,1H),1.86-1.79(m,2H). LC / MS(ESI)m / z:446.58[M+H] +,444.42[M+H] - .

[0674] Example 15: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0675] Step 1: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid

[0676]

[0677] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylate (1.3 g, 4.215 mmol) obtained in Step 2 of Example 13 in THF / MeOH / H₂O (2 / 1 / 2 mL) was added LiOH·H₂O (530 mg, 12.645 mmol, 3.0 equiv) and stirred for 12 hours. The reaction mixture was partially concentrated and then acidified with 1N aqueous HCl. The aqueous layer was extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was then purified on a silica gel column to afford 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid (350 mg, 28% yield) as a creamy white solid. 1 H NMR(400MHz,Chloroform-d)δ8.32-8.28(m,1H),7.64-7.60(m,2H),7.60-7.55 (m,2H),7.48-7.43(m,2H),7.37-7.32(m,3H),6.89-6.82(m,1H),4.34(s,2H).

[0678] Step 2: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxylic acid

[0679]

[0680] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid (200 mg, 0.66 mmol) in THF (1 mL) at 0°C was added Br2 (0.04 mL, 0.69 mmol) and stirred for 4 hours. The reaction solution was acidified with 1N aqueous HCl, and the aqueous layer was extracted with diethyl ether. The organic layer was then washed with distilled water, dried over magnesium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel flash column chromatography to afford 4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxylic acid (132 mg, 28% yield) as a brown solid. 1H NMR(500MHz,Chloroform-d)δ8.29(s,1H),7.59-7.54(m,2H),7.52-7.48(m,2H),7.44-7 .40(m,2H),7.36-7.31(m,1H),7.30-7.29(m,1H),7.29-7.27(m,1H),4.41-4.36(m,2H).

[0681] Step 3: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxamido)spiro[3.3]heptane-2-yl Synthesis of methyl carboxylate

[0682]

[0683] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxylic acid (50 mg, 0.134 mmol) and HATU (56 mg, 0.147 mmol) in DMF (1 mL) was added DIPEA (0.070 mL, 0.402 mmol), and intermediate A (17 mg, 0.120 mmol) was added to the reaction solution and stirred for 15 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water and brine solution. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (20% ethyl acetate in hexane) to give methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (44.9 mg, yield 64%) as a milky white solid. 1 H NMR(500MHz,Chloroform-d)δ7.56-7.53(m,3H),7.50-7.48(m,2H),7.44-7.39( m,2H),7.35-7.31(m,1H),7.26-7.22(m,2H),5.82-5.76(m,1H),4.28-4.23(m,1H ),4.22(s,2H),3.63(s,3H),3.02-2.91(m,1H),2.48-2.41(m,1H),2.35-2.31(m, 1H),2.30-2.25(m,2H),2.22-2.16(m,1H),2.04-1.96(m,1H),1.68-1.59(m,2H).

[0684] Step 4: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxamido)spiro[3.3]heptane-2-yl Synthesis of carboxylic acids

[0685]

[0686] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (20 mg, 0.038 mmol) in THF / MeOH / H₂O (2 / 1 / 2 mL) was added LiOH·H₂O (5 mg, 0.114 mmol, 3.0 equiv) and stirred for 3 hours. The reaction mixture was partially concentrated and then acidified with 1N HCl, and the aqueous layer was extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified on a silica gel column to afford Example 15 (15 mg, 77% yield) as an off-white solid. 1 H NMR(400MHz,Chloroform-d)δ7.58(s,1H),7.56-7.52(m,2H),7.51-7.47(m,2H) ,7.45-7.40(m,2H),7.36-7.30(m,1H),7.25-7.21(m,2H),5.74-5.68(m,1H),4.3 3-4.26(m,1H),4.23(s,2H),3.05-2.94(m,1H),2.50-2.41(m,1H),2.39-2.35(m, 1H),2.34-2.29(m,2H),2.24-2.16(m,1H),2.07-1.99(m,1H),1.68-1.58(m,2H). LC / MS(ESI)m / z:510.51[M+H] + ,508.35[MH] - .

[0687] Example 16: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0688] Step 1: Synthesis of methyl 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxylate

[0689]

[0690] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylate (100 mg, 0.324 mmol) obtained in Step 2 of Example 13 in DMF (3 mL) was added NBS (287 mg, 1.622 mmol), and the mixture was stirred at 80°C for 24 hours. 10% aqueous sodium bicarbonate solution and EA were added to the reaction solution, and the organic layer was dried over magnesium sulfate and concentrated to afford methyl 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxylate (76 mg, 50% yield) as a white solid. 1H NMR (300MHz, CDCl3) δ7.59-7.53(m,2H),7.51-7.46(m,2H),7.44-7.39(m,2H),7.30-7.33(m,1H),7.18(d,J=8.2Hz,2H),4.23(s,2H),3.76(s,3H).

[0691] Step 2: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxylic acid

[0692]

[0693] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxylate (76 mg, 0.163 mmol) in THF / MeOH / H₂O (1 / 1 / 1 mL) was added LiOH·H₂O (21 mg, 0.489 mmol) and stirred for 12 hours. The reaction mixture was partially concentrated and then acidified with 1N aqueous HCl. The aqueous layer was extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated to afford 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxylic acid (35.5 mg, 47% yield) as a white solid. 1 HNMR (300MHz, CDCl3) δ7.50-7.56(m,2H),7.47(d,J=8.2Hz,2H),7.45-7.40(m,2H),7.35-7.32(m,1H),7.19(d,J=8.2Hz,2H),4.29(s,2H).

[0694] Step 3: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxamido)spiro[3.3]heptane Synthesis of methyl 2-alkanecarboxylate

[0695]

[0696] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxylic acid (35.5 mg, 0.079 mmol) and HATU (33 mg, 0.086 mmol) in DMF (1 mL) was added DIPEA (0.041 mL, 0.237 mmol), followed by Intermediate A (18 mg, 0.086 mmol), and stirred for 15 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water and brine solution. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to give methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (43.8 mg, 92% yield) as a white solid. 1H NMR (300MHz, CDCl3) δ7.57-7.51(m,2H),7.50-7.40(m,4H),7.37-7.30(m,1H),7.20(s,2H),5.58(d,J=7.9Hz,1H),4.32-4.24(m,1H),4.1 1(s,2H),3.65(s,3H),3.02-2.91(m,1H),2.50-2.42(m,1H),2.25-2.40(m,3H),2.20-2.17(m,1H),2.06-1.99(m,1H),1.73-1.63(m,2H).

[0697] Step 4: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxamido)spiro[3.3]heptane Synthesis of alkane-2-carboxylic acids

[0698]

[0699] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dibromothiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (42 mg, 0.070 mmol) in THF / MeOH / H₂O (1 / 1 / 1 mL) was added LiOH·H₂O (9 mg, 0.209 mmol) and stirred for 12 hours. The reaction mixture was partially concentrated, then acidified with 1N aqueous HCl, and filtered to afford Example 16 (4 mg, 4% yield) as a white solid. 1 H NMR (300MHz, CDCl3) δ7.56-7.51(m,2H),7.50-7.39(m,4H),7.36-7.33(m,1H),7.21(d,J=8.2Hz,2H),5.58(d,J=7.7Hz,1H),4 .32-4.24(m,1H),4.11(s,2H),3.06-2.95(m,1H),2.51-2.29(m,4H),2.25-2.17(m,1H),2.14-2.04(m,1H),1.77-1.63(m,2H). LC / MS(ESI)m / z:590.4[M+H] + .

[0700] Example 17: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-2,5-dichlorothiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0701] Step 1: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dichlorothiophene-3-carboxylic acid

[0702]

[0703] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylic acid (110 mg, 0.374 mmol) obtained in Step 3 of Example 13 in DMF (3.6 mL) was added NCS (250 mg, 1.869 mmol), heated to 70°C, and stirred for 24 hours. The reaction solution was quenched with 10% aqueous sodium bicarbonate solution. After 15 minutes, it was extracted with EA and distilled water, dried over magnesium sulfate, and concentrated to give crude 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dichlorothiophene-3-carboxylic acid (34.4 mg, 25% yield). 1 H NMR (300MHz, CDCl3) δ7.58-7.52(m,2H),7.52-7.46(m,2H),7.42(td,J=8.2,1.8Hz,3H),7.36(s,1H),7.23(d,J=8.2Hz,2H),4.29(s,2H).

[0704] Steps 2 and 3: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dichlorothiophene-3-carboxamido)spiro[3.3] Synthesis of heptane-2-carboxylic acid

[0705]

[0706] The compound of Example 17 was prepared by reacting 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dichlorothiophene-3-carboxylic acid obtained in the above Step 1 in the same manner as in Steps 3 and 4 of Example 16. 1 H NMR (300MHz, CDCl3) δ7.57-7.51(m,2H),7.50-7.39(m,4H),7.34-7.31(m,1H),7.22(d,J=8.2Hz,2H),5.68(d,J=7.6 Hz,1H),4.33-4.25(m,1H),4.11(s,2H),3.07-2.95(m,1H),2.53-2.30(m,4H),2.27-2.03(m,2H),1.75-1.66(m,2H). LC / MS(ESI)m / z:500.3[M+H] + .

[0707] Example 18: 6-(3-([1,1′-biphenyl]-4-ylmethyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0708] Step 1: Synthesis of 3-([1,1'-biphenyl]-4-ylmethyl)thiophene-2-carboxylic acid

[0709]

[0710] To a solution of thiophene-2-carboxylic acid (200 mg, 1.561 mmol) in THF (15 mL) was slowly added n-BuLi (10 M in THF, 0.324 mL, 3.434 mmol) at -78°C for 0.5 hours, followed by the addition of 4-(bromomethyl)-1,1'-biphenyl (772 mg, 3.122 mmol). The reaction mixture was stirred for 6 hours, then quenched with 1N aqueous HCl and extracted with EA and distilled water. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by flash column chromatography to give 3-([1,1'-biphenyl]-4-ylmethyl)thiophene-2-carboxylic acid (28 mg, 6% yield) as a white solid. 1 H NMR (300MHz, CDCl3) δ7.60-7.55(m,2H),7.55-7.48(m,3H),7.45-7.40(m,2H),7.35-7.28(m,3H),6.93(d,J=5.1Hz,1H),4.45(s,2H).

[0711] Step 2: 6-(3-([1,1'-biphenyl]-4-ylmethyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylic acid Synthesis of esters

[0712]

[0713] To a DCM (1 mL) solution of 3-([1,1'-biphenyl]-4-ylmethyl)thiophene-2-carboxylic acid (26 mg, 0.088 mmol) and HATU (20 mg, 0.097 mmol) was added DIPEA (0.046 mL, 0.264 mmol) and stirred for 10 minutes. Intermediate A (20 mg, 0.097 mmol) was added to the reaction solution and stirred for 15 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water and brine solution. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (20% EtOAc in hexane) to give methyl 6-(3-([1,1'-biphenyl]-4-ylmethyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylate (32 mg, yield 82%) as a white solid. 1H NMR (300MHz, CDCl3) δ7.59-7.50(m,4H),7.42(t,J=7.3Hz,2H),7.34(d,J=7.3Hz,1H),7.32-7.27(m,3H),6.92(d,J=5.0Hz,1H),5.84(d,J=7.5Hz,1H ),4.50-4.34(m,3H),3.66(s,3H),3.07-2.96(m,1H),2.59-2.51(m,1H),2 .46-2.40(m,1H),2.35-2.22(m,3H),2.14-2.07(m,1H),1.87-1.76(m,2H).

[0714] Step 3: Preparation of 6-(3-([1,1'-biphenyl]-4-ylmethyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylic acid synthesis

[0715]

[0716] To a solution of methyl 6-(3-([1,1'-biphenyl]-4-ylmethyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylate (32 mg, 0.072 mmol) in THF / MeOH / H₂O (1 / 1 / 1) was added LiOH·H₂O (9 mg, 0.209 mmol), and the mixture was stirred for 12 hours. The reaction mixture was partially concentrated, then acidified with 1N aqueous HCl, and filtered to afford Example 18 (30.7 mg, 99% yield) as a light yellow solid. 1 H NMR (300MHz, CDCl3) δ7.59-7.50 (m, 4H), 7.42 (t, J = 7.4Hz, 2H), 7.34 (d, J = 7 .4Hz,1H),7.31-7.26(m,3H),6.92(d,J=5.0Hz,1H),5.85(d,J=7.5Hz,1H),4 .47-4.29(m,3H),3.11-2.99(m,1H),2.60-2.52(m,1H),2.46-2.40(m,1H), 2.38-2.36(m,2H),2.30-2.26(m,1H),2.18-2.14(m,1H),1.87-1.77(m,2H). LC / MS(ESI)m / z:432.4[M+H] + .

[0717] Example 19: 6-(3-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0718] Steps 1 and 2: Synthesis of methyl 6-(3-(4-chlorobenzyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylate

[0719]

[0720] Methyl 6-(3-(4-chlorobenzyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylate was obtained by the same procedure as in Steps 1 and 2 of Example 18, except that 4-(bromomethyl)-1,1′-biphenyl in Step 1 of Example 18 was replaced with 4-chlorobenzyl bromide. 1 H NMR(300MHz,chloroform-d)δ7.25-7.17(m,3H),7.17-7.09(m,2H),6.80(d,J=5.0Hz,1H),5.95(d,J=7.5Hz,1H),4.42-4.28(m,1H),4.2 4(s,2H),3.64(s,3H),3.06-2.95(m,1H),2.57-2.49(m,1H),2.46-2.36(m,1H),2.34-2.22(m,3H),2.17-2.07(m,1H),1.91-1.80(m,2H).

[0721] Step 3: 6-(3-((3'-Fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)thiophene-2-carboxamido )screw [3.3] Synthesis of methyl heptane-2-carboxylate

[0722]

[0723] Methyl 6-(3-(4-chlorobenzyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylate (286 mg, 0.7 mmol), 3-fluoro-5-methoxyphenylboronic acid (178 mg, 1.05 mmol, 1.5 equiv), Pd(OAc) (16 mg, 0.07 mmol, 0.1 equiv), XPhos (67 mg, 0.14 mmol, 0.2 equiv), and KPO (297 mg, 1.4 mmol, 2.0 equiv) were stirred in dioxane / H2O (10 / 1 mL) at 100°C under microwave irradiation for 2 hours. The reaction solution was poured into distilled water and extracted with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography to give methyl 6-(3-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylate. 1H NMR(300MHz,chloroform-d)δ7.47(d,J=8.2Hz,2H),7.33-7.27(m,2H),6.93-6.80(m,3H),6.58(dt,J=10.5,2.3Hz,1H),5.89(d,J=7.5Hz,1H),4.44 -4.35(m,1H),4.34(s,2H),3.83(s,3H),3.65(s,3H),3.07-2.96(m,1H),2 .63-2.49(m,1H),2.47-2.24(m,4H),2.15-2.07(m,1H),1.90-1.79(m,2H).

[0724] Step 4: 6-(3-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)thiophene-2-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[0725]

[0726] The compound of Example 19 was prepared by reacting methyl 6-(3-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)thiophene-2-carboxamido)spiro[3.3]heptane-2-carboxylate obtained in the above Step 3 in the same manner as in Step 3 of Example 18. 1 H NMR(300MHz, Methanol-d4); δ8.15(d,J=7.2Hz,1H),7.50(d,J=8.2Hz,2H),7.42 (d,J=5.0Hz,1H),7.26(d,J=8.3Hz,2H),6.94(t,J=1.9Hz,1H),6.92-6.86(m,2H ),6.64(dt,J=10.7,2.3Hz,1H),4.31-4.23(m,3H),3.83(s,3H),3.07-2.95(m,1 H),2.54-2.46(m,1H),2.39-2.30(m,3H),2.29-2.14(m,2H),2.07-1.96(m,2H). LC / MS(ESI)m / z:480.4[M+H] + .

[0727] Example 20: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0728] Step 1: Synthesis of methyl 4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxylate

[0729]

[0730] At room temperature, N-bromosuccinimide (NBS, 115 mg, 0.649 mmol) was slowly added to the AcOH solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)thiophene-3-carboxylate (200 mg, 0.649 mmol) obtained in step 2 of Example 13. After stirring for 15 hours, the reaction solution was extracted with DCM and washed with aqueous sodium carbonate solution and distilled water. The organic layer was washed twice with distilled water, dried over magnesium sulfate, then filtered and concentrated under reduced pressure. The crude product was purified by silica gel (hexane) column chromatography to give methyl 4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxylate (150 mg, yield 59%) as a yellow solid. 1 H NMR (300MHz, Chloroform-d) δ8.16(s,1H),7.64-7.59(m,2H),7.57-7.53(m,2H),7.49-7.43(m,2H),7.39-7.30(m,3H),4.42(s,2H),3.83(s,3H).

[0731] Step 2: Synthesis of methyl 4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxylate

[0732]

[0733] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)-5-bromothiophene-3-carboxylate (200 mg, 0.516 mmol) in THF (10 mL) was added iodomethane (0.065 mL, 1.548 mmol, 3.0 equiv) and cooled to -78°C. n-BuLi (2M in THF, 0.516 mL, 1.032 mmol) was added to the reaction mixture, stirred for 4 hours, then slowly warmed to room temperature, diluted with ethyl acetate, and washed with distilled water. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to yield crude methyl 4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxylate (49 mg) as a yellow oil. 1 H NMR(400MHz,Chloroform-d)δ7.99(s,1H),7.61-7.59(m,2H),7.53-7.51(m,2H),7.46-7 .44(m,2H),7.37-7.33(m,2H),7.23-7.22(m,1H),4.36(s,2H),3.82(s,3H),2.46(s,3H).

[0734] Step 3: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxylic acid

[0735]

[0736] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxylate (20 mg, 0.062 mmol) in THF / MeOH / H₂O (2 / 1 / 2) was added LiOH·H₂O (8 mg, 0.186 mmol, 3 equivalents) and stirred for 8 hours. The reaction mixture was partially concentrated and then acidified with 1N aqueous HCl. The aqueous layer was extracted with EtOAc, and the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified on a silica gel column to afford 4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxylic acid (4.3 mg, 22% yield) as a creamy white solid. 1 H NMR(300MHz,chloroform-d)δ8.10(s,1H),7.59-7.54(m,2H),7.50-7.47(m,2H),7 .45-7.39(m,2H),7.36-7.31(m,1H),7.22-7.16(m,2H),4.34(s,2H),2.44(s,3H).

[0737] Step 4: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxamido)spiro[3.3]heptane- Synthesis of methyl 2-carboxylate

[0738]

[0739] To a DMF solution of 4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxylic acid (7.3 mg, 0.024 mmol) and HATU (10 mg, 0.026 mmol) was added DIPEA (0.013 mL, 0.072 mmol) and stirred for 10 minutes, followed by the addition of Intermediate A (4 mg, 0.026 mmol) and stirring for 15 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water and brine. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (20% EtOAc in hexane) to give methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (6.9 mg, 63% yield) as a yellow solid. 1H NMR(400MHz,chloroform-d)δ7.58-7.56(m,2H),7.52-7.50(m,2H),7.47-7.43(m,2H), 7.41(s,1H),7.38-7.33(m,1H),7.22-7.17(m,2H),5.77-5.71(m,1H),4.36-4.28(m,1H ),4.19(s,2H),3.67(s,3H),3.04-2.95(m,1H),2.52-2.48(m,1H),2.46(s,3H),2.40-2 .34(m,1H),2.34-2.27(m,2H),2.26-2.18(m,1H),2.08-2.00(m,1H),1.68-1.63(m,2H).

[0740] Step 5: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxamido)spiro[3.3]heptane- Synthesis of 2-carboxylic acid

[0741]

[0742] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-5-methylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (6.8 mg, 0.015 mmol) in THF / MeOH / H₂O (2 / 1 / 2) was added LiOH·H₂O (2 mg, 0.044 mmol, 3.0 equiv) and stirred for 3 hours. The reaction mixture was partially concentrated and then acidified with 1N aqueous HCl. The aqueous layer was then extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified on a silica gel column to afford Example 20 (4.7 mg, 70% yield) as a creamy white solid. 1 H NMR(500MHz,chloroform-d)δ7.58-7.56(m,2H),7.53-7.50(m,2H),7.47-7.43(m,3H),7.38-7.34(m,1H),7.22-7.17(m,2H),5.76-5.71(m,1H),4.31-4 .29(m,1H),4.19(s,2H),3.05-2.98(m,1H),2.52-2.49(m,1H),2.46(s,3H), 2.36-2.33(m,3H),2.27-2.22(m,1H),2.10-2.05(m,1H),1.71-1.65(m,2H). LC / MS(ESI)m / z:446.11[M+H] + ,444.28[MH] - .

[0743] The compounds of Examples 21 and 22 were prepared using the same procedures as in Example 20 except for the differences described below.

[0744] [Table 3]

[0745]

[0746] [Table 4]

[0747]

[0748]

[0749] Example 23: 6-(4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0750] Step 1: Synthesis of 3-bromo-4-(4-chlorobenzyl)-2,5-dimethylthiophene

[0751]

[0752] To a solution of (4-chlorophenyl)methanol (427 mg, 3.0 mmol) in DCE (3 mL) were added intermediate C (1.15 g, 6.0 mmol), MsOH (78 μL, 1.20 mmol) and FeCl3 (194 mg, 1.20 mmol), then heated to 55 ° C and stirred for 12 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water and brine solution. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The crude product was purified by column chromatography to give bromo-4-(4-chlorobenzyl)-2,5-dimethylthiophene (541 mg, yield 57%) as a white solid. 1 H NMR (300MHz, chloroform-d) δ7.28-7.20 (m, 2H), 7.08 (d, J = 8.6Hz, 2H), 3.91 (s, 2H), 2.37 (s, 3H), 2.35 (s, 3H).

[0753] Step 2: Synthesis of 4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxylic acid

[0754]

[0755] To a solution of 3-bromo-4-(4-chlorobenzyl)-2,5-dimethylthiophene (541 mg, 1.71 mmol) and TMEDA (0.3 mL, 1.88 mmol) in THF (10 mL) was added n-BuLi (2.5 M in THF, 0.8 mL, 2.0 mmol) at -78°C and stirred for 1 hour. The reaction solution was quenched with CO2 gas at -78°C and allowed to stand at room temperature for 30 minutes. The reaction solution was acidified with 1N HCl solution, diluted with EtOAc, and then washed with distilled water. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure to give 4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxylic acid (450 mg, crude product) as a light yellow solid. LC / MS (ESI) m / z: 281.26 [M+H] + .

[0756] Step 3: 6-(4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid Synthesis of esters

[0757]

[0758] To a solution of 4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxylic acid (450 mg, 1.60 mmol) and HATU (670 mg, 1.76 mmol) in DMF (8 mL) was added DIPEA (0.8 mL, 4.81 mmol) and stirred for 10 minutes. Intermediate A (330 mg, 1.60 mmol) was then added to the reaction solution and stirred for 15 hours. The reaction solution was diluted with EtOAc and washed with distilled water and brine solution. The organic layer was dried over sodium sulfate and then concentrated under reduced pressure. The crude product was purified by column chromatography to give methyl 6-(4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (418 mg, yield 56%) as a white solid. 1 HNMR(400MHz,chloroform-d)δ7.23(d,J=8.5Hz,2H),7.04(d,J=8.4Hz,2H),5.47-5.17(m,1H),4.36-4.17(m,1H),3.91(s,2H),3.69(s ,3H),3.02(t,J=8.5Hz,1H),2.54-2.41(m,4H),2.40-2.29(m,5H),2.25(dd,J=11.7,8.4Hz,1H),2.13-2.01(m,1H),1.68-1.52(m,3H). LC / MS(ESI)m / z:432.37[M+H] + .

[0759] Step 4: Preparation of 6-(4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid synthesis

[0760]

[0761] To a solution of methyl 6-(4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (43 mg, 0.1 mmol) in H₂O:THF:MeOH (1:1:1) was added LiOH·H₂O (13 mg, 0.3 mmol) and stirred for 4 hours. The reaction mixture was partially concentrated under reduced pressure, acidified by adding 1N HCl (pH approximately 6), and then extracted with EtOAc. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to afford Example 23 (30 mg, 71% yield). 1 H NMR(300MHz,chloroform-d)δ7.27-7.18(m,2H),7.04(d,J=8.5Hz,2H),5.35(d,J=7.9Hz,1H),4.27(d,J=7.8Hz,1H),3.91(s,2H),3.06(t,J=8.5Hz,1H) ,2.53-2.44(m,1H),2.43(s,3H),2.41-2.35(m,2H),2.35-2.30(m,1H),2.33 (s,3H),2.31-2.21(m,1H),2.17-2.06(m,1H),1.60(dt,J=11.5,7.7Hz,2H). LC / MS(ESI)m / z:418.23[M+H] + .

[0762] The compounds of Examples 24 and 25 were prepared using the same procedure as Example 23 except for the differences described below.

[0763] [Table 5]

[0764]

[0765] [Table 6]

[0766]

[0767] Example 26: 6-(2,5-dimethyl-4-(4-(pyridin-4-yl)benzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0768] Step 1: 6-(2,5-dimethyl-4-(4-(pyridin-4-yl)benzyl)thiophene-3-carboxamido)spiro[3.3]heptane- Synthesis of methyl 2-carboxylate

[0769]

[0770] Under N2 atmosphere, methyl 6-(4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-carboxylate (27 mg, 0.06 mmol), pyridin-4-ylboronic acid (9 mg, 0.075 mmol), and K3PO4 (13 mg, 0.063 mmol) obtained in step 3 of Example 23 were replaced in dioxane:H2O (2:1), followed by the addition of Pd2(dba)3 (6 mg, 6.2 μmol) and PCy3 (3 mg, 9.4 μmol). The reaction solution was microwave-irradiated at 110°C for 1.5 hours, then filtered through celite and concentrated under reduced pressure to afford methyl 6-(2,5-dimethyl-4-(4-(pyridin-4-yl)benzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate. LC / MS(ESI)m / z:476.28[M+2] + .

[0771] Step 2: 6-(2,5-dimethyl-4-(4-(pyridin-4-yl)benzyl)thiophene-3-carboxamido)spiro[3.3]heptane- Synthesis of 2-carboxylic acid

[0772]

[0773] To a solution of methyl 6-(2,5-dimethyl-4-(4-(pyridin-4-yl)benzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (crude, 0.06 mmol) in H₂O:THF:MeOH (1:1:1) was added LiOH·H₂O (9 mg, 0.18 mmol) and stirred for 4 hours. The reaction mixture was concentrated under reduced pressure, diluted with distilled water, acidified with 1N HCl (pH approximately 6), and extracted with EtOAc. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to afford Example 26 (12 mg, 42% yield) as a white solid. 1 H NMR(300MHz, methanol-d4)δ8.92-8.31(m,2H),7.68(dd,J=14.7,7.0Hz,4H),7.25(d,J=8.1Hz,2H),4.34-3.95 (m,1H),4.00(s,2H),3.07-2.82(m,1H),2.38(s,6H),2.34-2.19(m,3H),2.20-1.93(m,3H),1.91-1.60(m,2H). LC / MS(ESI)m / z:462.31[M+2] + .

[0774] Example 27: 6-(2,5-dimethyl-4-(4-(pyridin-3-yl)benzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0775]

[0776] The compound of Example 27 was obtained as a white solid using the same procedure as in Example 26, except that pyridin-4-ylboronic acid was used in step 1 of Example 26 instead of pyridin-3-ylboronic acid. 1 H NMR (500MHz, methanol-d4) δ8.78 (s, 1H), 8.51 (d, J = 4.2 Hz, 1H), 8.08 (d, J = 8. 0Hz,1H),7.62-7.49(m,3H),7.24(d,J=8.2Hz,2H),4.26-4.08(m,1H),4.00(s ,2H),3.03-2.87(m,1H),2.45-2.37(m,1H),2.38(s,6H),2.35-2.21(m,3H),2 .13(dd,J=8.2Hz,1H),2.10-2.00(m,1H),1.79(ddd,J=24.7,11.0,8.9Hz,2H). LC / MS(ESI)m / z:462.24[M+2] + .

[0777] Example 28: 6-(4-((3',4'-dimethyl-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0778] Step 1: 6-(4-((3',4'-dimethyl-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxylate Synthesis of methyl (amino)spiro[3.3]heptane-2-carboxylate

[0779]

[0780] A solution of methyl 6-(4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-carboxylate (50 mg, 0.023 mmol) and 3,4-dimethylphenylboronic acid (4.1 mg, 0.027 mmol) in dioxane (0.2 mL) obtained in step 3 of Example 23 was placed in a sealed tube, and distilled water (0.01 mL) and Cs2CO3 (8 mg, 0.046 mmol) were added. Pd(OAc)2 (0.5 mg) and Xphos (13 mg, 0.023 mmol) were added under a N2 atmosphere, and the reaction solution was stirred at 90°C for 15 hours. The reaction solution was diluted with ethyl acetate, washed with distilled water, dried over sodium sulfate, filtered, and concentrated. The crude product was purified on a silica gel column (6% MeOH in CHCl 3 ) to give methyl 6-(4-((3′,4′-dimethyl-[1,1′-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (20 mg, mixture).1 H NMR(500MHz,Chloroform-d)δ7.48-7.45(m,2H),7.32(d,J=2.0Hz,1H),7.28(dd,J=7.8,2.1Hz,1H),7.19(d ,J=8.1Hz,1H),7.13(d,J=8.2Hz,2H),5.38(d,J=7.8Hz,1H),4.24(h,J=7.9Hz,1H),3.96(s,2H),3.63(s,3H ),2.96-2.90(m,1H),2.43(s,2H),2.42-2.39(m,2H),2.35(s,3H),2.32(s,3H),2.30(s,3H),2.27-2.23(m, 2H), 2.15(dd,J=11.7,8.5Hz,1H), 1.96(ddd,J=11.7,8.6,2.9Hz,1H), 1.49(ddd,J=14.9,11.4,8.5Hz,2H).

[0781] Step 2: 6-(4-((3',4'-dimethyl-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxylate Synthesis of (Amino)spiro[3.3]heptane-2-carboxylic acid

[0782]

[0783] To a solution of methyl 6-(4-((3',4'-dimethyl-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (20 mg) in THF / MeOH / H2O (2 / 1 / 2) was added LiOH·H2O (4 mg, 0.084 mmol, 3.0 equiv) and stirred for 3 hours. The reaction mixture was partially concentrated and then acidified with 1N aqueous HCl. The aqueous layer was extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by preparative TLC to provide Example 28 (3.4 mg, 30% yield). 1H NMR(500MHz,chloroform-d)δ7.49-7.45(m,2H),7.32(d,J=2.0Hz,1H),7.28(dd,J=7.8,2.1Hz,1H),7. 19(d,J=7.8Hz,1H),7.14-7.11(m,2H),5.35(d,J=7.8Hz,1H),4.24(h,J=8.0Hz,1H),3.96(s,2H),2.97( p,J=8.5Hz,1H),2.43(s,3H),2.42-2.36(m,2H),2.36(s,3H),2.32(s,3H),2.30(s,3H),2.28(t,J=4.1 Hz, 2H), 2.17 (dd, J=11.7, 8.3Hz, 1H), 1.99 (ddd, J=11.6, 8.7, 2.4Hz, 1H), 1.49 (dt, J=11.7, 9.1Hz, 2H). LC / MS(ESI)m / z:488.43[M+H] + .

[0784] The compounds of Examples 29 to 66 were prepared using the same procedures as in Example 28, except for the differences described below.

[0785] [Table 7]

[0786]

[0787]

[0788]

[0789]

[0790] [Table 8]

[0791]

[0792]

[0793]

[0794] [Table 9]

[0795]

[0796]

[0797]

[0798] [Table 10]

[0799]

[0800]

[0801]

[0802] [Table 11]

[0803]

[0804]

[0805]

[0806]

[0807]

[0808] [Table 12]

[0809]

[0810]

[0811]

[0812]

[0813] Example 67: 6-(4-(4-cyclohexylbenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0814] Step 1: 6-(2,5-dimethyl-4-((2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-yl)methyl)thiophene- Synthesis of methyl 3-formamido)spiro[3.3]heptane-2-carboxylate

[0815]

[0816] A solution of methyl 6-(4-(4-chlorobenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (50 mg, 0.11 mmol) and 2-(cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (27 mg, 0.13 mmol) in dioxane (1 mL) was placed in a sealed tube, and H2O (0.05 mL) and Cs2CO3 (40 mg, 0.22 mmol) were added. Pd(OAc)2 (2.5 mg) and Xphos (65 mg, 0.115 mmol) were added under a N2 atmosphere, and the mixture was stirred at 90°C for 15 hours. The reaction solution was diluted with ethyl acetate, washed with distilled water, dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (30% EtOAc in hexanes) to give methyl 6-(2,5-dimethyl-4-((2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-yl)methyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (59 mg, mixture). 1 H NMR(400MHz, Methanol-d4)δ7.28-7.22(m,2H),7.00(d,J=8.3Hz,2H),6.07(tt, J=3.9,1.7Hz,1H),4.13-4.09(m,1H),3.90(s,2H),3.66(s,3H),3.02(p,J=8.5Hz ,1H),2.50-2.42(m,1H),2.41-2.37(m,2H),2.35(d,J=5.5Hz,6H),2.32-2.25(m, 2H),2.24-2.13(m,4H),2.10-2.05(m,1H),1.81-1.75(m,4H),1.71-1.67(m,2H).

[0817] Step 2: 6-(4-(4-cyclohexylbenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic Synthesis of methyl ester

[0818]

[0819] To a solution of methyl 6-(2,5-dimethyl-4-((2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-yl)methyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (20 mg, 0.042 mmol) in ethyl acetate / methanol (8 / 2, 0.2 mL) was added 10% Pd / C (2.2 mg). The reaction was stirred under hydrogen for 24 hours and filtered through celite using ethyl acetate to afford methyl 6-(4-(4-cyclohexylbenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (12 mg). 1 H NMR(400MHz,Chloroform-d)δ7.16-7.10(m,2H),7.02(s,2H),5.32(d,J=7.9Hz,1H),4.31- 4.13(m,1H),3.91(s,2H),3.68(s,3H),3.03-2.95(m,1H),2.52-2.46(m,1H),2.45(s,3H),2 .40-2.36(m,1H),2.35(s,3H),2.30-2.26(m,2H),2.26-2.23(m,1H),2.22-2.16(m,1H),2.0 2-1.96(m,1H),1.87-1.83(m,4H),1.69-1.65(m,2H),1.48-1.43(m,2H),1.40-1.32(m,5H).

[0820] Step 3: 6-(4-(4-cyclohexylbenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic Acid synthesis

[0821]

[0822] To a solution of methyl 6-(4-(4-cyclohexylbenzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (12 mg) in THF / MeOH / H₂O (2 / 1 / 2) was added LiOH·H₂O (3 mg, 0.075 mmol, 3.0 equiv) and stirred for 3 hours. The reaction mixture was partially concentrated and then acidified with 1N aqueous HCl. The aqueous layer was extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to provide Example 67 (3.7 mg, 32% yield). 1HNMR(300MHz,Chloroform-d)δ7.14-7.08(m,2H),6.99(d,J=8.1Hz,2H),5.30(d,J=7.8Hz,1H),4 .29-4.12(m,1H),3.89(s,2H),3.00(p,J=8.5Hz,1H),2.52-2.45(m,1H),2.42(s,3H),2.40-2.35 (m,1H),2.33(s,3H),2.31-2.27(m,2H),2.26-2.21(m,1H),2.18(dd,J=10.6,7.2Hz,1H),2.06-1 .96(m,1H),1.82(d,J=8.1Hz,3H),1.74(d,J=13.0Hz,2H),1.47-1.31(m,6H),1.30-1.22(m,1H). LC / MS(ESI)m / z:466.43[M+H] + ,464.54[M+H] - .

[0823] Example 68: 6-(2,5-dimethyl-4-(4-(piperidin-4-yl)benzyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0824] Steps 1 to 3: 6-(4-(4-(1-(tert-Butyloxycarbonyl)piperidin-4-yl)benzyl)-2,5-dimethylthiophene-3-carboxamide Synthesis of (amino)spiro[3.3]heptane-2-carboxylic acid

[0825]

[0826] The same procedure as in Example 67 was used, except that 2-(cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in Step 1 of Example 67 was replaced with tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate to obtain 6-(4-(4-(1-(tert-butoxycarbonyl)piperidin-4-yl)benzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid as a milky white solid. 1H NMR(400MHz,Chloroform-d)δ7.13(s,2H),7.06-7.01(m,2H),5.34-5.29(m, 1H),4.30-4.20(m,3H),3.91(s,2H),3.05-2.96(m,1H),2.86-2.74(m,2H),2 .69-2.59(m,1H),2.43(s,3H),2.41-2.38(m,1H),2.35(s,3H),2.33-2.27(m ,4H),2.15-2.09(m,1H),1.82-1.76(m,2H),1.67-1.54(m,4H),1.50(s,9H).

[0827] Step 4: 6-(2,5-dimethyl-4-(4-(piperidin-4-yl)benzyl)thiophene-3-carboxamido)spiro[3.3]heptane- Synthesis of 2-carboxylic acid

[0828]

[0829] A solution of 6-(4-(4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (14 mg, 0.024 mmol) and 4N HCl in dioxane (0.5 mL) was stirred for 2 hours. The reaction was poured into diethyl ether and concentrated under reduced pressure to afford the hydrochloride salt of Example 68 (4 mg, 33%) as a creamy white solid. 1 HNMR(500MHz,Methanol-d4)δ7.15-7.08(m,2H),7.04-6.98(m,2H),4.16-4.09(m,1 H),3.86(s,2H),3.49-3.44(m,2H),3.16-3.08(m,2H),3.03-2.97(m,1H),2.86-2.79 (m,1H),2.41-2.35(m,2H),2.33(s,3H),2.30(s,3H),2.26-2.20(m,2H),2.17-2.12 (m,1H),2.12-2.06(m,1H),2.03-1.98(m,2H),1.93-1.81(m,3H),1.77-1.70(m,1H). LC / MS(ESI)m / z:465.7[MH] - .

[0830] Example 69: 6-(4-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0831]

[0832] A solution of the compound of Example 23 (30 mg, 0.069 mmol) and 4-fluoroboric acid (12 mg, 0.083 mmol) in dioxane (0.2 mL) was placed in a sealed tube, and H2O (0.01 mL) and Cs2CO3 (45 mg, 0.138 mmol) were added. Pd(OAc)2 (2 mg, 0.007 mmol) and Xphos (33 mg, 0.069 mmol) were added under a N2 atmosphere and stirred at 90°C for 12 hours. The reaction solution was diluted with ethyl acetate, washed with distilled water, dried over sodium sulfate, then filtered and concentrated. The crude product was purified by silica gel column (hexane: ethyl acetate = 1:1) to obtain the compound of Example 69 (3 mg, yield 12%) as a milky white solid. 1 H NMR(500MHz,Chloroform-d)δ7.55-7.49(m,2H),7.48-7.45(m,2H),7.19-7.17(m,2H),7.17-7.12(m,2H),5.46-5 .35(m,1H),4.33-4.25(m,1H),3.99(s,2H),3.04-2.96(m,1H),2.46(s,3H),2.44-2.41(m,0H),2.38(s,3H),2.36 2.30(m,4H),2.22-2.15(m,1H),2.06-1.98(m,1H),1.62-1.49(m,3H). LC / MS(ESI)m / z:478.6[M+H] + ,476.6[MH] - .

[0833] Example 70: 6-(4-((3'-cyano-5'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0834]

[0835] The compound of Example 70 was obtained by the same method as in Example 69, except that the 4-fluoroboric acid used in Example 69 was replaced by 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile and Cs2CO3 was replaced by K3PO4. 1H NMR(300MHz,MeOD)δ8.28(d,J=7.5Hz,1H),7.85(t,J=1.5Hz,1H),7.73(ddd,J=10.1,2.5 ,1.6Hz,1H),7.63-7.54(m,2H),7.52(ddd,J=8.1,2.5,1.3Hz,1H),7.23(d,J=8.2Hz,2H) ,4.22-4.08(m,1H),3.99(s,2H),2.95(p,J=8.4Hz,1H),2.49-2.38(m,1H),2.39(s,3H), 2.37(s,3H),2.35-2.20(m,3H),2.19-2.10(m,1H),2.09-1.99(m,1H),1.87-1.70(m,2H). LC / MS(ESI)m / z:503.02[M+H] + .

[0836] Example 71: 6-(4-((3'-fluoro-5'-hydroxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0837] Step 1: 6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-yl)- Synthesis of methyl (formamido)spiro[3.3]heptane-2-carboxylate

[0838]

[0839] Methyl 6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate was obtained by the same method as in Step 1 of Example 67, except that 2-(cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane used in Step 1 of Example 67 was replaced with (3-fluoro-5-methoxyphenyl)boronic acid. 1H NMR (400MHz, CDCl3) δ7.50-7.46(m,2H),7.18(d,J=8.2Hz,2H),7.01(d,J=5.4Hz,1H),6.89(q ,J=2.1,1.7Hz,1H),6.62(dt,J=10.5,2.3Hz,1H),5.39(d,J=7.8Hz,1H),4.28(q,J=8.1Hz,1H) ,3.99(s,2H),3.87(s,3H),3.66(s,3H),3.03-2.95(m,1H),2.45(s,3H),2.37(s,3H),2.30(d q,J=8.6,4.2,3.4Hz,3H),2.18(dd,J=11.7,8.4Hz,1H),2.02-1.97(m,1H),1.58-1.51(m,2H).

[0840] Step 2: 6-(4-((3'-fluoro-5'-hydroxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxylate Synthesis of (Amino)spiro[3.3]heptane-2-carboxylic acid

[0841]

[0842] To a solution of methyl 6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (94 mg, 0.18 mmol) in DCM (0.1 M) at 0°C was added BBr3 (0.7 mL, 0.72 mmol) and stirred at room temperature for 5 hours. The reaction solution was quenched with distilled water, further stirred for 15 hours, then extracted with ethyl acetate (2×20 mL) and washed with brine. The organic layer was dried over sodium sulfate, filtered, and then concentrated under reduced pressure. The crude product was purified by column chromatography (5% MeOH in DCM) to give Example 71 (22 mg, 25% yield) as an off-white solid. 1 H NMR (500 MHz, CDCl3) 1H NMR(400MHz,Chloroform-d)δ7.41(d,J=7.8Hz,2H),7.14(d,J=8.0Hz,2H),6.88( t,J=1.9Hz,1H),6.83-6.75(m,1H),6.62-6.54(m,1H),5.40-5.26(m,1H),4.24(h, J=8.1Hz,1H),3.98(s,2H),3.02(p,J=7.5Hz,1H),2.49-2.27(m,3H),2.41(s,3H) ,2.40(s,3H),2.17-2.08(m,2H),1.60(dd,J=12.1,8.1Hz,1H),1.38-1.22(m,2H). LC / MS(ESI)m / z:494.1[M+H] + .

[0843] Example 72: 6-(4-(4-(2-hydroxypyridin-4-yl)benzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0844] Steps 1 and 2: 6-(4-(4-(2-hydroxypyridin-4-yl)benzyl)-2,5-dimethylthiophene-3-carboxamido)spiro [3.3] Synthesis of methyl heptane-2-carboxylate

[0845]

[0846] The same method as in Example 71 was used, except that the (3-fluoro-5-methoxyphenyl)boric acid used in step 1 of Example 71 was replaced by (2-methoxypyridin-4-yl)boric acid and Cs2CO3 was replaced by K3PO4, to obtain methyl 6-(4-(4-(2-hydroxypyridin-4-yl)benzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate.

[0847] Step 3: 6-(4-(4-(2-hydroxypyridin-4-yl)benzyl)-2,5-dimethylthiophene-3-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[0848]

[0849] A solution of methyl 6-(4-(4-(2-hydroxypyridin-4-yl)benzyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate in HO (0.1 M) was stirred for 15 hours. The precipitated solid was filtered and dried to give a crude product, which was then purified by column chromatography (15% MeOH in DCM) to afford Example 72 as an off-white solid. 1HNMR(300MHz,MeOD)δ8.25(d,J=7.4Hz,1H),7.61-7.54(m,2H),7.51(d,J=7.6Hz,1H),7.22(d,J=8.2Hz,2H),6.78-6.69(m,2H),4.21-4.08(m ,1H),3.99(s,2H),2.96(p,J=8.4Hz,1H),2.38(s,6H),2.32-1.98(m,6H),1.76(ddd,J=17.0,11.4,8.6Hz,2H); LC / MS(ESI)m / z:477.16[M+H] + .

[0850] Example 73: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-N,2,5-trimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0851] Step 1: Synthesis of 3-([1,1'-biphenyl]-4-ylmethyl)-4-bromo-2,5-dimethylthiophene

[0852]

[0853] To a solution of [1,1'-biphenyl]-4-ylmethanol (553 mg, 3.0 mmol) in DCE (0.5 M) was added 3-bromo-2,5-dimethylthiophene (918 mg, 4.80 mmol), FeCl3 (195 mg, 1.20 mmol), and MsOH (78 μL, 1.20 mmol), and the mixture was stirred at 55°C for 10 hours. Ethyl acetate was added to the reaction solution, which was washed with distilled water and brine. The organic layer was then dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane) to yield 3-([1,1'-biphenyl]-4-ylmethyl)-4-bromo-2,5-dimethylthiophene (466 mg, 43% yield) as a white solid. 1 H NMR(500MHz,chloroform-d)δ7.61-7.57(m,2H),7.52(m,2H),7.44(t,J=7.7Hz,2H ),7.39-7.31(m,1H),7.24(d,J=7.9Hz,2H),4.00(s,2H),2.41(s,3H),2.40(s,3H).

[0854] Step 2: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxylic acid

[0855]

[0856] To a THF (0.1 M) solution of 3-([1,1'-biphenyl]-4-ylmethyl)-4-bromo-2,5-dimethylthiophene (169 mg, 0.47 mmol) and TMEDA (78 μL, 0.52 mmol) was added n-BuLi (0.228 mL, 0.57 mmol) at -78°C and stirred for 1.5 hours. The reaction solution was quenched with CO2 gas at -78°C and then slowly warmed to room temperature over 2 hours. The reaction solution was acidified with 1N HCl solution, extracted with ethyl acetate, and washed with water. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane) to give 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxylic acid (56 mg, 37% yield) as a white solid.

[0857] Step 3: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-N,2,5-trimethylthiophene-3-carboxamido)spiro[3.3] Synthesis of Methyl Heptane-2-Carboxylate

[0858]

[0859] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxylic acid (52 mg, 0.16 mmol) and HATU (68 mg, 0.18 mmol) in DMF (0.05 M) was added DIPEA (84 μL, 0.48 mmol), stirred for 10 minutes, and intermediate R (39 mg, 0.18 mmol) was added, followed by stirring for 15 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water and brine. The organic layer was dried over sodium sulfate, concentrated under reduced pressure, and then purified by column chromatography (20% EtOAc in hexane) to obtain methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-N,2,5-trimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (47 mg, 59% yield) as a white solid.

[0860] Step 4: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-N,2,5-trimethylthiophene-3-carboxamido)spiro[3.3] Synthesis of heptane-2-carboxylic acid

[0861]

[0862] To a stirred solution of methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-N,2,5-trimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (47 mg, 0.1 mmol) in H2O:THF:MeOH (0.1 M) was added LiOH·H2O (12 mg, 0.3 mmol) and stirred for 4 hours. The reaction solution was partially concentrated under reduced pressure, acidified with 2N aqueous HCl (pH approximately 6), and extracted with ethyl acetate (2 x 30 mL). The organic layer was dried over sodium sulfate, concentrated under reduced pressure, and then purified by column chromatography (70% EtOAc in hexanes) to afford Example 73 (36 mg, 79% yield) as a white solid. LC / MS (ESI) m / z: 474.25 [M+H] + .

[0863] Example 74: 6-(4-([1,1′-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0864] Step 1: Synthesis of methyl 4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxylate

[0865]

[0866] A solution of intermediate D (996 mg, 4.0 mmol), 4-phenylphenol (817 mg, 4.8 mmol, 1.2 equivalents), CuBr (115 mg, 0.8 mmol, 0.2 equivalents) and Cs2CO3 (3.9 g, 12.0 mmol, 3.0 equivalents) in pyridine (8 mL) was irradiated with microwaves and stirred at 150 ° C for 1 hour. The reaction solution was filtered through celite, added to distilled water, extracted with EtOAc, and then the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to give methyl 4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxylate (550 mg, yield 40%).

[0867] Step 2: Synthesis of 4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxylic acid

[0868]

[0869] To a solution of methyl 4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxylate (550 mg, 1.62 mmol) in THF / MeOH / H₂O (1:1:1) was added LiOH·H₂O (340 mg, 8.12 mmol, 5.0 equiv). The reaction was stirred at 70°C for 12 hours. The reaction mixture was partially concentrated and acidified with 1N HCl, and the aqueous layer was extracted with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. Purification by column chromatography afforded 4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxylic acid (100 mg, 19% yield).

[0870] Step 3: 6-(4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane Synthesis of methyl 2-alkanecarboxylate

[0871]

[0872] To a solution of 4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxylic acid (100 mg, 0.3 mmol) and HATU (137 mg, 0.36 mmol, 1.2 equiv) in DCM (2 mL) at 0°C was added DIPEA (80 μL, 0.45 mmol, 1.5 equiv) and stirred for 15 minutes. A solution of Intermediate A (68 mg, 0.33 mmol, 1.1 equiv) in DCM (1 mL) was added to the reaction solution, followed by stirring for 8 hours. The reaction solution was added to distilled water and extracted with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to afford methyl 6-(4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (50 mg, 34% yield).

[0873] Step 4: 6-(4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane Synthesis of alkane-2-carboxylic acids

[0874]

[0875] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-yloxy)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (50 mg, 0.5 mmol) in THF / MeOH / H₂O (1:1:1) was added LiOH·H₂O (13 mg, 0.3 mmol, 3.0 equiv) and stirred for 12 hours. The reaction mixture was partially concentrated, then acidified with 1N HCl and extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by column chromatography to afford Example 74 (22 mg, 47% yield). 1H NMR(300MHz, methanol-d4)δ7.60-7.49(m,4H),7.46-7.34(m,2H),7.34-7.23(m,1H),6.98-6.87(m,2H),4.12-3.96 (m,1H),2.96-2.85(m,1H),2.52(s,3H),2.36-2.28(m,1H),2.25-2.18(m,5H),2.18-1.95(m,3H),1.75-1.65(m,2H). LC / MS(ESI)m / z:462.5[M+H] + .

[0876] Example 75: 6-(4-([1,1′-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0877] Step 1: Synthesis of methyl 4-amino-2,5-dimethylthiophene-3-carboxylate

[0878]

[0879] To a solution of Intermediate D (1.25 g, 5.0 mmol, 1.0 equiv) and Cu2O (715 mg, 5.0 mmol, 1.0 equiv) in NMP (10 mL) was added aqueous ammonia solution (5 mL), heated to 100°C, and stirred for 12 hours. The reaction solution was added to distilled water and extracted with DCM. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by column chromatography to give methyl 4-amino-2,5-dimethylthiophene-3-carboxylate (182 mg, 19% yield).

[0880] Step 2: Synthesis of methyl 4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxylate

[0881]

[0882] A solution of methyl 4-amino-2,5-dimethylthiophene-3-carboxylate (182 mg, 0.98 mmol), 4-bromobiphenyl (274 mg, 1.18 mmol, 1.2 equiv), Pd(OAc)2 (22 mg, 0.098 mmol, 0.1 equiv), Xantphos (114 mg, 0.196 mmol, 0.2 equiv), and Cs2CO3 (639 mg, 1.96 mol, 2.0 equiv) in toluene (7 mL) was stirred at 110°C for 5 hours. The reaction solution was added to distilled water and extracted with DCM. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by column chromatography to give methyl 4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxylate (147 mg, 44% yield).

[0883] Step 3: Synthesis of 4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxylic acid

[0884]

[0885] To a solution of methyl 4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxylate (142 mg, 0.42 mmol) in THF / MeOH / H₂O (1:1:1) was added LiOH·H₂O (53 mg, 1.26 mmol, 3.0 equiv). The mixture was stirred at 70°C for 12 hours. The reaction solution was partially concentrated and then acidified with 1N HCl. The precipitated solid was removed by filtration, washed with distilled water, and dried to yield 4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxylic acid (135 mg, 99% yield).

[0886] Step 4: 6-(4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane Synthesis of methyl 2-alkanecarboxylate

[0887]

[0888] To a solution of 4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxylic acid (135 mg, 0.41 mmol) and HATU (186 mg, 0.49 mmol, 1.2 equiv) in DCM (2 mL) at 0°C was added DIPEA (110 μL, 0.62 mmol, 1.5 equiv) and stirred for 15 minutes. A solution of Intermediate A (93 mg, 0.45 mmol, 1.1 equiv) in DCM (1 mL) was added to the reaction mixture and stirred for 12 hours. The reaction mixture was added to distilled water and extracted with DCM. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by column chromatography to afford methyl 6-(4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (126 mg, 65% yield).

[0889] Step 5: 6-(4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane Synthesis of alkane-2-carboxylic acids

[0890]

[0891] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (50 mg, 0.1 mmol) in THF / MeOH / H₂O (1:1:1) was added LiOH·H₂O (13 mg, 0.3 mmol, 3.0 equiv) and stirred for 12 hours. The reaction mixture was partially concentrated, then acidified with 1N HCl and extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography to afford Example 75 (20 mg, 43% yield). 1 H NMR (300MHz, Methanol-d4) δ7.56-7.47(m,2H),7.47-7.30(m,4H),7.28-7.16(m,1H),6.67(d,J=8.6Hz,2H),4.16-3.99(m,1H),2.92- 2.80(m,1H),2.57(s,3H),2.35-2.27(m,1H),2.23(s,3H),2.22-2.11(m,3H),2.08-2.02(m,1H),1.98-1.90(m,1H),1.63-1.54(m,2H). LC / MS(ESI)m / z:461.6[M+1] + .

[0892] Example 76: 6-(4-([1,1′-biphenyl]-4-yl(methyl)amino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0893] Step 1: 6-(4-([1,1'-biphenyl]-4-yl(methyl)amino)-2,5-dimethylthiophene-3-carboxamido)spiro [3.3] Synthesis of methyl heptane-2-carboxylate

[0894]

[0895] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylamino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (120 mg, 0.25 mmol, 1.0 equiv) and KCO (104 mg, 0.75 mmol, 3.0 equiv) obtained in step 4 of Example 75 in DMF (3 mL) was added iodomethane (80 μL, 1.25 mmol, 5.0 equiv) and stirred at 80°C for 5 days. The reaction solution was added to distilled water and extracted with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography to give methyl 6-(4-([1,1'-biphenyl]-4-yl(methyl)amino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (18 mg). 1H NMR(300MHz,Chloroform-d)δ7.58-7.46(m,4H),7.40(dd,J=8.4,6.8Hz,2H), 7.32-7.26(m,1H),6.72-6.67(m,2H),4.27-4.19(m,1H),3.60(s,3H),3.20(s, 3H),2.96-2.84(m,1H),2.69-2.63(m,3H),2.44-2.33(m,1H),2.32-2.16(m,3H ),2.14-2.10(m,3H),2.10-2.03(m,1H),1.94-1.86(m,1H),1.48-1.38(m,2H).

[0896] Step 2: 6-(4-([1,1'-biphenyl]-4-yl(methyl)amino)-2,5-dimethylthiophene-3-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[0897]

[0898] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-yl(methyl)amino)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (18 mg, 0.036 mmol) in THF / MeOH / H₂O (3 / 2 / 3 mL) was added LiOH·H₂O (5 mg, 0.108 mmol, 3.0 equiv) and stirred for 3 hours. The reaction mixture was partially concentrated and then acidified with 1N HCl. The precipitated solid was filtered, washed with water, and dried to afford Example 76 (12 mg). 1 H NMR(500MHz, Methanol-d4)δ7.76(d,J=7.2Hz,1H),7.56-7.51(m,2H),7.47(d,J=8.8Hz,2H),7.36 (t,J=7.8Hz,2H),7.22(t,J=7.4Hz,1H),6.69(d,J=8.7Hz,2H),4.06-4.01(m,1H),3.23(s,3H),2. 88-2.81(m,1H),2.48(s,3H),2.30(dt,J=12.1,6.1Hz,1H),2.21-2.18(m,2H),2.18(s,3H),2.17- 2.12(m,1H),2.06-2.02(m,1H),1.96-1.90(m,1H),1.60-1.54(m,2H). LC / MS(ESI)m / z:475.7[M+H] + .

[0899] Example 77: 6-(2,5-Dimethyl-4-((4-phenylpiperazin-1-yl)methyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0900] Step 1: Synthesis of 4-bromo-2,5-dimethylthiophene-3-carboxylic acid

[0901]

[0902] To a solution of Intermediate D (2.25 g, 9.03 mmol) in H2O / THF / MeOH (0.3 M, 30 mL) was added LiOH·H2O (1.1 g, 27.1 mmol) and stirred for 12 hours. The reaction mixture was acidified by the addition of 1N HCl solution and extracted with EA (3 x 30 mL). The organic layer was dried over magnesium sulfate, filtered, concentrated, and then purified by silica gel column chromatography (n-hexane and ethyl acetate) to afford 4-bromo-2,5-dimethylthiophene-3-carboxylic acid (1.97 g, 93% yield). 1 H NMR (500MHz, DMSO-d6) δ13.06(s,1H),2.55(s,3H),2.32(s,3H).

[0903] Step 2: Synthesis of (4-bromo-2,5-dimethylthiophen-3-yl)(4-phenylpiperazin-1-yl)methanone

[0904]

[0905] To a solution of 4-bromo-2,5-dimethylthiophene-3-carboxylic acid (1.97 g, 8.4 mmol), 1-phenylpiperazine (1.4 mL, 9.24 mmol), and HATU (3.5 g, 9.24 mmol) in DMF (28 mL, 0.3 M) was added DIPEA (4.3 mL, 25.2 mmol) and stirred for 3 hours. The reaction solution was concentrated, diluted with 1N aqueous NaOH and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated, and then purified by silica gel column chromatography (n-hexane and ethyl acetate) to obtain (4-bromo-2,5-dimethylthiophen-3-yl)(4-phenylpiperazin-1-yl)methanone (2.92 g, 92% yield). 1H NMR(500MHz,Chloroform-d)δ7.34-7.29(m,2H),6.95(dd,J=13.9,7.6Hz,3H) ,4.07(dt,J=13.0,5.0Hz,1H),3.92(dt,J=13.0,5.3Hz,1H),3.54(ddd,J=13.0 ,6.6,3.3Hz,1H),3.45(ddd,J=13.0,7.2,3.3Hz,1H),3.29(t,J=5.2Hz,2H),3. 24(ddd,J=10.7,7.2,3.4Hz,1H),3.15-3.09(m,1H),2.41(s,3H),2.37(s,3H).

[0906] Step 3: Synthesis of 1-((4-bromo-2,5-dimethylthiophen-3-yl)methyl)-5-phenylpiperazine

[0907]

[0908] To a stirred solution of (4-bromo-2,5-dimethylthiophen-3-yl)(4-phenylpiperazin-1-yl)methanone (2.87 g, 7.6 mmol) and THF (19 mL, 0.4 M) was added BH3·Me2S (19.5 mL, 39 mmol) and stirred at 40°C for 12 hours. The reaction solution was cooled to room temperature and extracted with aqueous NaHCO3 (70 mL) and EA. The organic layer was dried over sodium sulfate and filtered, and the crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give 1-((4-bromo-2,5-dimethylthiophen-3-yl)methyl)-5-phenylpiperazine (1.4 g, 51% yield). 1 H NMR(500MHz,Chloroform-d)δ7.30-7.26(m,2H),6.94(d,J=7.8Hz,2H),6.87(t,J=7.3 Hz,1H),3.49(s,2H),3.21-3.16(m,4H),2.67-2.63(m,4H),2.46(s,3H),2.38(s,3H).

[0909] Step 4: Synthesis of 2,5-dimethyl-4-((4-phenylpiperazin-1-yl)methyl)thiophene-3-carboxylic acid

[0910]

[0911] To a stirred solution of 1-((4-bromo-2,5-dimethylthiophen-3-yl)methyl)-5-phenylpiperazine (500 mg, 1.37 mmol), dibutyleneamine (0.23 mL, 1.51 mmol), and THF (7.0 mL, 0.2 M) was slowly added n-BuLi (2.5 M in THF, 0.72 mL, 1.8 mmol) at -65°C. The mixture was stirred for 1 hour, and then an excess of dry ice was added. The reaction solution was acidified with 1N HCl and extracted with EtOAc. The organic layer was dried over magnesium sulfate, filtered, and concentrated to afford 2,5-dimethyl-4-((4-phenylpiperazin-1-yl)methyl)thiophene-3-carboxylic acid (502 mg).

[0912] Step 5: 6-(2,5-dimethyl-4-((4-phenylpiperazin-1-yl)methyl)thiophene-3-carboxamido)spiro[3.3] Synthesis of Methyl Heptane-2-Carboxylate

[0913]

[0914] To a solution of 2,5-dimethyl-4-((4-phenylpiperazin-1-yl)methyl)thiophene-3-carboxylic acid (576 mg, 1.52 mmol), Intermediate A (0.34 g, 1.67 mmol), and HATU (0.63 g, 1.67 mmol) in DMF (5.1 mL, 0.3 M) was added DIPEA (0.80 mL) and stirred for 3 hours. The reaction solution was concentrated, diluted with 1N aqueous NaOH and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated, and then purified by silica gel chromatography (n-hexane and ethyl acetate) to provide methyl 6-(2,5-dimethyl-4-((4-phenylpiperazin-1-yl)methyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (102 mg, 14% yield). 1 H NMR(500MHz,Chloroform-d)δ9.73(d,J=7.0Hz,1H),7.32(t,J=7.9Hz,2H),6.94(dd,J=1 7.1,7.9Hz,3H),4.45(h,J=8.2,7.7Hz,1H),3.68(s,3H),3.44(s,2H),3.23(s,4H),3.05 (p,J=8.5Hz,1H),2.72(s,4H),2.62(s,4H),2.47(dt,J=12.5,6.5Hz,1H),2.38(d,J=7.0 Hz, 5H), 2.31 (dd, J=11.6, 8.5Hz, 1H), 2.16-2.10 (m, 1H), 1.91 (dt, J=23.8, 10.4Hz, 2H).

[0915] Step 6: 6-(2,5-dimethyl-4-((4-phenylpiperazin-1-yl)methyl)thiophene-3-carboxamido)spiro[3.3] Synthesis of heptane-2-carboxylic acid

[0916]

[0917] To a solution of methyl 6-(2,5-dimethyl-4-((4-phenylpiperazin-1-yl)methyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (163 mg, 0.34 mmol) in HO / THF / MeOH (0.3 M, 1.1 mL) was added LiOH·HO (43 mg, 1.02 mmol) and stirred for 12 hours. The reaction mixture was acidified by adding 1N HCl solution and extracted with EA (3 x 20 mL). The organic layer was dried over magnesium sulfate, filtered, concentrated, and then purified by silica gel column chromatography (hexane and ethyl acetate) to provide Example 77 (12 mg, 8% yield). 1 H NMR(500MHz, Methanol-d4)δ7.27(t,J=7.8Hz,2H),7.00(d,J=8.3Hz,2H),6.88(t, J=7.3Hz,1H),4.37(p,J=8.2Hz,1H),3.64(s,2H),3.24(s,4H),3.01(p,J=8.4Hz,1 H),2.83(s,4H),2.59(dt,J=11.7,6.6Hz,1H),2.53(s,3H),2.41(s,4H),2.39-2.3 1(m,2H),2.28-2.23(m,1H),2.16(t,J=10.1Hz,1H),2.04(dt,J=28.7,9.7Hz,2H). LC / MS(ESI)m / z:468.3[M+H] + .

[0918] Example 78: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-N,2,5-trimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0919] Step 1: 6-(4-(((tert-Butyldimethylsilyl)oxy)methyl)-2,5-dimethylthiophene-3-carboxamide Synthesis of methyl (3-(4-(4-amino)spiro[3.3]heptane-2-carboxylate)

[0920]

[0921] To a DMF (0.1 M) solution of Intermediate S (300 mg, 1.0 mmol) and HATU (456 mg, 1.20 mmol) was added DIPEA (0.5 mL, 3.0 mmol), stirred for 10 minutes, and Intermediate A (169 mg, 1.0 mmol) was added, followed by stirring for 15 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water (3 × 25 mL) and brine. The organic layer was dried over sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (40% EtOAc in hexane) to obtain methyl 6-(4-(((tert-butyldimethylsilyl)oxy)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (260 mg, 83% yield) as a yellow liquid. 1 H NMR(300MHz,chloroform-d)δ7.85(d,J=7.6Hz,1H),4.58(s,2H),4.55-4.32(m,1H),3.69(s,3H),3.06(p,J=8.6Hz,1H),2.68-2 .59(m,1H),2.58(s,3H),2.52-2.41(m,1H),2.41-2.25(m,6H),2.20-2.09(m,1H),2.04-1.85(m,2H),0.94(s,9H),0.16(s,6H).

[0922] Step 2: Methyl 6-(4-(hydroxymethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate Synthesis

[0923]

[0924] To a solution of methyl 6-(4-(((tert-butyldimethylsilyl)oxy)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (226 mg, 0.50 mmol) in THF (0.1 M) was added tetrabutylammonium fluoride (TBAF) (1.0 M in THF, 0.75 mL, 0.75 mmol) and stirred for 15 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water (3×25 mL) and brine. The organic layer was dried over sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (30% EtOAc in hexanes) to afford methyl 6-(4-(hydroxymethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (171 mg) as a yellow liquid. 1H NMR(300MHz,chloroform-d)δ6.49(d,J=7.9Hz,1H),4.53-4.37(m,3H),3.69(s,3H),3.05(q,J=8.5Hz,1H),2.71-2 .58(m,1H),2.54(s,3H),2.53-2.44(m,1H),2.40(s,3H),2.38-2.27(m,3H),2.24-2.14(m,1H),2.07-1.86(m,2H).

[0925] Step 3: Methyl 6-(4-(bromomethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate Synthesis

[0926]

[0927] To a stirred solution of methyl 6-(4-(hydroxymethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (82 mg, 0.24 mmol) in DCM (0.1 M) at 0 ° C was added PBr3 (92 μL, 2.03 mmol) and stirred for 15 hours. The reaction solution was diluted with ethyl acetate and washed with bicarbonate solution and distilled water. The organic layer was dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (25% EtOAc in hexane) to give methyl 6-(4-(bromomethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (49 mg, 50% yield) as a white solid. 1 H NMR(300MHz,chloroform-d)δ6.18(d,J=7.0Hz,1H),4.53(s,2H),4.53-4.39(m,1H),3.69(s,3H),3.05(q,J=8.5Hz,1H),2.74-2.5 9(m,1H),2.57-2.51(m,1H),2.47(s,3H),2.42-2.35(m,1H),2.38(s,3H),2.38-2.28(m,2H),2.25-2.15(m,1H),2.11-1.91(m,2H).

[0928] Step 4: 6-(2,5-dimethyl-4-((4-phenyl-1H-pyrazol-1-yl)methyl)thiophene-3-carboxamido)spiro [3.3] Synthesis of methyl heptane-2-carboxylate

[0929]

[0930] To a 0.1 M solution of 4-phenyl-1H-pyrazole (12 mg, 0.08 mmol) in DMF was added NaH (5 mg, 0.12 mmol) and stirred for 15 minutes. Methyl 6-(4-(bromomethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (32 mg, 0.08 mmol) was added and stirred for 4 hours. The reaction solution was diluted with ethyl acetate (10 mL) and washed with distilled water (2 × 10 mL). The organic layer was dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (40% EtOAc in hexanes) to afford methyl 6-(2,5-dimethyl-4-((4-phenyl-1H-pyrazol-1-yl)methyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (16 mg, 43% yield) as a white solid.

[0931] Step 5: 6-(2,5-dimethyl-4-((4-phenyl-1H-pyrazol-1-yl)methyl)thiophene-3-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[0932]

[0933] To a solution of methyl 6-(2,5-dimethyl-4-((4-phenyl-1H-pyrazol-1-yl)methyl)thiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (16 mg, 0.03 mmol) in H2O:THF:MeOH (1:1:1, 0.1 M) was added LiOH·H2O (3 mg, 0.1 mmol) and stirred for 15 hours. The reaction mixture was partially concentrated, acidified with 1N HCl solution (pH approximately 4), and extracted with ethyl acetate (2 × 10 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure, then purified by column chromatography (5% MeOH in DCM) to afford Example 78 (5 mg, 32% yield) as a white solid. 1 H NMR(400MHz,MeOD)δ7.85(s,1H),7.81(s,1H),7.57-7.50(m,2H),7.36(t,J =7.7Hz,2H),7.26-7.17(m,1H),5.28(s,2H),4.20(p,J=8.1Hz,1H),2.91(p, J=8.5Hz,1H),2.46(s,3H),2.43-2.32(m,1H),2.40(s,3H),2.31-2.19(m,3H ),2.17-2.07(m,1H),2.01(ddd,J=11.4,8.7,2.7Hz,1H),1.93-1.80(m,2H). LC / MS(ESI)m / z:450.09[M+H] + .

[0934] Example 79: 6-(4-([1,1′-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0935] Step 1: Preparation of methyl 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate synthesis

[0936]

[0937] To a solution of intermediate T (780 mg, 3.0 mmol, 1.0 equiv) and Cs2CO3 (2.44 g, 7.5 mmol, 2.5 equiv) in DMF (10 mL) was added 4-bromomethylbiphenyl (890 mg, 3.6 mmol, 1.2 equiv) and stirred for 12 hours. The reaction solution was poured into distilled water and extracted with DCM. The organic layer was then dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography to afford methyl 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate (940 mg, 73% yield). 1 H NMR(300MHz,chloroform-d)δ7.57-7.48(m,4H),7.44-7.37(m,2H),7.36-7.29(m ,1H),7.26(s,1H),7.25(s,1H),7.11(d,J=8.1Hz,2H),6.14(s,2H),3.82(s,3H).

[0938] Step 2: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylic acid

[0939]

[0940] To a solution of methyl 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate (940 mg, 2.2 mmol) in THF / MeOH / H₂O (20 / 10 / 10 mL) was added LiOH·H₂O (277 mg, 6.6 mmol, 3.0 equiv). The mixture was stirred at 70°C for 12 hours. The reaction mixture was partially concentrated and then acidified with 1N HCl solution. The precipitated solid was filtered, washed with distilled water, and dried to yield 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylic acid (815 mg, 90% yield). 1H NMR (300MHz, chloroform-d) δ7.58-7.36(m,3H),7.43-7.36(m,2H),7.32(d,J=6.8Hz,2H),7.11(d,J=8.1Hz,2H),6.12(s,2H).

[0941] Step 3: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole

[0942]

[0943] A solution of 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylic acid (815 mg, 1.97 mmol) and copper powder (82 mg, 10 wt%) in quinoline (10 mL) was stirred at 140°C for 12 hours. The reaction mixture was cooled, acidified with 6N HCl solution, and extracted with Et2O. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography to afford 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole (170 mg, 23% yield).

[0944] Step 4: Synthesis of 4-([1,1'-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid

[0945]

[0946] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)-3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole (170 mg, 0.46 mmol, 1.0 equiv) in THF (5 mL) was added n-BuLi (2.0 M in cyclohexane, 0.3 mL, 1.2 equiv) at -78°C and stirred for 10 minutes. Dry ice was added to the reaction mixture, which was stirred at room temperature for 1 hour. The mixture was then acidified with 1N HCl solution and extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography to afford 4-([1,1'-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid (100 mg, mixture).

[0947] Step 5: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro [3.3] Synthesis of methyl heptane-2-carboxylate

[0948]

[0949] To a solution of 4-([1,1'-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid (100 mg, 0.3 mmol) and HATU (137 mg, 0.36 mmol, 1.2 equiv) in DCM (2 mL) at 0°C was added DIPEA (80 μL, 0.45 mmol, 1.5 equiv) and stirred for 15 minutes. Intermediate A (68 mg, 0.33 mmol, 1.1 equiv) was added to the reaction mixture and stirred for 12 hours. The reaction mixture was poured into distilled water and extracted with DCM. The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The crude product was purified by flash column chromatography to give methyl 6-(4-([1,1′-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylate (40 mg, yield 30%). 1 H NMR(300MHz,chloroform-d)δ7.56-7.50(m,2H),7.50-7.39(m,4H),7.36-7.29(m,1H),7.1 1(d,J=8.3Hz,2H),7.00(dd,J=2.9,1.3Hz,1H),6.44(d,J=2.9Hz,1H),5.99(d,J=7.8Hz,1H ),5.60(s,2H),4.36-4.28(m,1H),3.66(s,3H),3.05-2.94(m,1H),2.54-2.46(m,1H),2.42 -2.36(m,1H),2.33-2.30(m,2H),2.27-2.20(m,1H),2.09-2.01(m,1H),1.80-1.71(m,2H).

[0950] Step 6: 6-(4-([1,1'-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[0951]

[0952] To a solution of methyl 6-(4-([1,1'-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylate (40 mg, 0.08 mmol) in THF / MeOH / H₂O (1:1:1, 9 mL) was added LiOH·H₂O (10 mg, 0.24 mmol, 3.0 equiv) and stirred for 12 hours. The reaction mixture was partially concentrated and then acidified with 1N HCl solution. The precipitated solid was filtered, washed with distilled water, and dried. The crude product was then purified by flash column chromatography to provide Example 79 (15 mg, 40% yield). 1H NMR(300MHz, methanol-d4)δ8.34(d,J=7.3Hz,1H),7.58-7.52(m,2H),7.50-7.44( m,2H),7.44-7.35(m,3H),7.33-7.26(m,1H),7.15(dd,J=3.0,1.3Hz,1H),7.02(d, J=8.3Hz,2H),6.43(d,J=3.0Hz,1H),5.56(s,2H),4.25-4.11(m,1H),3.02-2.90(m ,1H),2.46-2.38(m,1H),2.35-2.23(m,3H),2.22-2.01(m,2H),1.91-1.81(m,2H). LC / MS(ESI)m / z:471.4[M+H] + .

[0953] The compounds of Examples 80 to 89 were prepared using the same procedures as Example 79 except for the differences described below.

[0954] [Table 13]

[0955]

[0956]

[0957] [Table 14]

[0958]

[0959]

[0960]

[0961] Example 90: 6-(4-(4-(Trifluoromethyl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid Steps 1 to 3: Synthesis of 3-bromo-4-(4-(trifluoromethyl)benzyl)-4H-thieno[3,2-b]pyrrole

[0962]

[0963] 3-Bromo-4-(4-(trifluoromethyl)benzyl)-4H-thieno[3,2-b]pyrrole was obtained as a yellow liquid using the same procedure as in Steps 1 to 3 of Example 79, except that 4-bromomethylbiphenyl in Step 1 of Example 79 was replaced with 1-bromomethyl-4-(trifluoromethyl)benzene. 1H NMR (300MHz, chloroform-d) δ7.60-7.55(m,2H),7.23-7.17(m,2H),7.03-6.98(m,1H),6.88-6.85(m,1H),6.44(d,J=3.0Hz,1H),5.57(d,J=9.4Hz,2H).

[0964] Step 4: Synthesis of 4-(4-(trifluoromethyl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid

[0965]

[0966] Pd(OAc)2 (3 mol%) and Xantphos (3 mol%) were placed in a vacuum oven and replaced with argon three times. Formic acid (0.24 mL, 6.258 mmol) and a solution of 3-bromo-4-(4-(trifluoromethyl)benzyl)-4H-thieno[3,2-b]pyrrole (322 mg, 0.894 mmol) in DMF (3.0 mL) were then added. DCC (37 mg, 0.179 mmol) and Et3N (0.25 mL, 1.788 mmol) were then added, and the tube was sealed. The mixture was stirred at 100°C for 20 hours. The reaction mixture was filtered and concentrated under reduced pressure. The crude product was then purified by silica gel column chromatography to yield 4-(4-(trifluoromethyl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid (124 mg, 43% yield) as a white solid. 1 H NMR(300MHz,chloroform-d)δ8.09(d,J=1.3Hz,1H),7.51(d,J=8.1Hz,2H),7.11( d, J=8.1Hz, 2H), 6.95 (dd, J=3.1, 1.3Hz, 1H), 6.51 (d, J=3.1Hz, 1H), 5.81 (s, 2H).

[0967] Steps 5 and 6: 6-(4-(4-(trifluoromethyl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[0968]

[0969] Using the same procedure as in Steps 5 and 6 of Example 79, 4-(4-(trifluoromethyl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid was reacted to give the compound of Example 90. 1H NMR(300MHz,DMSO-d6)δ12.0(br s,1H)8.42(d,J=7.5Hz,1H),7.61(d,J=8.0Hz,2H),7.58(d,J=1.3Hz,1H),7.30(dd,J=3.0,1.3Hz,1H),7.16(d,J=8.0H z, 2H), 6.47 (d, J = 3.0Hz, 1H), 5.68 (s, 2H), 4.18-4.04 (m, 1H), 2.96-2.85 (m, 1H), 2.39-2.00 (m, 6H), 1.92-1.85 (m, 2H). LC / MS(ESI)m / z:463.4[M+H] + .

[0970] The compounds of Examples 91 to 94 were prepared using the same procedures as in Example 90 except for the differences described below.

[0971] [Table 15]

[0972]

[0973]

[0974] [Table 16]

[0975]

[0976]

[0977] Example 95: 6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0978] Steps 1 to 3: 3-Bromo-4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thiol Synthesis of pheno[3,2-b]pyrrole

[0979]

[0980] Using Intermediate U and Intermediate Y as starting materials, the same method as Steps 1 to 3 of Example 79 was used to obtain 3-bromo-4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)2-methyl-4H-thieno[3,2-b]pyrrole. 1HNMR(400MHz, CDCl3) δ7.50(d,J=8.3Hz,2H),7.18(d,J=8.1Hz,2H),6.92-6.79(m,3H),6. 60(td,J=2.3,10.5Hz,1H),6.37(d,J=2.9Hz,1H),5.57(s,2H),3.84(s,3H),2.44(s,3H). LC / MS(ESI)m / z:430.2[M+1].

[0981] Step 4: 4-((3'-Fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thieno[3, Synthesis of methyl 2-b]pyrrole-3-carboxylate

[0982]

[0983] To a solution of 3-bromo-4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)2-methyl-4H-thieno[3,2-b]pyrrole (410 mg, 953 μmol, 1.00 equiv) in MeOH (4 mL) was added Pd(dppf)Cl2.CH2Cl2 (156 mg, 191 μmol, 0.2 equiv) and TEA (289 mg, 2.86 mmol, 398 μL, 3.0 equiv) under an N2 atmosphere. The reaction mixture was purged with CO2 three times and then stirred at 70°C under CO2 (50 Psi) for 24 h. The reaction solution was cooled, filtered, and concentrated, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 50 / 1 to 20 / 1) to give 4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thieno[3,2-b]pyrrole-3-carboxylic acid methyl ester (280 mg, yield 71.7%) as a yellow oil. 1 H NMR (400MHz, DMSO) δ7.46 (d, J = 8.40Hz, 2H), 7.07 (d, J = 8.40Hz, 2H), 6.93-6.82 (m, 3H), 6.59 (td, J=2.40,10.4Hz,1H),6.40(d,J=3.00Hz,1H),5.64(s,2H),3.84(s,3H),3.76(s,3H),2.69(s,3H).

[0984] Step 5: 4-((3'-Fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thieno[3, Synthesis of 2-b]pyrrole-3-carboxylic acid

[0985]

[0986] To a solution of methyl 4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thieno[3,2-b]pyrrole-3-carboxylate (250 mg, 611 μmol, 1.00 equiv) in MeOH (1 mL) and THF (1 mL) was added LiOH·H2O (1 M, 3.66 mL, 6.00 equiv), and the mixture was stirred at 55°C for 24 hours. The reaction mixture was partially concentrated and then acidified with 1N HCl solution (pH = 3), and the aqueous layer was extracted with EtOAc (50 mL x 2). The organic layer was washed with brine (50 mL × 1), dried over sodium sulfate, then filtered and concentrated under reduced pressure to give 4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thieno[3,2-b]pyrrole-3-carboxylic acid (220 mg, yield 91.1%) as a yellow solid. 1 H NMR (400MHz, DMSO) δ13.29-12.68(m,1H),7.60(d,J=8.40Hz,2H),7.21(d,J=3.00Hz,1H),7.09-6.98( m, 4H), 6.80 (td, J = 2.20, 11.2Hz, 1H), 6.41 (d, J = 3.00Hz, 1H), 5.66 (s, 2H), 3.81 (s, 3H), 2.61 (s, 3H).

[0987] Steps 6 and 7: 6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thiophene Synthesis of (3,2-b)pyrrole-3-carboxamido)spiro[3,3]heptane-2-carboxylic acid

[0988]

[0989]

[0990] Using the same method as in Steps 5 and 6 of Example 79, 4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4H-thieno[3,2-b]pyrrole-3-carboxylic acid was reacted to give the compound of Example 95. 1H NMR (400MHz, DMSO) δ12.26-11.69(m,1H),8.40(d,J=7.60Hz,1H),7.57(d,J=8.20Hz ,2H),7.19(d,J=3.00Hz,1H),7.10(d,J=8.20Hz,2H),7.06-6.96(m,2H),6.86-6.77 (m,1H),6.35(d,J=2.80Hz,1H),5.35(s,2H),4.30-4.14(m,1H),3.82(s,3H),2.98- 2.83(m,1H),2.42(s,3H),2.39-2.16(m,4H),2.10-1.95(m,2H),1.91-1.77(m,2H). LC / MS(ESI)m / z:533.1[M+1].

[0991] Example 96: 6-(2-methyl-4-(3-phenylprop-2-yn-1-yl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid

[0992] Step 1: Synthesis of 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid

[0993]

[0994] To a solution of Intermediate U (3.00 g, 10.9 mmol, 1.00 equiv) in THF (15 mL) and MeOH (15 mL) was added LiOH·H₂O (1 M, 32.8 mL, 3.00 equiv) and stirred at 55°C for 2 hours. The reaction mixture was partially concentrated and acidified with 1N HCl (pH = 3), and the aqueous layer was extracted with EtOAc (50 mL x 2). The organic layer was filtered and concentrated under reduced pressure to afford 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid (2.70 g, 10.38 mmol, 94.8% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ7.09 (d, J=8.60Hz, 2H), 6.91-6.82 (m, 2H), 6.77 (d, J= 3.00Hz, 1H), 6.32 (d, J = 3.00Hz, 1H), 5.47 (s, 2H), 3.79 (s, 3H), 2.44 (s, 3H).

[0995] Step 2: Synthesis of 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole

[0996]

[0997] To a solution of 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid (2.00 g, 7.69 mmol, 1.00 equiv) in quinoline (20 mL) was added copper powder (210 mg, 3.32 mmol) and stirred at 140°C for 12 hours. The reaction solution was washed with 1N HCl (1 × 150 mL) and brine (1 × 50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by preparative HPLC (FA conditions) to give 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole (810 mg, 3.75 mmol, 48.7% yield) as a gray solid. 1 H NMR (400MHz, CDCl3) δ8.17 (br s, 1H), 6.96 (t, J = 2.60Hz, 1H), 6.44 (dd, J = 2.00, 3.00Hz, 1H), 2.47 (s, 3H).

[0998] Step 3: Synthesis of 3-bromo-2-methyl-4-(3-phenylprop-2-yn-1-yl)-4H-thieno[3,2-b]pyrrole

[0999]

[1000] To a solution of 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole (300 mg, 1.39 mmol, 1.00 equiv) and intermediate FF (406 mg, 2.08 mmol, 1.50 equiv) in DMF (3 mL) was added CsCO (1.13 g, 3.47 mmol, 2.50 equiv) and stirred at 20°C for 1 hour. The reaction mixture was partially concentrated and extracted with 50 mL of distilled water and EA (2 × 50 mL). The organic layer was washed with brine (3 × 20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by preparative HPLC (FA conditions) to afford 3-bromo-2-methyl-4-(3-phenylprop-2-yn-1-yl)-4H-thieno[3,2-b]pyrrole (180 mg, 39.2% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ7.52-7.43(m,2H),7.39-7.28(m,3H),7.04(d,J=2.80Hz,1H),6.40-6.32(m,1H),5.35(s,2H),2.46(s,3H).

[1001] Steps 4 to 7: 6-(2-methyl-4-(3-phenylprop-2-yn-1-yl)-4H-thieno[3,2-b]pyrrole-3-carboxylate Synthesis of (amino)spiro[3.3]heptane-2-carboxylic acid

[1002]

[1003] Using the same procedure as steps 4 to 7 of Example 95, 3-bromo-2-methyl-4-(3-phenylprop-2-yn-1-yl)-4H-thieno[3,2-b]pyrrole was reacted to give Example 96 as an off-white solid. 1 H NMR (400MHz, CDCl3) δ7.42-7.35(m,2H),7.35-7.29(m,3H),6.98(d,J=3.00Hz,1H),6.34(d,J=3.00Hz,1H),5.92(br d,J=7.60Hz,1H),5.16(s,2H),4.54-4.40(m,1H),3.09-2.99(m,1H),2.64-2.59(m,3H),2.59-2.53(m ,1H),2.49-2.34(m,3H),2.31-2.22(m,1H),2.15-2.06(m,1H),1.92(ddd,J=8.60,11.2,16.0Hz,2H). LC / MS (ESI) m / z: 433.2 [M+1].

[1004] The compounds of Examples 97 and 98 were prepared using the same procedures as Example 96 except for the differences described below.

[1005] [Table 17]

[1006]

[1007] [Table 18]

[1008]

[1009] Example 99: 6-(4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid Step 1: 3-Bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid Synthesis of methyl ester

[1010]

[1011] Intermediate GG (392 mg, 2.1145 mmol) was dissolved in THF and cooled to 0°C. Intermediate T (500 mg, 1.9223 mmol) and tributylphosphine (0.62 mL, 2.499 mmol) were then added. Di-tert-butyl azodicarboxylate (0.49 mL, 2.499 mmol) was slowly added, and the mixture was stirred at 50°C for 12 hours. Saturated aqueous sodium bicarbonate was added, and the reaction mixture was stirred for 10 minutes, then extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was then purified by silica gel column chromatography (petroleum ether:EtOAc = 80:20 to 50:50) to obtain methyl 3-bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-5-carboxylate (639 mg, 78% yield). 1 H NMR(300MHz,Chloroform-d)δ8.90-8.81(m,1H),8.62(dd,J=5.1,1.5Hz,1H),8.17(dt,J=8.1,1.9Hz,1H),7.64(dd ,J=8.1,5.1Hz,1H),7.51(d,J=8.3Hz,2H),7.27(d,J=3.7Hz,1H),7.19(d,J=8.3Hz,2H),6.16(s,2H),3.82(s,3H).

[1012] Step 2: Synthesis of 3-bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid

[1013]

[1014] To a solution of methyl 3-bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-5-carboxylate (639 mg, 1.4954 mmol) in THF / MeOH / H₂O (1 / 1 / 1) was added LiOH·H₂O (188 mg, 4.4862 mmol) and stirred for 12 hours. The reaction mixture was partially concentrated, then acidified with 1N HCl solution and washed with distilled water to afford 3-bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid (609 mg, 98% yield) as a white solid. 1H NMR (300MHz, DMSO-d6) δ12.82(s,1H),8.93(d,J=2.3Hz,1H),8.62(dd,J=5.0,1.5Hz,1H),8.21(dt,J=8.2,1.9Hz, 1H),7.73(s,1H),7.72-7.67(m,2H),7.61(dd,J=8.0,5.0Hz,1H),7.35(s,1H),7.06(d,J=8.2Hz,2H),6.11(s,2H).

[1015] Step 3: Synthesis of 3-bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole

[1016]

[1017] A solution of 3-bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-5-carboxylic acid (759 mg, 1.8365 mmol) and copper powder (76 mg, 10 wt%) in quinoline (20 mL) was stirred at 140°C for 12 hours. The reaction mixture was cooled, acidified with 6N HCl solution, and extracted with Et2O. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography to yield 3-bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole (crude).

[1018] Step 4: Synthesis of 4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid

[1019]

[1020] Under a nitrogen atmosphere, Pd(OAc) (3 mol%) and Xantphos (3 mol%) were added to a drying tube, which was then refilled with argon three times. Formic acid (0.4 mL, 10.5966 mmol) and a solution of 3-bromo-4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole (559 mg, 1.5138 mmol) in DMF (3.0 mL) were added. DCC (62 mg, 0.3028 mmol) and EtN (0.42 mL, 3.0276 mmol) were added, and the tube was sealed. The reaction mixture was stirred at 100°C for 20 hours. The reaction mixture was filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to yield 4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid (crude).

[1021] Step 5: 6-(4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro [3.3] Synthesis of methyl heptane-2-carboxylate

[1022]

[1023] To a solution of 4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid (512 mg) and HATU (582 mg, 1.531 mmol) in DMF (4 mL) was added DIPEA (0.8 mL, 4.593 mmol), stirred for 10 minutes, and then intermediate A (315 mg, 1.531 mmol) was added and stirred for 12 hours. The reaction solution was diluted with ethyl acetate and washed with distilled water and brine. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was then purified by column chromatography to yield methyl 6-(4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylate (147 mg, 16% yield). 1 H NMR (300MHz, Chloroform-d) δ8.87(d,J=2.1Hz,1H),8.64(d,J=5.5Hz,1H),8.46(d,J=8.1Hz,1H),7.90( dd,J=8.1,5.5Hz,1H),7.48(d,J=8.2Hz,2H),7.36-7.32(m,1H),7.27(s,1H),7.24(s,1H),6.98(dd,J=3. 0,1.3Hz,1H),6.47(d,J=3.0Hz,1H),6.06(d,J=7.7Hz,1H),5.71(d,J=5.9Hz,2H),4.37-4.29(m,1H),3.6 6(s,3H),3.07-2.95(m,1H),2.62-2.47(m,1H),2.47-2.22(m,4H),2.19-2.07(m,1H),1.92-1.75(m,2H).

[1024] Step 6: 6-(4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro [3.3] Synthesis of heptane-2-carboxylic acid

[1025]

[1026] To a solution of methyl 6-(4-(4-(pyridin-3-yl)benzyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylate (147 mg, 0.3027 mmol) in THF / MeOH / H₂O (1 / 1 / 1) was added LiOH·H₂O (38 mg, 0.9081 mmol), and the mixture was stirred for 12 hours. The reaction mixture was partially concentrated, then acidified with 1N HCl solution, and the aqueous layer was extracted with EtOAc. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to provide Example 99 (92 mg, 64% yield). 1H NMR (300MHz, DMSO-d6) δ12.04(s,1H),8.83(s,1H),8.54(d,J=4.6Hz,1H),8.48(d,J=7 .5Hz,1H),8.01(d,J=8.0Hz,1H),7.63-7.59(m,2H),7.58(d,J=1.3Hz,1H),7.46(t,J=6 .3Hz,1H),7.31(dd,J=3.0,1.3Hz,1H),7.16(d,J=8.2Hz,2H),6.45(d,J=3.0Hz,1H),5. 63(s,2H),4.24-4.16(m,1H),2.99-2.85(m,1H),2.43-2.35(m,1H),2.32-1.85(m,7H). LC / MS(ESI)m / z:472.4[M+H] + .

[1027] The compounds of Examples 100 to 113 were prepared using the same procedures as in Example 99 except for the differences described below.

[1028] [Table 19]

[1029]

[1030]

[1031]

[1032]

[1033] [Table 20]

[1034]

[1035]

[1036]

[1037]

[1038] [Preparation of Isomers]

[1039] Examples 1a and 1b: (2S,4S,6S)-6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (1a) and (2R,4R,6R)-6-(4-([1,1'-biphenyl]-4-ylmethyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (1b)

[1040]

[1041] The compound of Example 1 (106 g, 231 mmol, 1.00 equiv) was purified by supercritical fluid chromatography (SFC) under the following conditions to separate Example 1a (66.06 g, 143 mmol, 61.9% yield, 99.3% purity) and Example 1b (16.02 g, 34.4 mmol, 14.9% yield, 98.6% purity) as white solids.

[1042] Chromatographic column: DAICEL CHIRALCEL OJ column (250 mm × 50 mm, 10 μm)

[1043] Mobile phase: [Neu-MeOH]; B%: 30%-30%, 4.6; 1860 minutes.

[1044] Example 1a: 1 H NMR (400MHz, DMSO) δ12.00 (br s, 1H), 8.26 (br d, J = 7.60Hz, 1H), 7.60 (br d,J=7.20Hz,2H),7.51(d,J=8.40Hz,2H),7.45(t,J=7.60Hz,2H),7.37-7.31(m,1 H),7.18(d,J=8.00Hz,2H),4.22-4.11(m,1H),3.90(s,2H),2.91(m,1H),2.38(br s,1H),2.33(br d,J=7.60Hz,6H),2.29-2.14(m,3H),2.12-1.98(m,2H),1.94-1.80(m,2H). LC / MS(ESI)m / z=460.2[M+H] + .

[1045] Example 1b: 1H NMR(400MHz,DMSO)δ11.99(br s,1H),8.26(d,J=7.60Hz,1H),7.65-7.57(m,2H),7.51(d,J=8.00Hz,2H),7.45(t,J=7.60Hz,2H),7.37-7.31(m,1H),7.19(d,J=8.00Hz,2H) ,4.16(m,1H),3.90(s,2H),2.91(m,1H),2.40-2.35(m,1H),2.33(d,J= 7.20Hz,6H),2.29-2.14(m,3H),2.12-1.99(m,2H),1.93-1.80(m,2H). LC / MS (ESI) m / z = 460.2 [M+H] + .

[1046] Examples 34a and 34b: (2S,4S,6S)-6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (34a) and (2R,4R,6R)-6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (34b)

[1047] Step 1: (2S,4S,6S)-6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-diol methylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylate (34a') and (2R,4R,6R)-6-(4-((3'-fluoro-5'- methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid methyl Isolation of ester (34b')

[1048]

[1049] The 6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5-dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid methyl ester (91.0 g, 174 mmol, 1.00 equiv) obtained in Step 1 of Example 34 was purified by supercritical fluid chromatography (SFC) under the following conditions to give Intermediate 34a' (62.2 g, 119 mmol, 68.3% yield) and Intermediate 34b' (24.2 g, 46.4 mmol, 26.5% yield) as gray solids and off-white solids, respectively.

[1050] Neutral conditions: DAICEL CHIRALPAK AD column (250 mm × 50 mm, 10 μm)

[1051] Mobile phase: [Neu-ETOH]; B%: 50%-50%, 6.0; 1200 min

[1052] Intermediate 34a': 1 H NMR(400MHz,CDCl3)δ7.46(d,J=8.3Hz,2H),7.17(d,J=8.3Hz,2H),6.91 - 6.80(m,2H),6.60(td,J=2.2,10.6Hz,1H),5.37(br d,J=7.7Hz,1H),4.27(q,J=8.2Hz,1H),3.98(s,2H),3.85(s,3H),3.65(s,3H),3.02 - 2.90(m,1H),2.44(s,4H),2.38 - 2.24(m,6H),2.17(dd,J=8.3,11.6Hz,1H),1.98(ddd,J=2.5,8.7,11.5Hz,1H),1.54(dt,J=8.6,12.3Hz,2H). LC / MS(ESI)m / z:522.1[M + H] + .

[1053] Intermediate 34b': 1 H NMR(400MHz,CDCl3)δ7.45(d,J=8.2Hz,2H),7.16(d,J=8.0Hz,2H),6.90 - 6.81(m,2H),6.60(td,J=2.2,10.5Hz,1H),5.40(br d,J=7.8Hz,1H),4.34 - 4.20(m,1H),3.97(s,2H),3.85(s,3H),3.64(s,3H),2.96(quin,J=8.5Hz,1H),2.43(s,4H),2.38 - 2.24(m,6H),2.17(dd,J=8.4,11.7Hz,1H),2.05 - 1.92(m,1H),1.54(dt,J=8.6,12.3Hz,2H). LC / MS(ESI)m / z:522.1[M + H] + .

[1054] Step 2a: (2S,4S,6S)-6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5- Preparation of dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (34a)

[1055]

[1056] To a solution of Intermediate 34a' (62.2 g, 119 mmol, 1.00 equiv) in THF / MeOH / H2O (200 mL, 100 mL, 200 mL) was added LiOH·H2O (15.0 g, 358 mmol, 3.00 equiv) and stirred at 20°C for 3 h. The reaction was partially concentrated, then diluted with H2O (2.00 L) and acidified with 1N HCl solution (pH = 3). The aqueous layer was extracted with EtOAc (1.50 L x 2), and the organic layer was washed with brine (2 x 1.00 L), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was triturated with MTBE (300 mL) at 20°C for 12 h, then with MTBE (100 mL) at 25°C for 30 min to afford Example 34a (30.0 g, 59.1 mmol, 49.7% yield) as a white solid. 1 H NMR (400MHz, DMSO) δ12.01(brd,J=2.5Hz,1H),8.27(d,J=7.5Hz,1H),7.54(d,J=8 .2Hz,2H),7.17(d,J=8.2Hz,2H),7.07-6.96(m,2H),6.80(td,J=2.1,11.0Hz,1H), 4.23-4.10(m,1H),3.89(s,2H),3.82(s,3H),2.97-2.84(m,1H),2.40-2.33(m,1H ), 2.31 (d, J = 3.3Hz, 6H), 2.28-2.13 (m, 3H), 2.12-1.97 (m, 2H), 1.92-1.79 (m, 2H). LC / MS(ESI)m / z=508.1[M+H] + .

[1057] Step 2b: (2R,4R,6R)-6-(4-((3'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-2,5- Preparation of dimethylthiophene-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (34b)

[1058]

[1059] Intermediate 34b' was used in the same manner as in step 2a to give Example 34b (10.0 g, 19.7 mmol, 42.4% yield) as an off-white solid. 1H NMR(400MHz,DMSO)δ12.00(brs,1H),8.27(d,J=7.5Hz,1H),7.54(d,J=8.2Hz,2H) ,7.17(d,J=8.2Hz,2H),7.06-6.96(m,2H),6.80(td,J=2.2,10.9Hz,1H),4.21-4. 09(m,1H),3.89(s,2H),3.82(s,3H),2.90(quin,J=8.5Hz,1H),2.39-2.33(m,1H) ,2.31(d,J=3.3Hz,6H),2.28-2.13(m,3H),2.11-1.95(m,2H),1.93-1.78(m,2H). LC / MS(ESI)m / z:508.3[M+H] + .

[1060] Examples 79a and 79b: (2S,4S,6S)-6-(4-([1,1'-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (79a) and (2R,4R,6R)-6-(4-([1,1'-biphenyl]-4-ylmethyl)-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (79b)

[1061]

[1062] The compound of Example 79 was purified by supercritical fluid chromatography (SFC) under the following conditions.

[1063] Chromatographic column: Daicel ChiralPak IG column (250 mm × 30 mm, 10 μm)

[1064] Mobile phase: [0.1% NH3H2O ​​ETOH]; B% / 50%-50%, 4.4 minutes; 70 minutes

[1065] The eluate was concentrated, and the residue was added to distilled water (10 mL) and acidified with aqueous HCl (1 M) (pH 1 to 2). The suspension was filtered and concentrated to a filter cake of white solid to isolate the compound of Example 79a (171 mg, 356 μmol, 55.9% yield, 98.0% purity) and the compound of Example 79b (36 mg, 11.7% yield, 98% purity), respectively.

[1066] Example 79a: 1H NMR(400MHz,DMSO)δ12.71-11.10(m,1H),8.50(br d,J=7.60Hz,1H),7.64-7.56(m,3H),7.54(d,J=8.20Hz,2H),7.44(t,J=7 .60Hz,2H),7.39-7.29(m,2H),7.15(d,J=8.20Hz,2H),6.46(d,J=2.80Hz, 1H),5.62(s,2H),4.23(sxt,J=8.20Hz,1H),2.94(quin,J=8.20Hz,1H),2. 45-2.37(m,1H),2.33-2.19(m,3H),2.16-2.03(m,2H),2.02-1.89(m,2H). LC / MS(ESI)m / z:470.9[M+H] + .

[1067] Example 79b: 1 H NMR(400MHz,DMSO)δ12.02(br s,1H),8.49(d,J=7.60Hz,1H),7.63-7.56(m,3H),7.53(d,J=8.20Hz,2H) ,7.43(t,J=7.60Hz,2H),7.36-7.29(m,2H),7.14(d,J=8.20Hz,2H),6.45 (d,J=3.00Hz,1H),5.62(s,2H),4.30-4.13(m,1H),2.99-2.90(m,1H),2. 44-2.36(m,1H),2.32-2.18(m,3H),2.16-2.02(m,2H),2.01-1.86(m,2H). LC / MS(ESI)m / z:471.0[M+H] + .

[1068] Examples 80a and 80b: (2S,4S,6S)-6-(4-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (80a) and (2R,4R,6R)-6-(4-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-4H-thieno[3,2-b]pyrrole-3-carboxamido)spiro[3.3]heptane-2-carboxylic acid (80b)

[1069]

[1070] The compound of Example 80 (80.0 g, 165 mmol, 1.00 equiv) was purified by supercritical fluid chromatography (SFC) under the following conditions to separate the compound of Example 80a (30.0 g, 61.9 mmol, 37.5% yield) and the compound of Example 80b (10.0 g, 20.6 mmol, 12.5% ​​yield) as a white solid and an off-white solid, respectively.

[1071] Chromatographic column: DAICEL CHIRALPAK AD column (250 mm × 50 mm, 10 μm)

[1072] Mobile phase: [Neu-ETOH]; B%: 40%-40%, 14.2; 870 minutes

[1073] Example 80a: 1 H NMR (400MHz, DMSO) δ11.74-12.27(m,1H)8.43(d,J=7.58Hz,1H)7.60(d,J=7.58Hz,2H)7 .54(d,J=8.19Hz,2H)7.45(t,J=7.64Hz,2H)7.32-7.38(m,1H)7.20(d,J=2.81Hz,1H)7. 16(d,J=8.19Hz,2H)6.36(d,J=2.81Hz,1H)5.35(s,2H)4.18-4.29(m,1H)2.86-2.95(m, 1H)2.43(s,3H)2.33-2.40(m,1H)2.16-2.31(m,3H)1.96-2.11(m,2H)1.79-1.93(m,2H). LC / MS(ESI)m / z=485.1[M+H] + .

[1074] Example 80b: 1H NMR(400MHz, DMSO)δ11.44-12.66(m,1H)8.42(d,J=7.58Hz,1H)7.60(d,J=7.46Hz,2H)7.5 4(d,J=8.19Hz,2H)7.45(t,J=7.64Hz,2H)7.32-7.37(m,1H)7.20(d,J=2.81Hz,1H)7.13(d ,J=8.19Hz,2H)6.35(d,J=2.93Hz,1H)5.35(s,2H)4.19-4.29(m,1H)2.90(quin,J=8.47Hz ,1H)2.43(s,3H)2.34-2.39(m,1H)2.17-2.28(m,3H)1.96-2.10(m,2H)1.79-1.91(m,2H). LC / MS(ESI)m / z=485.1[M+H] + .

[1075] [Experimental Example: Evaluation of Inhibitory Activity against EP2 and / or EP4]

[1076] Experimental Example 1.1: hEP2 cAMP Assay

[1077] HEK293 cells overexpressing hEP2 were cultured in growth medium (GM:MEM (Gibco TM ,11095080) / 10%HI FBS(Gibco TM , 10082147) / 1% penicillin / streptomycin). Before the experiment, the growth medium was removed and starvation medium (HBSS (Gibco TM , 14025076) / 10% GM). Subsequently, the cells were incubated for 4 hours. Enzyme-free cell dissociation buffer (Gibco TM HEK293 cells carrying hEP2 were detached from the culture dish (Biotinylated ELISA kit, 15040066) and resuspended in assay buffer (AB: HBSS, 0.1% BSA stabilizer, 0.5 mM IBMX, 5 mM HEPES).

[1078] 5 μL AB containing 1000 cells was inoculated into a 384-well plate ( 3570), a stock solution of the test compound at a concentration of 1 mM was prepared in DMSO and serially diluted in DMSO to the concentration required for the inhibitory dose-response curve (test concentration range 10 μM to 0.001 nM). PGE2 (Sigma, P0409, stock solution: 1 μM) was used as an agonist at a final concentration of 400 pM, corresponding to EC 50-802.5 μL of diluted compound and 2.5 μL of PGE2 (final concentration 400 pM) were transferred to the assay plate, and the plate was incubated at room temperature for 12 minutes.

[1079] 5 μL of donor (Eu-cAMP tracer) and 5 μL of acceptor (ULight-cAMP antibody) were added to each plate, and the plate was incubated at room temperature in the dark for 1 hour. The results were then obtained using a Varioskan LUX multifunctional microplate reader (excitation: 334 nm, emission: 615 and 665 nm). The resulting FRET fluorescence value (665 nm / 615 nm*10000) was converted and then calculated as the percentage of cAMP relative to the DMSO control value. IC was generated using GraphPad Prism software using logarithm (inhibitor) and reaction-variable slope (4 parameters). 50 The values ​​and curves are plotted, and the middle value of multiple experiments is taken as the experimental result.

[1080] Experimental Example 1.2: hEP4 cAMP Assay

[1081] HEK293 cells overexpressing hEP4 were cultured in growth medium (GM:MEM (Gibco TM ,11095080) / 10%HI FBS(Gibco TM , 10082147) / 1% penicillin / streptomycin). Before the experiment, the growth medium was removed and starvation medium (HBSS (Gibco TM , 14025076) / 10% GM). Subsequently, the cells were incubated for 4 hours. Enzyme-free cell dissociation buffer (Gibco TM HEK293 cells carrying hEP4 were detached from the culture dish (Biotinylated ELISA kit, 15040066) and resuspended in assay buffer (AB: HBSS, 0.1% BSA stabilizer, 0.5 mM IBMX, 5 mM HEPES).

[1082] 5 μL AB containing 1000 cells was inoculated into a 384-well plate ( 3570), a stock solution of the test compound at a concentration of 1 mM was prepared in DMSO and serially diluted in DMSO to the concentration required for the inhibitory dose-response curve (test concentration range 10 μM to 0.001 nM). PGE2 (Sigma, P0409, stock solution: 100 μM) was used as an agonist at a final concentration of 20 nM, corresponding to EC 50-80 2.5 μL of diluted compound and 2.5 μL of PGE2 (final concentration 20 nM) were transferred to the assay plate, and the plate was incubated at room temperature for 18.5 minutes.

[1083] 5 μL of donor (Eu-cAMP tracer) and 5 μL of acceptor (ULight-cAMP antibody) were added to each plate, and the plate was incubated at room temperature in the dark for 1 hour. The results were then obtained using a Varioskan LUX multifunctional microplate reader (excitation: 334 nm, emission: 615 and 665 nm). The resulting FRET fluorescence value (665 nm / 615 nm*10000) was converted and then calculated as the percentage of cAMP relative to the DMSO control value. IC was generated using GraphPad Prism software using logarithm (inhibitor) and reaction-variable slope (4 parameters). 50 The values ​​and curves are plotted, and the middle value of multiple experiments is taken as the experimental result.

[1084] 3. Experimental Results

[1085] The inhibitory activities of the compounds of Examples 1 to 113 against EP2 and EP4 measured by the above experimental method were evaluated according to the standards in Table 21 below. The results are shown in Tables 22 to 25.

[1086] [Table 21]

[1087]

[1088] [Table 22]

[1089]

[1090]

[1091] [Table 23]

[1092]

[1093]

[1094] [Table 24]

[1095]

[1096]

[1097] [Table 25]

[1098]

[1099] As shown in Tables 22 to 25 above, the compounds of Examples 1 to 113 exhibited excellent inhibitory activities against EP2 and EP4.

[1100] Experimental Example 2: Evaluation of the anticancer effect of combined administration of immune checkpoint inhibitors in a mouse-derived cancer tumor model

[1101] Experimental Example 2.1. Evaluation of the anticancer effect of combined administration in the CT26 mouse-derived colorectal cancer tumor model

[1102] CT26 cells were subcultured and maintained in a cell culture incubator (CO2 incubator) at 37°C and 5% CO2 using RPMI-1640 medium containing 10% FBS (fetal bovine serum). 5 CT26 cells were resuspended at a concentration of 100 μL / 100 μL and transplanted into the right subcutaneous region of 6- to 7-week-old BALB / c mice (Shanghai Lingchang Biotechnology Co., Ltd., Shanghai) at 100 μL per mouse to prepare a CT26 tumor model.

[1103] Tumor size was calculated by measuring the minor and major axes using a vernier caliper and substituting them into Equation 1 below.

[1104] [Equation 1]

[1105] Tumor size (volume, mm 3 )=(minor axis, mm) 2 ×(long axis, mm)×0.5

[1106] When the tumor size reaches an average of 70 to 100 mm 3 The mice were randomly divided into several groups to evaluate the drug efficacy (average tumor size in each group = 79 mm 3 The tumor growth inhibition ability among the groups was calculated and compared by substituting the measured tumor size into Equation 2 to evaluate the drug efficacy.

[1107] [Equation 2]

[1108] Tumor growth inhibition ability = [{(tumor size of the control group at the time of measurement, C)-(tumor size of the control group at the start of administration, C0)}-{(tumor size of the experimental group at the time of measurement, T)-(tumor size of the experimental group at the start of administration, T0)}] / {(tumor size of the control group at the time of measurement, C)-(tumor size of the control group at the start of administration, C0)}

[1109] The test group was divided into an A01 treatment group (Example 34b), an anti-PD-1 antibody (immune checkpoint inhibitor) treatment group, and a combination treatment group of A01 and anti-PD-1 antibody, and the drug was administered for 12 days. Anti-PD-1 antibody (BioXcell, Cat#BP0146) was diluted in PBS and injected intraperitoneally once every 3 days at a concentration of 200 μg / mouse. Tween 80 was added to a 0.5% methylcellulose (40000cp) aqueous solution until it reached 0.2%, and A01 was suspended as an adjuvant and orally administered at a concentration of 150 mg / kg per day.

[1110] As a result, the changes in the weight of mice during the administration period were examined at the start and end points of the experiment. The weight of the A01-administered group increased from 20.4±0.4g to 22.2±0.6g, and the weight of the anti-PD-1 antibody-administered group increased from 20.2±0.4g to 22.7±0.4g. In addition, the weight of the A01 and anti-PD-1 antibody-administered group increased from 19.5±0.3g to 20.7±0.5g. The results were similar to those of the control group, and no weight loss due to administration was observed ( Figure 1 ).

[1111] The tumor size of mice during the administration period was measured and compared based on the starting and ending points of the experiment. The tumor size of the control group increased from 79.4±2.5mm 3 Increased to 1725.5±239.8mm 3 In the A01-treated group, the tumor size increased from 79.4 ± 2.3 mm 3 Increased to 1092.6±237.5mm 3 , compared with the control group, the tumor growth inhibition effect was 38.5%. In the anti-PD-1 antibody administration group, the tumor size was reduced from 79.4±2.1mm 3 Increased to 1270.8±200.6mm 3 , compared with the control group, the tumor growth inhibition rate was 27.6%. In addition, in the A01 and anti-PD-1 combined administration group, the tumor size was reduced from 79.4±1.7mm 3 Increased to 717.9±110.6mm 3 , compared with the control group, the tumor growth inhibition rate was 61.2% ( Figure 2 ).

[1112] The above results found that compared with A01 or immune checkpoint inhibitors administered alone, the combined administration of A01 and immune checkpoint inhibitors showed superior tumor growth inhibition ability without weight loss.

[1113] Experimental Example 2.2. Evaluation of the anticancer effect of combined drug administration in the MC38 mouse-derived colorectal cancer tumor model

[1114] MC38 cells were subcultured in a cell culture incubator (CO2 incubator) at 37°C and 5% CO2 using DMEM medium containing 10% FBS (fetal bovine serum). 6 MC38 cells were resuspended at a concentration of 100 cells / 100 μL and transplanted into the right subcutaneous area of ​​6- to 7-week-old C57B / 6 mice (Shanghai Lingchang Biotechnology Co., Ltd., Shanghai) at 100 μL per mouse to prepare the MC38 tumor model.

[1115] The tumor size was measured and calculated in the same manner as in Experimental Example 2.1.

[1116] When the average tumor size reaches 70 to 100 mm 3 The mice were randomly divided into several groups to evaluate the drug efficacy (mean tumor size = 91 mm 3 The tumor growth inhibition ability among the groups was calculated and compared by substituting the measured tumor size into Equation 2 of Experimental Example 2.1, thereby evaluating the drug efficacy.

[1117] The test group was divided into an A02 treatment group (Example 1b), an anti-PD-1 antibody (immune checkpoint inhibitor) treatment group, and a combined treatment group of A02 and anti-PD-1 antibodies for 18 days of drug administration. Anti-PD-1 antibody (BioXcell, Cat#BP0146) was diluted in PBS and injected intraperitoneally once every 3 days at a concentration of 200 μg / mouse. Tween 80 was added to a 0.5% methylcellulose (40000cp) aqueous solution until it reached 0.2%, and A02 was suspended as an adjuvant and orally administered at a concentration of 150 mg / kg per day.

[1118] As a result, the weight of the mice increased from 19.1±0.2g to 22.0±0.4g in the A02-administered group and from 19.10±0.3g to 21.6±0.5g in the anti-PD-1 antibody-administered group. In addition, the weight of the A02 and anti-PD-1 antibody-administered group increased from 19.4±0.2g to 20.4±0.5g, which was similar to the control group. No weight loss due to drug administration was observed ( Figure 3 ).

[1119] The tumor size of mice during the administration period was measured and compared based on the starting and ending points of the experiment. The tumor size of the control group increased from 91.5±2.9mm 3 Increased to 2496.6±238.1mm 3 In the A02-treated group, the tumor size increased from 91.5 ± 3.1 mm 3 Increased to 1711.0±236.4mm 3 , compared with the control group, the tumor growth inhibition ability was 32.7%. In the anti-PD-1 antibody administration group, the tumor size was reduced from 91.6±3.0mm 3 Increased to 1422.1±273.9mm 3 , compared with the control group, the tumor growth inhibition effect was 44.7%. In addition, in the A02 and anti-PD-1 antibody combined administration group, the tumor size was reduced from 91.6±3.2mm 3 Increased to 610.2±156.9mm 3 , compared with the control group, the tumor growth inhibition rate was 78.4% ( Figure 4).

[1120] The above results found that compared with A02 or immune checkpoint inhibitors administered alone, the combined administration of A02 and immune checkpoint inhibitors showed superior tumor growth inhibition ability without weight loss.

[1121] Experimental Example 3. Evaluation of the anticancer effect of combined administration of standard treatment in a mouse lung cancer tumor model

[1122] TC1 cells were cultured in a cell culture incubator at 37°C and 5% CO2 using RPMI 1640 medium containing 10% FBS. 6 The TC1 tumor animal model was prepared by injecting the cells into the right subcutaneous area of ​​C57BL / 6 mice at a concentration of 10 cells / mouse.

[1123] The tumor size was measured and calculated in the same manner as in Experimental Example 2.1.

[1124] When the average tumor size reaches about 100 mm 3 The mice were randomly divided into several groups to evaluate the drug efficacy.

[1125] When the average tumor size reaches about 100 mm 3 Start dosing when

[1126] Cisplatin, pemetrexed, and anti-PD-1 antibodies were diluted in PBS and administered intravenously twice a week at doses of 5 mg / kg, 100 mg / kg, and 10 mg / kg, respectively. A01 (Example 34b) was diluted in a borate buffer solution containing 5% ethanol and 20% hydroxypropyl-β-cyclodextrin and administered orally daily at a dose of 30 mg / kg. As a standard treatment for lung cancer, cisplatin, pemetrexed, and anti-PD-1 antibodies were administered for three cycles as initial treatment, followed by continuous co-administration of pemetrexed and anti-PD-1 antibodies as maintenance therapy. In the A01 (Example 34b) co-administration group, A01 (Example 34b) was additionally administered according to standard treatment methods.

[1127] The results are shown in Table 26 and Figure 5 As shown. Until day 12 after the start of dosing, which is the completion point of the initial treatment of cisplatin, pemetrexed and anti-PD-1 antibody in combination over three cycles, mice co-administered with A01 (Example 34b) showed a lower tumor growth rate compared to the vehicle control group (PBS and borate buffer) or the standard of care treatment group. After 17 days of maintenance treatment, the tumor size of mice co-administered with A01 (Example 34b) was reduced to nearly 0 mm 3In contrast, in the standard-of-care treatment group, tumor size began to decrease from day 22 after the start of drug administration and then began to increase again.

[1128] [Table 26]

[1129]

[1130] The above results found that compared with the administration of A01, chemotherapy agents or immune checkpoint inhibitors alone, the combined administration of A01, chemotherapy agents and immune checkpoint inhibitors showed superior tumor growth inhibition ability without weight loss.

[1131] These results suggest that the combined administration of EP2 and EP4 dual inhibitors, chemotherapeutic agents, and / or immune checkpoint inhibitors may provide an anticancer pharmaceutical composition and combination therapy strategy with excellent anticancer effects and fewer side effects.

Claims

1. A pharmaceutical composition for preventing or treating cancer, comprising as active ingredients a compound as shown in formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof; and an anticancer agent: [Formula I] in, One of X and Y is S, the other is CR 1 ,and is a single bond or a double bond, of which there are two double bonds; R 1 and R 2 is selected from hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl and C6-C 10 The group consisting of aryl groups, wherein the C1-C6 alkyl and C1-C6 alkoxy groups are each independently optionally substituted by one or more halogen, hydroxyl, cyano or amino groups, and the C3-C8 cycloalkyl and C6-C 10 The aryl groups are each independently optionally substituted with one or more halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy; and R 3 for or R 1 is selected from hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl and C6-C 10 The group consisting of aryl groups, wherein the C1-C6 alkyl and C1-C6 alkoxy groups are each independently optionally substituted by one or more halogen, hydroxyl, cyano or amino groups, and the C3-C8 cycloalkyl and C6-C 10 The aryl groups are each independently optionally substituted with one or more halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy; and R 2 and R 3 Together with the carbon atoms to which they are attached, they form in, and The nitrogen atoms on One or two carbon atoms are optionally substituted by halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy; W is -(CH2) o -、-(CH2) o -C≡C-, -C(O)-, -O-, -S-, -NH- or -N(C1-C6 alkyl)-, wherein the H in the CH2 is optionally substituted by one or more halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy; Cy is selected from C6-C 14 The group consisting of aryl, 4- to 14-membered heteroaryl, 4- to 14-membered heterocycloalkyl, C3-C8 cycloalkyl and C3-C8 cycloalkenyl, and optionally substituted with one or more R'; R a is hydrogen, halogen, hydroxyl, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, oxo or -V-Cy2, wherein the C1-C6 alkyl and C1-C6 alkoxy are optionally substituted by one or more halogen, hydroxyl, cyano or amino, Wherein, V is absent or -NH-, -NHCH2-, -NHCH3-, -CONH-, -NHCO-, -NHSO2-, -S-, -SO2-, -CH2-, -OCH2- or -O-, Cy2 is selected from C6-C 14 The group consisting of aryl, 4- to 14-membered heteroaryl, 4- to 14-membered heterocycloalkyl, C3-C8 cycloalkyl and C3-C8 cycloalkenyl, and optionally substituted with one or more R"; R' is independently selected from the group consisting of halogen, hydroxyl, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl) and -N(C1-C6 alkyl)2, wherein the C1-C6 alkyl and C1-C6 alkoxy are optionally substituted with one or more halogen, hydroxyl, cyano or amino; R" is selected from halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -CO-(C1-C6 alkyl), -C(O)H, -COO-(C1-C6 alkyl), -COOH, -CONH2, -CONH-(C1-C6 alkyl), -CON(C1-C6 alkyl)2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-CO-(C1-C6 alkyl), -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH, 3- to 7-membered heterocycloalkyl, C3-C8 cycloalkyl and -(CH2) p -(C3-C8 cycloalkyl), wherein the C1-C6 alkyl and C1-C6 alkoxy are optionally substituted by one or more halogen, hydroxy, cyano or amino, and the 3- to 7-membered heterocycloalkyl and C3-C8 cycloalkyl are optionally substituted by one or more halogen, hydroxy, cyano, oxo or amino; R 4 is hydrogen or C1-C6 alkyl; R 5 , R 6 and R 7 Each is defined as follows: (i)R 5 and R 6 is H, and R 7 For does not exist, (ii) R 5 and R 6 Together for -(CH2) q -, and R 7 is not present, or (iii) R 5 is H, and R 6 and R 7 Together for -(CH2) r -;and P is absent or -CH2-, if R 7 If does not exist, then P also does not exist; R 8 for Where Z is -(CH2) s , and R 8 ' is hydrogen, hydroxy, C1-C6 alkyl or C1-C6 alkoxy; l, m and n are each independently an integer from 0 to 2, wherein at least one of m and n is not 0. If P and R 7 If it does not exist, then l is 0; o and p are each independently an integer from 0 to 3; q and r are each independently an integer of 1 or 2; and s is an integer from 0 to 3.

2. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: R 1 is hydrogen, halogen, hydroxyl, cyano, amino, C1-C3 alkyl, C1-C3 alkoxy, -NH-(C1-C3 alkyl) or -N(C1-C3 alkyl)2, wherein the C1-C3 alkyl and C1-C3 alkoxy are each independently optionally substituted with one or more halogen, hydroxyl, cyano or amino; and R 2 It is hydrogen, halogen, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C3-C6 cycloalkyl or phenyl, wherein the C1-C3 alkyl and C1-C3 alkoxy are each independently and optionally substituted by one or more halogen, hydroxyl, cyano or amino.

3. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: Cy is selected from C6-C 10 The group consisting of aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, and 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O and S, and optionally substituted with one or more R'; Cy2 is selected from C6-C 10 The group consisting of aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O and S, C3-C8 cycloalkyl and C3-C8 cycloalkenyl, and optionally substituted with one or more R"; R' is halogen, hydroxy, cyano, amino, oxo, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NH-(C1-C3 alkyl) or -N(C1-C3 alkyl)2; and R" is selected from halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH, 3- to 5-membered heterocycloalkyl containing 1 heteroatom selected from N, O and S, C3-C5 cycloalkyl and -(CH2) p -(C3-C5 cycloalkyl), wherein the C1-C6 alkyl and C1-C6 alkoxy are optionally substituted by one or more halogen, hydroxyl, cyano or amino, and the 3 to 5 membered heterocycloalkyl and C3-C5 cycloalkyl are optionally substituted by one or more halogen, hydroxyl, cyano, oxo or amino.

4. The pharmaceutical composition for preventing or treating cancer according to claim 3, wherein: Cy is phenyl; a heteroaryl selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, quinolyl and isoquinolyl; or a heterocycloalkyl selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, pyrazolidinyl, imidazolidinyl, thiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl and morpholinyl; and Cy2 is phenyl; a heteroaryl selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, quinolyl and isoquinolyl; a heterocycloalkyl selected from azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, pyrazolidinyl, imidazolidinyl, thiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl and morpholinyl; a cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; or a cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl.

5. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: R a is -V-Cy2, and Having a structure selected from the following: wherein Cy and Cy2 are each optionally substituted by R' and R".

6. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: R 8 for Where Z is -(CH2) s , and R 8 ' is hydroxy or C1-C6 alkoxy, and s is an integer of 0 or 1.

7. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The formula I is formula IA-1 or IA-2: [Formula IA-1] [Formula IA-2] in, R 1 and R 2 is selected from hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl and C6-C 10 The group consisting of aryl groups, wherein the C1-C6 alkyl and C1-C6 alkoxy groups are each independently optionally substituted by one or more halogen, hydroxyl, cyano or amino groups, and the C3-C8 cycloalkyl and C6-C 10 The aryl groups are each independently optionally substituted with one or more halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy; R 3 for and W, Cy, Ra, R 4 , R 8 , n, m, r and l are as defined in claim 1.

8. The pharmaceutical composition for preventing or treating cancer according to claim 7, wherein: R 1 is hydrogen, halogen, hydroxyl, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl) or -N(C1-C6 alkyl)2, wherein the C1-C6 alkyl and C1-C6 alkoxy are each independently and optionally substituted by one or more halogen, hydroxyl, cyano or amino; R 2 is hydrogen, halogen, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C3-C6 cycloalkyl or phenyl, wherein the C1-C3 alkyl and C1-C3 alkoxy are each independently and optionally substituted with one or more halogen, hydroxyl, cyano or amino groups; R 3 for W is -(CH2) o -, -C(O)-, -O-, -NH- or -N(C1-C6 alkyl)-, wherein the H in the CH2 is optionally substituted by one or more halogen, hydroxyl or C1-C6 alkoxy; Cy is selected from C6-C 10 The group consisting of aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, and 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O and S, and optionally substituted with one or more R'; R a is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl or -V-Cy2, wherein V is absent or -NH-, -NHCH2-, -NHCH3-, -S-, -SO2-, -CH2-, -OCH2- or -O-, and Cy2 is selected from C6-C 10 The group consisting of aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O and S, C3-C8 cycloalkyl and C3-C8 cycloalkenyl, and optionally substituted with one or more R"; R' is halogen, hydroxy, cyano, amino, oxo, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NH-(C1-C3 alkyl) or -N(C1-C3 alkyl)2; R" is selected from halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH, 3- to 5-membered heterocycloalkyl containing 1 heteroatom selected from N, O and S, C3-C5 cycloalkyl and -(CH2) p -(C3-C5 cycloalkyl), wherein the C1-C6 alkyl and C1-C6 alkoxy are optionally substituted by one or more halogen, hydroxy, cyano or amino, and the 3- to 5-membered heterocycloalkyl and C3-C5 cycloalkyl are optionally substituted by one or more halogen, hydroxy, cyano, oxo or amino; R 4 is hydrogen or C1-C3 alkyl; R 8 for Where Z is -(CH2) s , and R 8 ' is hydroxyl or C1-C6 alkoxy; l, m, n and r are each independently an integer of 1 or 2; o and p are each independently an integer of 0, 1 or 2; and s is an integer of 0 or 1.

9. The pharmaceutical composition for preventing or treating cancer according to claim 8, wherein: R 1 is hydrogen, halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl or C1-C3 haloalkoxy; R 2 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, cyclobutyl or phenyl; Cy is phenyl, 5- to 10-membered heteroaryl containing 1 or 2 nitrogen atoms, or 4- to 7-membered heterocycloalkyl containing 1 or 2 nitrogen atoms, and is optionally substituted with one or more R'; R a is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl or -V-Cy2, wherein V is absent or -CH2- or -O-, and Cy2 is selected from the group consisting of phenyl, 5- to 10-membered heteroaryl containing 1 or 2 heteroatoms selected from N or O, 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N or O, C4-C7 cycloalkyl and C4-C7 cycloalkenyl, and is optionally substituted with one or more R"; R' is halogen, amino, C1-C3 alkyl or C1-C3 haloalkyl; and R" is selected from halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH; azetidinyl or oxetanyl optionally substituted by hydroxy or oxo; and cyclopropyl or cyclopropylmethyl optionally substituted by hydroxy or oxo.

10. The pharmaceutical composition for preventing or treating cancer according to claim 9, wherein: Cy is phenyl, pyrazolyl or piperazinyl; and Cy2 is phenyl, furyl, pyrazolyl, pyridyl, morpholinyl, piperidinyl, cyclohexyl or cyclohexenyl.

11. The pharmaceutical composition for preventing or treating cancer according to claim 7, wherein: The formula IA-1 or IA-2 is the formula IA-3 or IA-4: [Formula IA-3] [Formula IA-4] Among them, R 1 , R 2 , R 3 , R 4 and R 8 As defined in claim 7.

12. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The formula I is formula IB-1: [Formula IB-1] in, R 1 is selected from hydrogen, halogen, hydroxy, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl), -N(C1-C6 alkyl)2, C3-C8 cycloalkyl and C6-C 10 The group consisting of aryl groups, wherein the C1-C6 alkyl and C1-C6 alkoxy groups are each independently optionally substituted by one or more halogen, hydroxyl, cyano or amino groups, and the C3-C8 cycloalkyl and C6-C 10 The aryl groups are each independently optionally substituted with one or more halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy; One or two carbon atoms in are optionally substituted with halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy; and W, Cy, R a , R 4 , R 5 , R 6 , R 7 , R 8 , P, n, m and l are as defined in claim 1.

13. The pharmaceutical composition for preventing or treating cancer according to claim 12, wherein: The formula IB-1 is formula IB-2, IB-3 or IB-4: [Formula IB-2] [Formula IB-3] [Formula IB-4] in, R 1 is hydrogen, halogen, hydroxyl, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, -NH-(C1-C6 alkyl) or -N(C1-C6 alkyl)2, wherein the C1-C6 alkyl and C1-C6 alkoxy are each independently and optionally substituted by one or more halogen, hydroxyl, cyano or amino; One or two carbon atoms in are optionally substituted by halogen, C1-C3 alkyl or C1-C3 haloalkyl; W is -(CH2) o -or-(CH2) o -C≡C-, wherein the H in the CH2 is optionally substituted by one or more halogens, hydroxyls or C1-C6 alkoxyls; Cy is selected from C6-C 10 The group consisting of aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, and 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O and S, and optionally substituted with one or more R'; R a is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl or -V-Cy2, wherein V is absent or -NH-, -NHCH2-, -NHCH3-, -S-, -SO2-, -CH2-, -OCH2- or -O-, and Cy2 is selected from C6-C 10 The group consisting of aryl, 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, 4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O and S, C3-C8 cycloalkyl and C3-C8 cycloalkenyl, and optionally substituted with one or more R"; R' is halogen, hydroxy, cyano, amino, oxo, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NH-(C1-C3 alkyl) or -N(C1-C3 alkyl)2; R" is selected from halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 alkoxy, -S-(C1-C6 alkyl), -SO2-(C1-C6 alkyl), -COO-(C1-C6 alkyl), -COOH, -CONH2, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2, -(CH2) p -NH-COO-(C1-C6 alkyl), -(CH2) p -OH, 3- to 5-membered heterocycloalkyl containing 1 heteroatom selected from N, O and S, C3-C5 cycloalkyl and -(CH2) p -(C3-C5 cycloalkyl), wherein the C1-C6 alkyl and C1-C6 alkoxy are optionally substituted by one or more halogen, hydroxy, cyano or amino, and the 3- to 5-membered heterocycloalkyl and C3-C5 cycloalkyl are optionally substituted by one or more halogen, hydroxy, cyano, oxo or amino; R 4 is hydrogen or C1-C3 alkyl; R 8 for Where Z is -(CH2) s , and R 8 ' is hydroxyl or C1-C6 alkoxy; l, m and n are each independently an integer of 1 or 2; o and p are each independently an integer from 0 to 2; q and r are each independently an integer of 1 or 2; and s is an integer of 0 or 1.

14. The pharmaceutical composition for preventing or treating cancer according to claim 13, wherein: R 1 is hydrogen, halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl or C1-C3 haloalkoxy; One or two carbon atoms in are optionally substituted by halogen, C1-C3 alkyl or C1-C3 haloalkyl; Cy is phenyl, or a 5- to 10-membered heteroaryl group containing 1 or 2 nitrogen atoms; R a is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or -V-Cy2, wherein V is absent or -CH2-, and Cy2 is phenyl, or a 5- to 10-membered heteroaryl group containing 1 or 2 nitrogen atoms; R' is halogen, amino, C1-C3 alkyl or C1-C3 haloalkyl; and R" is halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(CH2) p -NH2, -(CH2) p -NH-(C1-C6 alkyl), -(CH2) p -N(C1-C6 alkyl)2; azetidinyl or oxetanyl optionally substituted by hydroxy or oxo; cyclopropyl or cyclopropylmethyl optionally substituted by hydroxy or oxo.

15. The pharmaceutical composition for preventing or treating cancer according to claim 14, wherein: Cy is selected from the group consisting of phenyl, pyridyl, pyrimidinyl and indolyl; and Cy2 is selected from the group consisting of phenyl, pyrazolyl, pyridinyl and pyrimidinyl.

16. The pharmaceutical composition for preventing or treating cancer according to claim 12, wherein: The formula IB-1 is formula IB-5, IB-6, IB-7 or IB-8: [Formula IB-5] [Formula IB-6] [Formula IB-7] [Formula IB-8] Among them, R 1 ,W,Cy,R a , R 4 and R 8 As defined in claim 12.

17. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The compound is selected from the group consisting of the following compounds:

18. The pharmaceutical composition for preventing or treating cancer according to claim 17, wherein: The compound is selected from the group consisting of the following compounds:

19. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The anticancer agent is selected from any one of the group consisting of chemotherapeutic agents, targeted anticancer agents, oncolytic viruses, antibody therapeutic agents, cell therapeutic agents and immune checkpoint inhibitors.

20. The pharmaceutical composition for preventing or treating cancer according to claim 19, wherein: The chemotherapeutic agent is any one selected from the group consisting of alkylating agents, microtubule inhibitors, antimetabolites and topoisomerase inhibitors.

21. The pharmaceutical composition for preventing or treating cancer according to claim 20, wherein: The chemotherapeutic agent is any one selected from the group consisting of nitrogen mustard, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine, procarbazine, busulfan, streptozotocin, carmustine, lomustine, dacarbazine, cisplatin, carboplatin, oxaliplatin, docetaxel, vinblastine, vincristine, isovinblastine, fluorouracil, capecitabine, cytarabine, gemcitabine, fludarabine, methotrexate, pemetrexed, mercaptopurine, topotecan, irinotecan, etoposide, paclitaxel, bleomycin, doxorubicin and daunorubicin.

22. The pharmaceutical composition for preventing or treating cancer according to claim 19, wherein: The targeted anti-cancer agent targets any one protein selected from the group consisting of EGFR, VEGFR, CD20, CD38, RNAK-L, BTK, Bcr-abl, PDGFR / FGFR family, MEK / RAF / KRAS, HER2 / Neu, ubiquitin, JAK, ALK, PARP, TGFβR, proteasome, Bcl-2, C-Met, VR1, VR2, VR3, C-kit, AXL, RET, Braf, DNMT, CDK4 / 6 and STING.

23. The pharmaceutical composition for preventing or treating cancer according to claim 22, wherein: The targeted anticancer agent is selected from the group consisting of cetuximab, trastuzumab, pertuzumab, gefitinib, erlotinib, osimertinib, panitumumab, axitinib, lenvatinib, bevacizumab, ramucirumab, aflibercept, rituximab, obotuzumab, daratumumab, denosumab, ibrutinib, dasatinib, nilotinib, imatinib, bosutinib, galunisertib, vactosertib, nintedanib, sunitinib, sorafenib, cabozantinib, regorafenib, masitinib, semaxanib, tivozanib, vandetanib, Any of the group consisting of nivolumab, pazopanib, trametinib, dabrafenib, sotolacib, afatinib, lapatinib, neratinib, lenalidomide, ixazomib, ruxolitinib, lestaurtinib, pactinib, cobimetinib, selumetinib, bemetinib, alectinib, crizotinib, venetoclax, bimetinib, gilteritinib, sepretib, pralsetinib, vemurafenib, olaparib, talazoparib, niraparib, rucaparib, azacitidine, decitabine, avidecitabine, abemaciclib, ribociclib, palbociclib, CDN, SB11285, and DMXAA.

24. The pharmaceutical composition for preventing or treating cancer according to claim 19, wherein: The oncolytic virus is Talimogen Laherparepvec.

25. The pharmaceutical composition for preventing or treating cancer according to claim 19, wherein: The antibody therapeutic agent is any one selected from the group consisting of cetuximab, trastuzumab, pertuzumab, panitumumab, emtansine, rituximab, daratumumab, denosumab, ibritumomab tiuxetan, tositumomab, brentuximab, ofatumumab, obinutuzumab, necituzumab, bevacizumab, ramucirumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, and ipilimumab.

26. The pharmaceutical composition for preventing or treating cancer according to claim 19, wherein: The cell therapy agent is any one selected from the group consisting of silifermin and akiramine.

27. The pharmaceutical composition for preventing or treating cancer according to claim 19, wherein: The immune checkpoint inhibitor can be any one selected from the group consisting of anti-CTLA-4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-PDP-L2 antibody, anti-B7-H4 antibody, anti-HVEM antibody, anti-TIM3 antibody, anti-GAL9 antibody, anti-LAG3 antibody, anti-VISTA antibody, anti-KIR antibody, anti-BTLA antibody and anti-TIGIT antibody.

28. The pharmaceutical composition for preventing or treating cancer according to claim 19, wherein: The immune checkpoint inhibitor may be any one selected from the group consisting of ipilimumab, pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab and durvalumab.

29. The pharmaceutical composition for preventing or treating cancer according to claim 19, wherein: The anticancer agents include chemotherapeutic agents and immune checkpoint inhibitors.

30. The pharmaceutical composition for preventing or treating cancer according to claim 29, wherein: The chemotherapeutic agents include alkylating agents and antimetabolites.

31. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, glioma, bone cancer, gastric cancer, kidney cancer, lung cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, head and neck cancer, renal cell carcinoma, esophageal cancer, pancreatic cancer, brain cancer, gastrointestinal cancer, liver cancer, leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, colorectal cancer, bile duct cancer, choriocarcinoma, oral cancer, neuroblastoma, skin cancer, testicular cancer, stromal tumors, germ cell tumors and thyroid cancer.

32. A method for preventing or treating cancer, comprising administering to a subject the pharmaceutical composition for preventing or treating cancer according to any one of claims 1 to 31.

33. Use of the pharmaceutical composition for preventing or treating cancer as claimed in any one of claims 1 to 31 in the preparation of a medicament for preventing or treating cancer.